乳腺癌临床试验导航 | 海外癌症临床试验导航

正在招募 Phase 3

NCI NCT04157985 / NCI-2020-02016

Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors

AI 简述这是一项III期试验，比较免疫治疗不同治疗时长用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募 Phase 3

NCI NCT05812807 / NCI-2022-07859

Pembrolizumab versus Observation in Patients with Early Stage Triple-Negative Breast Cancer who had a Pathologic Complete Response after Chemotherapy plus Pembrolizumab, OptimICE-PCR Trial

AI 简述这是一项III期试验，研究Pembrolizumab对比观察用于早期三阴性乳腺癌化疗后病理完全缓解者。

?

适用疾病: Stage II Breast Cancer；Stage IIIA Breast Cancer；Stage IIIB Breast Cancer
干预: 未列出
地点: United States，Canada
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3

NCI NCT05774678 / NCI-2023-01985

Comparing Hypofractionated versus Conventionally Fractionated Radiation Therapy Before Mastectomy with Breast Reconstructive Surgery for the Treatment of Breast Cancer

AI 简述这是一项III期试验，比较大分割与常规分割放疗在乳腺癌乳房切除术前应用。

?

适用疾病: Stage II Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT05929768 / NCI-2023-02688

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer

AI 简述这是一项III期试验，在美国和墨西哥研究不含蒽环类药物的短程化免疫疗法用于早期三阴性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage IIIA Breast Cancer
干预: 未列出
地点: United States，Mexico
申办方: SWOG

正在招募 Phase 3

NCI NCT05774951 / NCI-2023-03766

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

AI 简述这是一项III期试验，研究Camizestrant用于ER+/HER2-早期乳腺癌标准辅助内分泌治疗至少2年后。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；HER2 Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 3

NCI NCT05952557 / NCI-2023-06834

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

AI 简述这是一项III期试验，研究Camizestrant用于ER+/HER2-早期乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2, Phase 3

NCI NCT06367972 / NCI-2024-03278

Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial

AI 简述这是一项II/III期试验，研究局部巩固治疗联合系统治疗用于寡进展转移性癌症，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 3

NCI NCT06507618 / NCI-2024-06875

Pre-Operative Window of Endocrine Therapy to Inform Radiation Therapy Decisions in Older Women with Early Stage Estrogen Receptor Positive Breast Cancer, the POWER II Trial

AI 简述这是一项III期试验，研究术前内分泌治疗用于早期雌激素受体阳性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage IIA Breast Cancer；HER2 Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: University of Virginia Cancer Center

正在招募 Phase 3

NCI NCT06876714 / NCI-2024-10478

ShortStop-HER2: 12 months vs. 6 months of HER2-targeted Medications for People with HER2+ Breast Cancer who Had a Pathologic Complete Response after Chemotherapy Plus Trastuzumab

AI 简述这是一项III期试验，比较12个月与6个月HER2靶向药物用于早期HER2阳性乳腺癌，在美国开展。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Early Stage HER2-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Alliance for Clinical Trials in Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov NCT01785420

Pre Operative Trastuzumab in Operable Breast Cancer

AI 简述这是一项III期试验，比较Trastuzumab与安慰剂用于HER2阳性乳腺癌术前治疗，在印度开展。

?

适用疾病: Carcinoma Breast Stage I；HER2 Positive Breast Cancer
干预: Trastuzumab，Placebo
地点: India
申办方: Dr Rajendra A. Badwe

正在招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT03150576

Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

AI 简述这是一项II/III期试验，研究铂类联合PARP抑制剂用于三阴性乳腺癌和/或胚系BRCA阳性乳腺癌的新辅助治疗，在英国开展。

?

适用疾病: Breast Cancer
干预: Olaparib，Paclitaxel and Carboplatin
地点: United Kingdom
申办方: Cambridge University Hospitals NHS Foundation Trust

正在招募 Phase 3 药物

ClinicalTrials.gov NCT03671044

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

AI 简述这是一项III期试验，研究纳米多西他赛脂质混悬液用于三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: Nanosomal Docetaxel Lipid Suspension (75 mg/m2)，Nanosomal Docetaxel Lipid Suspension (100 mg/m2)，Taxotere® (100 mg/m2)
地点: United States，India
申办方: Jina Pharmaceuticals Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05078047

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

AI 简述这是一项III期试验，比较标准免疫治疗与每3个月给药一次的方案用于多种癌症。

?

适用疾病: Lung Cancer Metastatic；Renal Cell Carcinoma；Head and Neck Cancer
干预: Reduced dose intensity of IO
地点: France
申办方: UNICANCER

正在招募 Phase 3 生物制剂

ClinicalTrials.gov / NCI NCT05232916 / NCI-2022-03768

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

AI 简述这是一项III期试验，研究GLSI-100用于HER2阳性乳腺癌。

?

适用疾病: Breast Cancer；Stage I Breast Cancer；Stage II Breast Cancer
干预: Placebo，GLSI-100
地点: United States，Belgium，France，Germany 等 6 个
申办方: Greenwich LifeSciences, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05512364

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

AI 简述这是一项III期试验，比较Elacestrant与标准内分泌治疗用于ctDNA复发的ER+/HER2-乳腺癌，在多个欧洲国家开展。

?

适用疾病: ER-positive Breast Cancer；HER2-negative Breast Cancer；Stage IIB Breast Cancer
干预: Elacestrant，Tamoxifen，Letrozole 2.5mg，Anastrozole 1mg
地点: Belgium，Cyprus，France，Germany 等 8 个
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT05552001

Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer

AI 简述一项III期试验，研究Sacituzumab govitecan联合化疗用于三阴性转移性乳腺癌（法国）。

?

适用疾病: Triple Negative Breast Cancer；Metastatic Breast Cancer
干预: Sacituzumab govitecan
地点: France
申办方: UNICANCER

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05633654 / NCI-2023-03800

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

AI 简述这是一项III期试验，比较Sacituzumab Govitecan联合Pembrolizumab与医生选择治疗用于三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Triple-Negative Breast Cancer；Invasive Breast Cancer
干预: Sacituzumab govitecan-hziy (SG)，Pembrolizumab，Capecitabine
地点: United States，Australia，Belgium，Brazil 等 7 个
申办方: Gilead Sciences

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT05879926 / NCI-2023-04529

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

AI 简述这是一项III期试验，比较辅助化疗后卵巢功能抑制加内分泌治疗与单独内分泌治疗用于早期乳腺癌。

?

适用疾病: Breast Cancer；Stage I Breast Cancer；Stage II Breast Cancer
干预: Ovarian Function Suppression + Aromatase Inhibitor，Adjuvant Chemotherapy + Ovarian Function Suppression
地点: United States，Canada，Colombia，Japan 等 4 个
申办方: NRG Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06016738 / NCI-2023-09687

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

AI 简述这是一项III期试验，在美国、阿根廷、澳大利亚、奥地利等地研究OP-1250对比标准治疗用于ER+/HER2-晚期乳腺癌。

?

适用疾病: Breast Cancer；Advanced Breast Cancer；Metastatic Breast Cancer
干预: Palazestrant，Fulvestrant，Anastrozole，Letrozole
地点: United States，Argentina，Australia，Austria 等 22 个
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 3 生物制剂药物其他

ClinicalTrials.gov / NCI NCT06058377 / NCI-2023-04566

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

AI 简述这是一项3期试验，研究度伐利尤单抗联合化疗（紫杉醇、环磷酰胺、多柔比星）用于2-3期乳腺癌。

?

适用疾病: Anatomic Stage II Breast Cancer AJCC v8；Anatomic Stage III Breast Cancer AJCC v8；HER2-Negative Breast Carcinoma
干预: Biospecimen Collection，Cyclophosphamide，Doxorubicin，Durvalumab
地点: United States，Puerto Rico
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT06072612 / NCI-2023-10928

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

AI 简述这是一项III期试验，比较Bria-IMT方案联合CPI与医生选择方案用于晚期转移性乳腺癌。

?

适用疾病: Breast Cancer；Metastatic Breast Cancer；Breast Neoplasm
干预: SV-BR-1-GM，Cyclophosphamide，Interferon infiltration of the inoculation site，Retifanlimab
地点: United States
申办方: BriaCell Therapeutics Corporation

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06081244

NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)

AI 简述这是一项III期试验，比较SG联合或不联合Pembrolizumab用于低风险三阴性乳腺癌新辅助治疗，在德国开展。

?

适用疾病: Triple Negative Breast Cancer
干预: Sacituzumab govitecan，Pembrolizumab
地点: Germany
申办方: West German Study Group

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov NCT06135714

Metastasis-directed Therapy for Oligometastases of Breast Cancer

AI 简述这是一项III期试验，在日本的乳腺癌寡转移患者中比较系统性治疗联合局部治疗（放疗或手术）与单独系统性治疗。

?

适用疾病: Breast Cancer；Oligometastasis；Metastatic Breast Cancer
干预: Systemic therapy for 12 weeks after primary registration，Radiation therapy (SBRT/conventional RT)，Surgery，Same systemic therapy after secondary registration
地点: Japan
申办方: Tokyo Medical and Dental University

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT06312176 / NCI-2024-03670

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

AI 简述这是一项III期试验，研究Sacituzumab Tirumotecan单药或联合帕博利珠单抗用于HR+/HER2-晚期乳腺癌。

?

适用疾病: Breast Neoplasms；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Sacituzumab tirumotecan，Pembrolizumab，Paclitaxel，Nab-paclitaxel
地点: United States，Argentina，Australia，Belgium 等 36 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06377852

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

AI 简述这是一项III期试验，研究Palbociclib和Ribociclib的剂量方案用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Palbociclib 125mg，Ribociclib 600mg，Ribociclib，Palbociclib
地点: United States
申办方: American Society of Clinical Oncology

正在招募 Phase 3 药物

ClinicalTrials.gov NCT06382948

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

AI 简述这是一项III期试验，在多个国家研究Elacestrant联合Everolimus用于ER+/HER2-、ESR1突变的晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer；ER-positive Breast Cancer；HER2-negative Breast Cancer
干预: Everolimus，Elacestrant，Placebo，Auxiliary Medicinal Product - Dexamethasone
地点: Austria，Brazil，Czechia，France 等 5 个
申办方: MedSIR

正在招募 Phase 3 生物制剂药物

ClinicalTrials.gov / NCI NCT06393374 / NCI-2024-05650

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

AI 简述这是一项III期试验，比较MK-2870联合帕博利珠单抗与标准化疗用于未达到病理完全缓解的三阴性乳腺癌，在美国等地开展。

?

适用疾病: Triple-Negative Breast Cancer
干预: Pembrolizumab，Sacituzumab tirumotecan，Capecitabine
地点: United States，Argentina，Australia，Austria 等 27 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06435429 / NCI-2024-07865

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

AI 简述这是一项III期试验，在美国等地比较Zanidatamab与曲妥珠单抗联合化疗用于HER2阳性转移性乳腺癌。

?

适用疾病: Metastatic HER2-positive Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Zanidatamab，Trastuzumab，Eribulin，Vinorelbine
地点: United States，Australia，Austria，Belgium 等 11 个
申办方: Jazz Pharmaceuticals

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06492616 / NCI-2025-00399

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

AI 简述这是一项III期试验，比较Elacestrant与标准内分泌治疗用于ER+/HER2-早期乳腺癌高风险复发患者。

?

适用疾病: Breast Cancer；Stage I Breast Cancer；Stage II Breast Cancer
干预: Elacestrant，Anastrozole，Letrozole，Exemestane
地点: United States，Argentina，Australia，Austria 等 24 个
申办方: Stemline Therapeutics, Inc.

正在招募 Phase 3 手术/操作放疗

ClinicalTrials.gov NCT06500455

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

AI 简述这是一项III期试验，比较长疗程放疗与常规放疗用于脑转移瘤，在美国、加拿大等地开展。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Digestive System Carcinoma
干预: Computed Tomography，Fractionated Stereotactic Radiation Therapy，Magnetic Resonance Imaging，Stereotactic Radiosurgery
地点: United States，Canada，Hong Kong，Ireland
申办方: NRG Oncology

正在招募 Phase 3 其他手术/操作放疗

ClinicalTrials.gov / NCI NCT06500481 / NCI-2024-04895

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

AI 简述这是一项III期试验，比较质子全脑全脊髓放疗与常规放疗用于柔脑膜转移，在美国开展。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Computed Tomography，Involved-Field Radiation Therapy，Lumbar Puncture
地点: United States
申办方: NRG Oncology

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT06606730

Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer

AI 简述这是一项III期试验，在比利时、法国等地研究帕博利珠单抗用于早期三阴性乳腺癌。

?

适用疾病: Breast Cancers；Triple Negative Breast Cancer (TNBC)
干预: Pembrolizumab，Deescalation
地点: Belgium，France
申办方: UNICANCER

正在招募 Phase 3 药物其他

ClinicalTrials.gov NCT06643585

A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse

AI 简述这是一项III期试验，比较Trastuzumab-Deruxtecan与医生选择的治疗用于早期乳腺癌分子复发患者。

?

适用疾病: Breast Cancer
干预: Trastuzumab-Deruxtecan，Physicians Choice (PhC).
地点: Germany
申办方: Prof. Wolfgang Janni

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06757634 / NCI-2025-04135

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

AI 简述这是一项III期试验，比较Gedatolisib联合方案与Ribociclib联合方案用于HR+/HER2-晚期乳腺癌。

?

适用疾病: Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Arm A: Gedatolisib + Palbociclib + Fulvestrant，Arm B: Ribociclib + Fulvestrant，Arm C: Gedatolisib + Palbociclib + Letrozole，Arm D: Ribociclib + Letrozole
地点: United States，Argentina，Australia，Belgium 等 18 个
申办方: Celcuity Inc

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT06982521 / NCI-2025-04974

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

AI 简述这是一项III期试验，比较RLY-2608联合Fulvestrant与Capivasertib联合Fulvestrant用于PIK3CA突变HR+/HER2-晚期乳腺癌。

?

适用疾病: PIK3CA Mutation；HER2- Negative Breast Cancer；Hormone Receptor Positive Tumor
干预: RLY-2608，Capivasertib，Fulvestrant
地点: United States，Argentina，Australia，Austria 等 19 个
申办方: Relay Therapeutics, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07085767 / NCI-2026-02023

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

AI 简述这是一项III期试验，在美国、澳大利亚等地开展，研究Palazestrant联合Ribociclib一线治疗ER+/HER2-晚期乳腺癌。

?

适用疾病: Breast Cancer；Locally Advanced Breast Cancer；Metastatic Breast Cancer
干预: Palazestrant，Letrozole-matching placebo，Ribociclib，Letrozole
地点: United States，Australia，Austria，Belgium 等 18 个
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 3 药物

ClinicalTrials.gov NCT07190443

Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)

AI 简述这是一项III期试验，在Japan等地比较Abemaciclib联合内分泌治疗与内分泌治疗用于HR阳性HER2阴性乳腺癌局部复发。

?

适用疾病: Breast Cancer；Locoregional Recurrence；Abemaciclib
干预: Endocrine therapy + Abemaciclib，Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
地点: Japan
申办方: Japanese Foundation for Cancer Research

正在招募 Phase 3 药物手术/操作

ClinicalTrials.gov / NCI NCT07391774 / NCI-2026-00634

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

AI 简述这是一项III期试验，比较内分泌治疗联合Ribociclib与化疗后内分泌治疗联合Ribociclib用于高分期低复发风险乳腺癌，在美国开展。

?

适用疾病: Anatomic Stage II Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIC Breast Cancer AJCC v8
干预: Anastrozole，Biospecimen Collection，Bone Scan，Chemotherapy
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 3 药物

ClinicalTrials.gov / NCI NCT07492641 / NCI-2026-03707

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

AI 简述这是一项3期试验，研究BGB-43395联合来曲唑对比CDK4/6抑制剂联合来曲唑用于HR+/HER2-晚期或转移性乳腺癌。

?

适用疾病: HR+/HER2- Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: BGB-43395，Letrozole，Abemaciclib，Palbociclib
地点: United States，Australia，Japan，Malaysia 等 1 个
申办方: BeOne Medicines

正在招募 Phase 2

NCI NCT02896335 / NCI-2016-02025

Palbociclib and Pembrolizumab for the Treatment of Patients with Brain Metastases

AI 简述这是一项II期试验，在美国开展，研究Palbociclib和Pembrolizumab用于恶性实体瘤、IV期乳腺癌、中枢神经系统转移瘤。

?

适用疾病: Malignant Solid Tumor；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT03018405 / NCI-2017-00722

A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications

AI 简述这是一项I/II期试验，研究多种肿瘤适应症的药物。

?

适用疾病: Metastatic Urothelial Cancer；Advanced Malignant Solid Tumor；Refractory Acute Myeloid Leukemia (AML)
干预: 未列出
地点: United States
申办方: Celyad Oncology SA

正在招募 Phase 2

NCI NCT02939274 / NCI-2017-01289

An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer

AI 简述这是一项II期试验，研究维替泊芬光动力疗法用于乳腺癌皮肤转移。

?

适用疾病: Metastatic Breast Cancer in the Skin；Stage IV Breast Cancer；Stage IIIB Breast Cancer
干预: 未列出
地点: United States
申办方: Rogers Sciences Inc.

正在招募 Phase 2

NCI NCT01221870 / NCI-2017-02185

Tesetaxel as First-line Therapy for Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Tesetaxel用于转移性乳腺癌一线治疗。

?

适用疾病: Stage IV Breast Cancer；Breast Adenocarcinoma
干预: 未列出
地点: United States
申办方: Genta Inc

正在招募 Phase 2

NCI NCT01174121 / NCI-2019-00142

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

AI 简述这是一项II期试验，研究肿瘤浸润淋巴细胞联合Pembrolizumab用于转移性癌症。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: National Cancer Institute

正在招募 Phase 1, Phase 2

NCI NCT04143789 / NCI-2019-07561

Evaluation of AP-002 in Patients With Solid Tumors

AI 简述这是一项I/II期试验，评估AP-002用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Altum Pharmaceuticals Inc

正在招募 Phase 1, Phase 2

NCI NCT04092673 / NCI-2019-07863

Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies

AI 简述这是一项I/II期试验，研究eFT226用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Effector Therapeutics

正在招募 Phase 2

NCI NCT04197687 / NCI-2019-08038

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage I-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery

AI 简述这是一项II期试验，研究TPIV100和Sargramostim用于HER2阳性I-III期乳腺癌化疗和手术后残留病变。

?

适用疾病: Breast Adenocarcinoma；Stage II Breast Cancer；Stage I Breast Cancer
干预: 未列出
地点: United States
申办方: Academic and Community Cancer Research United

正在招募 Phase 2

NCI NCT04305834 / NCI-2019-08847

Abemaciclib in Combination with Endocrine Therapy for the Treatment of Older Patients with Hormone Receptor Positive Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Abemaciclib联合内分泌治疗用于老年HR阳性转移性乳腺癌。

?

适用疾病: Stage IV Breast Cancer；Metastatic Breast Carcinoma；Metastatic HER2-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04145622 / NCI-2020-03139

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

AI 简述这是一项I/II期试验，研究Ifinatamab Deruxtecan用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 2

NCI NCT03412643 / NCI-2020-04537

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

AI 简述这是一项II期试验，研究新辅助化疗联合曲妥珠单抗和帕妥珠单抗用于HER2信号异常的HER2阴性乳腺癌。

?

适用疾病: Stage II Breast Cancer；Stage IIA Breast Cancer；Stage IIB Breast Cancer
干预: 未列出
地点: United States
申办方: NSABP Foundation Inc

正在招募 Phase 1, Phase 2

NCI NCT04300556 / NCI-2020-06147

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

AI 简述这是一项I/II期试验，研究MORAb-202用于多种实体瘤，包括卵巢癌和肺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eisai Inc

正在招募 Phase 1, Phase 2

NCI NCT04588545 / NCI-2020-11618

Radiation Therapy Followed by Trastuzumab and Pertuzumab for the Treatment of HER2 Positive Breast Cancer that has Spread to the Leptomeninges

AI 简述这是一项I/II期试验，研究放疗后序贯Trastuzumab和Pertuzumab用于HER2阳性乳腺癌软脑膜转移。

?

适用疾病: Stage IV Breast Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04503265 / NCI-2020-14258

A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies

AI 简述这是一项I/II期试验，研究AMXI-5001用于晚期实体瘤。在美国开展。

?

适用疾病: Homologous Recombination Deficiency；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: AtlasMedx, Incorporated

正在招募 Phase 2

NCI NCT04959474 / NCI-2021-02646

A Research Study to See If Reducing Calories while Undergoing Stereotactic Ablative Radiation Therapy Affects Tumor Growth

AI 简述这是一项II期试验，研究立体定向放疗期间减少热量摄入对乳腺癌患者肿瘤生长的影响，在美国开展。

?

适用疾病: Stage 0 Breast Cancer；Stage I Breast Cancer；Stage II Breast Cancer
干预: 未列出
地点: United States
申办方: Thomas Jefferson University Hospital

正在招募 Phase 1, Phase 2

NCI NCT04711824 / NCI-2021-05777

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases

AI 简述这是一项I/II期试验，研究立体定向放射外科联合Olaparib后Durvalumab和医生选择系统治疗用于乳腺癌脑转移。

?

适用疾病: Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma；Metastatic HER2-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Colette Shen

正在招募 Phase 1, Phase 2

NCI NCT04939610 / NCI-2021-07632

A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-FAP-2286用于晚期实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Novartis Pharmaceuticals Corporation

正在招募 Phase 2

NCI NCT05064280 / NCI-2021-11329

Pembrolizumab and Lenvatinib for the Treatment of Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, and Other Tumors with Brain Metastases

AI 简述这是一项2期试验，研究Pembrolizumab和Lenvatinib用于三阴性乳腺癌、非小细胞肺癌等脑转移实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Lung Cancer；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT04723810 / NCI-2022-03872

Indocyanine Green for Imaging of Solid Tumors during Surgery Compared to Standard of Care

AI 简述这是一项I/II期试验，研究吲哚青绿用于实体瘤术中成像，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Metastatic Sarcoma
干预: 未列出
地点: United States
申办方: University of Pennsylvania/Abramson Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05358379 / NCI-2022-04029

A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

AI 简述这是一项I/II期试验，研究CYC140用于晚期实体瘤和淋巴瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Peripheral T-Cell Lymphoma, Unclassifiable
干预: 未列出
地点: United States
申办方: Cyclacel Pharmaceuticals, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05417594 / NCI-2022-05317

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

AI 简述这是一项1/2期试验，研究AZD9574单药或联合其他抗癌药用于晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 2

NCI NCT05472792 / NCI-2022-06147

Comparison of Adjuvant Endocrine Therapy and Accelerated Partial Breast Irradiation following Lumpectomy for the Treatment of Early-Stage Breast Cancer Patients Over 65, CAMERAN Study

AI 简述这是一项II期试验，比较辅助内分泌治疗与加速部分乳腺照射用于65岁以上早期乳腺癌。

?

适用疾病: Stage IA Breast Cancer；HER2 Negative Breast Carcinoma；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05101070 / NCI-2022-06439

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究S-531011单药及联合免疫检查点抑制剂用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Shionogi

正在招募 Phase 2

NCI NCT05453825 / NCI-2022-07031

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors

AI 简述这是一项II期试验，研究Navicixizumab单药或联合用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: OncXerna Theraputics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05533697 / NCI-2022-07826

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究mRNA-4359单用或联合免疫检查点抑制剂用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: ModernaTX, Inc.

正在招募 Phase 2

NCI NCT05464082 / NCI-2022-08187

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Stage I-III Triple Negative and Hormone Receptor Low/HER2 Negative Breast Cancer, the TOWARDS-II Study

AI 简述这是一项II期试验，在美国开展，用于预测和预防I-III期三阴性及HR低/HER2阴性乳腺癌的早期转移复发。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Huntsman Cancer Institute/University of Utah

正在招募 Phase 1, Phase 2

NCI NCT05394103 / NCI-2022-10300

Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究CDK7抑制剂Q901用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Qurient Co., Ltd.

正在招募 Phase 1, Phase 2

NCI NCT05592626 / NCI-2023-00103

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究STAR0602用于多种晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Marengo Therapeutics, Inc.

正在招募 Phase 2

NCI NCT05645380 / NCI-2023-00467

Evaluation of Immune Cells and Response-Adapted Chemoimmunotherapy before Surgery for the Treatment of Triple-Negative Breast Cancer, The NeoTRACT Trial

AI 简述这是一项II期试验，研究免疫细胞和反应适应性化学免疫治疗用于三阴性乳腺癌术前治疗，在美国开展。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage IIIA Breast Cancer
干预: 未列出
地点: United States
申办方: University of Kansas Hospital-Westwood Cancer Center

正在招募 Phase 2

NCI NCT05741164 / NCI-2023-00641

Propranolol, Pembrolizumab and Chemotherapy for Tumor Re-sensitization and Treatment of Patients with PD-L1 Positive Metastatic or Unresectable Triple Negative Breast Cancer

AI 简述这是一项II期试验，在美国研究普萘洛尔联合Pembrolizumab和化疗用于PD-L1阳性转移性或不可切除三阴性乳腺癌。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Emory University Hospital/Winship Cancer Institute

正在招募 Phase 2

NCI NCT05770531 / NCI-2023-01721

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer

AI 简述这是一项2期试验，利用循环肿瘤DNA指导转移性三阴性乳腺癌化疗调整，在美国开展。

?

适用疾病: Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma；Metastatic HER2-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Vanderbilt University/Ingram Cancer Center

正在招募 Phase 4

NCI NCT04973930 / NCI-2023-02751

Tele-IPT and Tele-Pharmacotherapy for Treatment of Depression in Patients with Stage I-III Breast Cancer

AI 简述这是一项IV期试验，研究远程心理治疗和药物治疗用于I-III期乳腺癌患者的抑郁，在美国开展。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT05934539 / NCI-2023-05619

ALG.APV-527 First-in-human Study

AI 简述这是一项I/II期试验，研究ALG.APV-527用于转移性尿路上皮癌及晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Aptevo Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT05684965 / NCI-2023-06173

XTX301 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究XTX301用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Xilio Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT05785741 / NCI-2023-06649

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究DB-1310用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Castration-Resistant Prostate Cancer；Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 2

NCI NCT05949021 / NCI-2023-06870

Liposomal Doxorubicin and Carboplatin for the Treatment of Patients with Early Stage Triple Negative Breast Cancer, OCTANE Trial

AI 简述这是一项2期试验，研究脂质体多柔比星联合卡铂用于早期三阴性乳腺癌。

?

适用疾病: Stage 0 Breast Cancer；Stage I Breast Cancer；Stage II Breast Cancer
干预: 未列出
地点: United States
申办方: Rutgers Cancer Institute of New Jersey

正在招募 Phase 2

NCI NCT04680442 / NCI-2023-07497

Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction

AI 简述这是一项II期试验，研究继续HER-2靶向治疗用于HER2阳性乳腺癌伴左心室功能障碍。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Population Health Research Institute

正在招募 Phase 1, Phase 2

NCI NCT05898399 / NCI-2023-08450

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)

AI 简述这是一项I/II期试验，研究ART6043用于晚期/转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Artios Pharma Ltd

正在招募 Phase 1, Phase 2

NCI NCT05000294 / NCI-2023-08761

Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types

AI 简述这是一项I/II期试验，研究阿特珠单抗联合Tivozanib用于免疫冷肿瘤类型，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage IVA Ovarian Cancer；FIGO Stage IVB Ovarian Cancer
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 1, Phase 2

NCI NCT05074290 / NCI-2023-08826

Epidiferphane and Taxane Chemotherapy for the Treatment of Breast Cancer

AI 简述这是一项1/2期试验，研究Epidiferphane联合紫杉类化疗用于乳腺癌，在美国开展。

?

适用疾病: Metastatic Breast Carcinoma；Breast Cancer
干预: 未列出
地点: United States
申办方: UF Health Cancer Institute - Gainesville

正在招募 Phase 2

NCI NCT05501704 / NCI-2023-08848

Comparing Different Endocrine Therapies for Male Breast Cancer, ETHAN Trial

AI 简述这是一项II期试验，比较不同内分泌疗法用于男性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 2

NCI NCT06103669 / NCI-2023-09083

Testing the Addition of Locally Ablative Therapy to Systemic Therapy Treatment for Oligo-Progressive Solid Tumors

AI 简述这是一项II期试验，研究局部消融治疗联合系统治疗用于寡进展实体瘤，在美国开展。

?

适用疾病: Metastatic Head and Neck Cancer；Metastatic Malignant Solid Tumor；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06260033 / NCI-2023-11094

Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer

AI 简述这是一项II期试验，在美国研究立体定向放射治疗用于雌激素受体阳性转移性乳腺癌。

?

适用疾病: Stage IV Breast Cancer；Metastatic Breast Carcinoma；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06014658 / NCI-2024-00437

Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究MBRC-101用于晚期难治性实体瘤。

?

适用疾病: Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Hormone Receptor Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: mBrace Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06253130 / NCI-2024-03012

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究IMP1734用于晚期实体瘤。在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06249048 / NCI-2024-03569

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

AI 简述这是一项I/II期试验，研究STX-001瘤内注射单药或联合Pembrolizumab用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Strand Therapeutics Inc.

正在招募 Phase 2

NCI NCT06518057 / NCI-2024-05661

Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases from Breast Cancer or Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究海马保护性全脑脊髓放疗用于乳腺癌或非小细胞肺癌的软脑膜转移。在美国开展。

?

适用疾病: Stage IV Lung Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium

正在招募 Phase 1, Phase 2

NCI NCT06425926 / NCI-2024-05762

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究GIM-531单独或联合抗PD-1抗体用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Georgiamune Inc

正在招募 Phase 2

NCI NCT06525766 / NCI-2024-06184

Adaptive Therapy with Capecitabine for the Treatment of Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer

AI 简述这是一项II期试验，在美国开展，研究卡培他滨适应性治疗用于转移性雌激素受体阳性HER2阴性乳腺癌。

?

适用疾病: Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma；Metastatic Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Arizona

正在招募 Phase 1, Phase 2

NCI NCT06526819 / NCI-2024-06528

SMP-3124LP in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国开展，研究SMP-3124LP用于晚期实体瘤。

?

适用疾病: Recurrent Endometrial Serous Adenocarcinoma；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Sumitomo Pharma America, Inc.

正在招募 Phase 4

NCI NCT06169371 / NCI-2024-08089

Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)

AI 简述这是一项IV期试验，研究Abemaciclib剂量递增用于早期激素受体阳性、HER2阴性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Hormone Receptor Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: University of Illinois

正在招募 Phase 2

NCI NCT06635980 / NCI-2024-08356

Hypofractionated Radiotherapy Before or After Breast Surgery for the Treatment of Patients with Non-Metastatic Breast Cancer

AI 简述这是一项II期试验，在美国研究乳腺手术前或后大分割放疗用于非转移性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Arizona

正在招募 Phase 2

NCI NCT06444269 / NCI-2024-09045

Pre-operative Partial Breast Irradiation (SPBI) and Microbubble-Ultrasound for the Treatment and Imaging of Early Stage Hormone Receptor-Positive Breast Cancer, RAPS Trial

AI 简述这是一项II期试验，研究术前部分乳腺照射联合微泡超声用于早期激素受体阳性乳腺癌。

?

适用疾病: Stage IA Breast Cancer；Stage IIA Breast Cancer；HER2 Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: UT Southwestern/Simmons Cancer Center-Dallas

正在招募 Phase 2

NCI NCT05933395 / NCI-2024-09317

Fulvestrant and Neratinib, Alpelisib, Everolimus or Abemaciclib for the Treatment of Estrogen Receptor Positive HER2 Negative Metastatic or Locally Recurrent Breast Cancer Previously Treated with a CDK4/6 Inhibitor, GERTRUDE Trial

AI 简述这是一项II期试验，研究氟维司群联合靶向药物用于雌激素受体阳性HER2阴性转移性乳腺癌，在美国开展。

?

适用疾病: Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma；Locally Recurrent Breast Carcinoma
干预: 未列出
地点: United States
申办方: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06234098 / NCI-2024-10364

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

AI 简述这是一项1/2期试验，研究AT-1965用于晚期、难治或复发实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Alyssum Therapeutics

正在招募 Phase 2

NCI NCT06330064 / NCI-2025-00431

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

AI 简述这是一项II期试验，研究Ifinatamab deruxtecan用于复发或转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Bladder Urothelial Cancer；Metastatic Malignant Solid Tumor；Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1, Phase 2

NCI NCT06795412 / NCI-2025-01950

Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究PYX-201联合帕博利珠单抗用于晚期实体瘤。在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Pyxis Oncology, Inc

正在招募 Phase 2

NCI NCT06910761 / NCI-2025-02015

Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer

AI 简述这是一项II期试验，研究光子颅脊髓照射用于乳腺癌或非小细胞肺癌软脑膜转移。在美国开展。

?

适用疾病: Stage IV Lung Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: City of Hope Comprehensive Cancer Center

正在招募 Phase 2

NCI NCT06897488 / NCI-2025-02147

Radiation Therapy without Endocrine Therapy for Treatment in Older Patients with Stage IA-IB Estrogen Receptor Positive Breast Cancer, EMERALD Trial

AI 简述这是一项II期试验，研究仅放疗（无内分泌治疗）用于老年IA-IB期雌激素受体阳性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage IIA Breast Cancer；HER2 Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06695845 / NCI-2025-02546

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

AI 简述这是一项2期试验，研究Zanidatamab用于HER2表达肿瘤，在美国、韩国、西班牙等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Jazz Pharmaceuticals

正在招募 Phase 2

NCI NCT06764940 / NCI-2025-03673

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

AI 简述这是一项II期试验，研究Utidelone联合卡培他滨用于HER2阴性乳腺癌脑转移。

?

适用疾病: Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma；Metastatic Malignant Neoplasm in the Brain
干预: 未列出
地点: United States
申办方: Biostar Pharma, Inc.

正在招募 Phase 2

NCI NCT07158021 / NCI-2025-03933

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women with Breast Cancer, OFS Trial

AI 简述这是一项II期试验，在美国研究Leuprolide和Goserelin用于绝经前乳腺癌患者的卵巢功能抑制。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06956690 / NCI-2025-04298

A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors

AI 简述这是一项I/II期试验，在美国和澳大利亚研究ENV-501用于HER3表达实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Hummingbird Bioscience

正在招募 Phase 1, Phase 2

NCI NCT06943521 / NCI-2025-04636

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究MT-4561用于多种晚期实体瘤，在美国和日本开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tanabe Pharma America, Inc.

正在招募 Phase 2

NCI NCT06953089 / NCI-2025-05085

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

AI 简述这是一项II期试验，研究DB-1311联合BNT327或DB-1305用于晚期转移性实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: DualityBio Inc.

正在招募 Phase 1, Phase 2

NCI NCT06966453 / NCI-2025-05385

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

AI 简述这是一项I/II期试验，研究Disitamab Vedotin用于HER2表达的晚期乳腺癌。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Metastatic HER2-Low Breast Carcinoma
干预: 未列出
地点: United States
申办方: Pfizer Inc

正在招募 Phase 1, Phase 2

NCI NCT07070232 / NCI-2025-06009

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

AI 简述这是一项I/II期试验，研究BNT326联合BNT327用于晚期恶性实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: BioNTech SE

正在招募 Phase 2

NCI NCT07191717 / NCI-2025-06030

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients with Minimal Residual Disease, MIRI Trial

AI 简述这是一项II期试验，在美国等地研究Imlunestrant和Abemaciclib用于雌激素受体阳性乳腺癌微小残留病灶。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: UCLA / Jonsson Comprehensive Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT06907043 / NCI-2025-06439

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

AI 简述这是一项I/II期试验，研究PARP1抑制剂EIK1004用于晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Eikon Therapeutics

正在招募 Phase 1, Phase 2

NCI NCT06998407 / NCI-2025-06541

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究AVZO-023单药或联合AVZO-021用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Breast Cancer；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: Avenzo Therapeutics, Inc.

正在招募 Phase 1, Phase 2

NCI NCT07160725 / NCI-2025-08065

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，在美国研究BMS-986517用于晚期实体瘤和头颈部鳞状细胞癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募 Phase 2

NCI NCT07229417 / NCI-2025-08557

Ivonescimab for the Treatment of Metastatic Endocrine Refractory HR Positive HER2 negative or Triple Negative Invasive Lobular Breast Cancer, IvoLoC Trial

AI 简述这是一项II期试验，研究Ivonescimab用于转移性内分泌治疗耐药HR阳性/HER2阴性或三阴性浸润性小叶乳腺癌。

?

适用疾病: Stage IV Breast Cancer；Metastatic Hormone Receptor-Positive Invasive Breast Lobular Carcinoma；Refractory Estrogen Receptor-Positive Invasive Breast Lobular Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 2

NCI NCT06979596 / NCI-2025-08586

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

AI 简述这是一项II期试验，研究MK-5684用于高级别浆液性卵巢癌、腹膜癌、输卵管癌及III-IV期乳腺癌。

?

适用疾病: High Grade Ovarian Serous Adenocarcinoma；Primary Peritoneal High Grade Serous Adenocarcinoma；High Grade Fallopian Tube Serous Adenocarcinoma
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募 Phase 2

NCI NCT07071038 / NCI-2025-09080

Medication Switch versus Guideline-directed Intervention (Side Effect Management) in Reducing Side Effects of Aromatase Inhibitors in Estrogen Receptor Positive HER2 Negative Breast Ductal Carcinoma In Situ and Stage I-III Invasive Breast Cancer, SWIVEL Trial

AI 简述这是一项II期试验，比较换药与指南指导的干预用于减少芳香化酶抑制剂副作用，针对雌激素受体阳性HER2阴性乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07145255 / NCI-2026-00044

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

AI 简述这是一项I/II期试验，在美国研究ADC用于多种晚期难治实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: mBrace Therapeutics

正在招募 Phase 2

NCI NCT07460752 / NCI-2026-00968

Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients

AI 简述这是一项II期试验，评估戈舍瑞林醋酸酯不同部位注射用于局部晚期激素受体阳性乳腺癌的卵巢功能抑制。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募 Phase 2

NCI NCT07483307 / NCI-2026-02092

Neoadjuvant Endocrine Therapy to Improve Surgical Outcomes in Stage II-III ER+ HER2- Invasive Lobular Breast Cancer

AI 简述这是一项II期试验，研究新辅助内分泌治疗用于II-III期ER+ HER2-浸润性小叶乳腺癌。

?

适用疾病: Stage II Breast Cancer；Stage IIIA Breast Cancer；Estrogen Receptor-Positive Invasive Breast Lobular Carcinoma
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2

NCI NCT07287995 / NCI-2026-02678

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

AI 简述这是一项I/II期试验，研究ASP2998单用及联合标准疗法用于实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 1, Phase 2

NCI NCT07446855 / NCI-2026-03698

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

AI 简述这是一项1/2期试验，研究AZD4956单药或联合用药用于晚期/转移性HRD实体瘤，在美国等地开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: AstraZeneca Pharmaceuticals LP

正在招募 Phase 1, Phase 2

NCI NCT07488676 / NCI-2026-04341

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

AI 简述这是一项I/II期试验，研究ASP546C用于胃食管癌、胰腺癌或其他实体瘤，在美国和日本开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Astellas Pharma Global Development, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT01042379

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

AI 简述这是一项II期试验，在新辅助化疗背景下研究多种个体化药物用于乳腺癌。

?

适用疾病: Breast Neoplasms；Breast Cancer；Breast Tumors
干预: Standard Therapy，AMG 386 with or without Trastuzumab，AMG 479 (Ganitumab) plus Metformin，MK-2206 with or without Trastuzumab
地点: United States
申办方: QuantumLeap Healthcare Collaborative

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT02422641 / NCI-2015-01159

Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis

AI 简述这是一项II期试验，研究高剂量甲氨蝶呤用于乳腺癌伴脑膜转移。

?

适用疾病: Metastatic Breast Cancer；Leptomeningeal Disease；Hormone-Resistant Breast Cancer
干预: High-dose Methotrexate (8 gm/m2; HD-MTX)
地点: United States
申办方: Wake Forest University Health Sciences

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT02830724 / NCI-2018-03328

Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

AI 简述这是一项I/II期试验，在美国开展，研究Anti-hCD70 CAR转导淋巴细胞用于表达CD70的胰腺癌、肾癌、乳腺癌、黑色素瘤、卵巢癌。

?

适用疾病: Pancreatic Cancer；Renal Cell Cancer；Breast Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Anti-hCD70 CAR transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT03412877 / NCI-2018-03627

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

AI 简述这是一项II期试验，研究基因工程T细胞用于多种转移性癌症。

?

适用疾病: Endocrine Tumors；Non-Small Cell Lung Cancer；Ovarian Cancer
干预: Cyclophosphamide，Fludarabine，Aldesleukin，Individual Patient TCR-Transduced PBL
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT03424005 / NCI-2018-00650

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

AI 简述这是一项I/II期试验，研究卡培他滨、阿特珠单抗等联合用于转移性或局部晚期乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Capecitabine，Atezolizumab，Ipatasertib，SGN-LIV1A
地点: United States，Australia，France，Germany 等 5 个
申办方: Hoffmann-La Roche

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT03449238

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

AI 简述这是一项I/II期试验，研究Pembrolizumab联合立体定向放射手术用于乳腺癌脑转移。

?

适用疾病: Metastatic Breast Cancer；Brain Metastases
干预: Pembrolizumab
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT03591276

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

AI 简述这是一项I/II期试验，研究聚乙二醇脂质体多柔比星联合Pembrolizumab用于内分泌耐药乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Chemotherapy Drugs, Cancer
地点: Israel
申办方: Shaare Zedek Medical Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT03606967 / NCI-2018-01581

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究个体化疫苗联合Durvalumab、Tremelimumab和化疗用于转移性三阴性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Invasive Breast Carcinoma；Metastatic Triple-Negative Breast Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Carboplatin，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT03808337 / NCI-2019-00436

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

AI 简述这是一项II期试验，研究立体定向体部放疗联合标准治疗用于转移性实体瘤。在美国开展。

?

适用疾病: Triple Negative Breast Cancer；Non Small Cell Lung Cancer；Metastatic Breast Cancer
干预: Stereotactic Body Radiotherapy/SBRT，Systemic Therapy/Standard of Care
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03815890

Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO

AI 简述这是一项II期试验，研究纳武利尤单抗联合伊匹木单抗用于乳腺癌术前治疗。在荷兰开展。

?

适用疾病: Breast Cancer
干预: Nivolumab，Ipilimumab，Ipilimumab
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03915678

Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

AI 简述这是一项II期试验，研究Atezolizumab联合BDB001和放疗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Pancreatic Cancer；Virus-associated Tumors
干预: Association atezolizumab + BDB001 + RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001+ RT，Association atezolizumab + BDB001 + RT
地点: France
申办方: Institut Bergonié

正在招募 Phase 2 药物

ClinicalTrials.gov NCT03990896

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

AI 简述这是一项II期试验，研究Talazoparib用于BRCA突变的转移性乳腺癌。

?

适用疾病: Breast Cancer
干预: Talazoparib
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04090567 / NCI-2019-04148

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

AI 简述这是一项II期试验，研究Olaparib联合Cediranib或AZD6738用于晚期BRCA突变乳腺癌。

?

适用疾病: Advanced Breast Carcinoma；Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8
干预: Cediranib，Ceralasertib，Olaparib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04115306 / NCI-2020-01104

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

AI 简述这是一项I/II期试验，研究PMD-026联合氟维司群用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: PMD-026，fulvestrant
地点: United States
申办方: Phoenix Molecular Designs

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04159818

Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

AI 简述这是一项II期试验，在荷兰研究Nivolumab联合顺铂或低剂量阿霉素用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Nivolumab，Cisplatin，Low dose doxorubicin
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04230109 / NCI-2020-06537

Sacituzumab Govitecan In TNBC

AI 简述这是一项II期试验，研究Sacituzumab Govitecan用于三阴性乳腺癌。

?

适用疾病: Invasive Breast Cancer；Triple Negative Breast Cancer；ER-Negative Breast Cancer
干预: Sacituzumab Govitecan，Pembrolizumab
地点: United States
申办方: Massachusetts General Hospital

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04273061

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

AI 简述这是一项II期试验，研究阿替利珠单抗用于肿瘤DNA或RNA提示可能敏感的多种癌症。

?

适用疾病: Breast Cancer；Lung Cancer；Gastrointestinal Cancer
干预: Atezolizumab
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 1, Phase 2 联合产品药物

ClinicalTrials.gov / NCI NCT04333706 / NCI-2024-01735

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)

AI 简述这是一项I/II期试验，研究Sarilumab联合卡培他滨用于HER2阴性转移性乳腺癌及三阴性乳腺癌。

?

适用疾病: Breast；Metastatic；Triple Negative
干预: Capecitabine，Sarilumab 150mg or 200 mg plus Capecitabine，Sarilumab 150mg plus Capecitabine
地点: United States
申办方: University of Southern California

正在招募 Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04348747 / NCI-2020-01520

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

AI 简述这是一项II期试验，研究树突状细胞疫苗联合帕博利珠单抗用于三阴性或HER2+乳腺癌脑转移。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Malignant Neoplasm in the Brain；Metastatic Triple-Negative Breast Carcinoma
干预: Anti-HER2/HER3 Dendritic Cell Vaccine，Pembrolizumab
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04434040 / NCI-2020-06549

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

AI 简述这是一项II期试验，研究Atezolizumab联合Sacituzumab Govitecan用于三阴性乳腺癌。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer；Residual Cancer
干预: Atezolizumab，Sacituzumab govitecan
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04468061 / NCI-2020-06546

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

AI 简述这是一项II期试验，研究戈沙妥珠单抗单用或联合帕博利珠单抗用于转移性三阴性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer；PD-L1 Negative
干预: Sacituzumab Govitecan，Pembrolizumab
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT04529044 / NCI-2020-04795

177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer

AI 简述这是一项2期试验，研究177Lu-DOTATATE用于4期或复发乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Recurrent Breast Carcinoma
干预: Biopsy，Biospecimen Collection，Computed Tomography，Gallium Ga 68-DOTATATE
地点: United States
申办方: OHSU Knight Cancer Institute

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT04550494 / NCI-2020-06906

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

AI 简述这是一项II期试验，研究Talazoparib用于携带DNA修复变异的晚期癌症患者。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Castration-Resistant Prostate Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Computed Tomography，Magnetic Resonance Imaging
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov NCT04553770

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

AI 简述这是一项II期试验，研究Trastuzumab Deruxtecan单用或联合Anastrozole用于早期HER2低表达、激素受体阳性乳腺癌。

?

适用疾病: Early-stage Breast Cancer；Hormone Receptor Positive Breast Carcinoma；Invasive Breast Cancer
干预: Anastrozole，Therapeutic Conventional Surgery，Trastuzumab Deruxtecan
地点: United States
申办方: Jonsson Comprehensive Cancer Center

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04563507 / NCI-2021-01374

Combined Immunotherapies in Metastatic ER+ Breast Cancer

AI 简述这是一项II期试验，研究SBRT联合来曲唑和Palbociclib用于转移性ER+乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)，Letrozole 2.5Mg Tab，Palbociclib 125mg
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04585750

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

AI 简述这是一项I/II期试验，研究rezatapopt用于TP53 Y220C突变晚期实体瘤，在美澳法德开展。

?

适用疾病: Advanced Solid Tumor；Advanced Malignant Neoplasm；Metastatic Cancer
干预: rezatapopt，pembrolizumab
地点: United States，Australia，France，Germany 等 5 个
申办方: PMV Pharmaceuticals, Inc

正在招募 Phase 2 Dietary_Supplement药物其他

ClinicalTrials.gov / NCI NCT04677816 / NCI-2021-06483

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients

AI 简述这是一项II期试验，研究维生素D3补充用于维生素D缺乏的三阴性乳腺癌患者。

?

适用疾病: Triple Negative Breast Cancer；Vitamin D Deficiency；Invasive Breast Cancer
干预: Standard of Care Neoadjuvant Chemotherapy (NAC)，Vitamin D3，Drug Diary
地点: United States
申办方: Wake Forest University Health Sciences

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04683679 / NCI-2021-03576

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

AI 简述这是一项II期试验，研究放疗联合Pembrolizumab和Olaparib用于三阴性或激素受体阳性/HER2阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；TNBC - Triple-Negative Breast Cancer；Breast Cancer
干预: Pembrolizumab，Olaparib，Radiation
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04768426 / NCI-2021-01757

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究卡培他滨用于早期三阴性乳腺癌术后ctDNA监测。

?

适用疾病: Triple Negative Breast Cancer；Breast Cancer；Stage I Breast Cancer
干预: Capecitabine
地点: United States
申办方: Stanford University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04771520 / NCI-2021-00702

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

AI 简述这是一项II期试验，研究Avapritinib用于CKIT或PDGFRA突变阳性晚期实体瘤。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: Avapritinib
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04771871

MicroRNA Profiles in Triple Negative Breast Cancer

AI 简述这是一项II期试验，在尼日利亚开展，研究化疗药物用于三阴性乳腺癌的miRNA谱

?

适用疾病: Triple Negative Breast Cancer
干预: Epirubicin，Cyclophosphamide，Paclitaxel，Carboplatin
地点: Nigeria
申办方: University College Hospital, Ibadan

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT04787042 / NCI-2021-09248

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

AI 简述这是一项I/II期试验，研究ST-067用于实体瘤、黑色素瘤、肾细胞癌和三阴性乳腺癌，在美国开展。

?

适用疾病: Cancer；Solid Tumor；Melanoma
干预: ST-067，Obinutuzumab 25 MG/1 ML Intravenous Solution [GAZYVA]，pembrolizumab
地点: United States
申办方: Simcha IL-18, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT04802759 / NCI-2021-02649

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

AI 简述这是一项I/II期试验，研究Giredestrant联合Abemaciclib等多种组合用于ER阳性乳腺癌。

?

适用疾病: Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Giredestrant，Abemaciclib，Ipatasertib，Inavolisib
地点: United States，Australia，Israel，South Korea 等 1 个
申办方: Hoffmann-La Roche

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04819243

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

AI 简述这是一项II期试验，比较Palbociclib内分泌治疗加Talazoparib方案与Talazoparib-Atezolizumab方案用于HR+/HER2-乳腺癌。

?

适用疾病: Premenopausal HR+/HER2- Metastatic Breast Cancer
干预: Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib, Atezolizumab，Pabociclib, Endocrine(or ET + CDK4/6 inhibitors), Talazoparib,
地点: South Korea
申办方: Samsung Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04886531 / NCI-2023-01659

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

AI 简述这是一项II期试验，研究术前Neratinib联合内分泌治疗和Trastuzumab用于ER阳性、HER2阳性乳腺癌。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer；ER Positive Breast Cancer
干预: Neratinib，Letrozole (L) or Anastrozole (A)，Trastuzumab
地点: United States
申办方: Ruth O'Regan

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT04893109 / NCI-2021-06637

ATEMPT 2.0: Adjuvant T-DM1 vs TH

AI 简述这是一项II期试验，比较辅助T-DM1与TH方案用于HER2阳性早期乳腺癌。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer；Stage I Breast Cancer
干预: trastuzumab-emtansine，Trastuzumab SC，Paclitaxel
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04895709

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986340单药或联合治疗用于晚期实体瘤，包括宫颈癌、肺癌等。

?

适用疾病: Cervical Cancer；Gastric/Gastroesophageal Junction Adenocarcinoma；Microsatellite Stable Colorectal Cancer
干预: BMS-986340，BMS-936558-01，Docetaxel，Pumitamig
地点: United States，Australia，Canada，Germany 等 4 个
申办方: Bristol-Myers Squibb

正在招募 Phase 2 药物其他放疗

ClinicalTrials.gov / NCI NCT04899908 / NCI-2021-09443

Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

AI 简述这是一项II期试验，研究立体定向脑部放疗联合AGuIX钆基纳米颗粒用于脑转移瘤，来自肺癌、乳腺癌、黑色素瘤等。

?

适用疾病: Brain Cancer；Brain Metastases；Melanoma
干预: Stereotactic Radiation，AGuIX gadolinium-based nanoparticles，Placebo
地点: United States
申办方: Brigham and Women's Hospital

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT04923542 / NCI-2021-08582

Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases

AI 简述这是一项I/II期试验，研究立体定向放疗联合Abemaciclib用于HR+/HER2-乳腺癌脑转移，在美国开展。

?

适用疾病: Brain Metastases；HR+ Metastatic Breast Cancer；Stage IV Breast Cancer
干预: Stereotactic Radiosurgery (SRS)，Abemaciclib，Endocrine therapy
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT04947189

Seviteronel in Combination With Chemotherapy in Androgen-receptor Positive Metastatic Triple-negative Breast Cancer

AI 简述这是一项1/2期试验，研究Seviteronel联合化疗用于雄激素受体阳性转移性三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: Seviteronel-D (Seivteronel in combination with dexamethasone)，Docetaxel
地点: Australia
申办方: St Vincent's Hospital, Sydney

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04965064

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

AI 简述这是一项II期试验，研究Neratinib联合卡培他滨用于HER2阴性乳腺癌脑转移且HER2信号异常活跃，在美国开展。

?

适用疾病: Breast Cancer
干预: Capecitabine and Neratinib.
地点: United States
申办方: University of Rochester

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04965766

Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Patritumab Deruxtecan用于不可切除局部晚期或转移性乳腺癌，在法国开展。

?

适用疾病: Metastatic Breast Cancer；Advanced Breast Cancer
干预: U3-1402
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 2 药物

ClinicalTrials.gov NCT04985266

A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

AI 简述这是一项II期试验，研究Palbociclib联合Fulvestrant用于ER阳性HER2阴性乳腺癌。

?

适用疾病: ER+ Breast Cancer；HER2-negative Breast Cancer
干预: Palbociclib 125Mg Tab，Fulvestrant injection，Tamoxifen，Letrozole
地点: France，United Kingdom
申办方: Royal Marsden NHS Foundation Trust

正在招募 Phase 2 联合产品

ClinicalTrials.gov NCT04990921

Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer

AI 简述这是一项II期试验，研究姑息放疗联合Pembrolizumab用于IV期不可切除转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Palliative Radiation and Pembrolizumab
地点: United States
申办方: University of Louisville

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT04993014

Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer

AI 简述这是一项II期试验，根据循环肿瘤细胞指导HER2阳性乳腺癌新辅助治疗后降阶梯治疗，在巴西开展。

?

适用疾病: Breast Neoplasms；HER2-positive Breast Cancer；Circulating Tumor Cell
干预: Pertuzumab，Trastuzumab，Circulating tumor cells
地点: Brazil
申办方: AC Camargo Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05020860 / NCI-2023-04794

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

AI 简述这是一项II期试验，研究紫杉醇、卡铂、曲妥珠单抗和帕妥珠单抗用于早期乳腺癌的临床与病理反应相关性。

?

适用疾病: Breast Cancer；Breast Neoplasm；Breast Cancer Female
干预: Paclitaxel，Carboplatin，Trastuzumab，Pertuzumab
地点: United States
申办方: Baylor Breast Care Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05035745

Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)

AI 简述这是一项I/II期试验，研究Selinexor联合Talazoparib用于晚期难治性实体瘤和三阴性乳腺癌。

?

适用疾病: Advanced Refractory Solid Tumors；Advanced Triple Negative Breast Cancers；Metastatic Triple Negative Breast Cancers
干预: Talazoparib，Selinexor
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05035836 / NCI-2021-09420

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

AI 简述这是一项II期试验，研究Zanidatamab用于早期HER2阳性乳腺癌。

?

适用疾病: Breast Cancer；HER2-positive；Stage I Breast Cancer
干预: Zanidatamab，Letrozole，Tamoxifen
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05086692 / NCI-2022-02678

A Beta-only IL-2 ImmunoTherapY Study

AI 简述这是一项I/II期试验，研究MDNA11联合Pembrolizumab用于晚期实体瘤，在美、澳、加、爱等地开展。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Clear Cell Renal Cell Carcinoma
干预: MDNA11，Pembrolizumab (KEYTRUDA®)
地点: United States，Australia，Canada，Ireland 等 3 个
申办方: Medicenna Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05095207 / NCI-2021-09617

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

AI 简述这是一项I/II期试验，研究Abemaciclib联合比卡鲁胺用于雄激素受体阳性、HER2阴性转移性乳腺癌。

?

适用疾病: Breast Cancer；Metastasis；Stage III Breast Cancer
干预: Abemaciclib，Bicalutamide
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05181033

Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor

AI 简述这是一项II期试验，比较Lenvatinib+Letrozole与Fulvestrant用于转移性ER+/HER2-乳腺癌患者，在新加坡开展。

?

适用疾病: Breast Cancer
干预: Lenvatinib + Letrozole，Fulvestrant
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05183126

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer

AI 简述这是一项IV期试验，研究基于骨骼肌面积的紫杉醇输注药代动力学，用于乳腺癌、转移性胃癌、食管癌患者，在美国开展。

?

适用疾病: Breast Cancer；Metastatic Gastric Cancer；Esophageal Cancer
干预: Paclitaxel，Paclitaxel
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05190094

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

AI 简述这是一项II期试验，研究Palbociclib联合来曲唑或阿那曲唑用于HR阳性HER2阴性晚期乳腺癌。

?

适用疾病: Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
干预: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
地点: Algeria，Jordan，Saudi Arabia
申办方: International Cancer Research Group, United Arab Emirates

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05215106

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)

AI 简述这是一项II期试验，在法国研究Durvalumab用于早期小三阴性乳腺癌的术前治疗。

?

适用疾病: Early Small (cT1N0) Triple Negative Breast Cancer
干预: Durvalumab
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05256745

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer

AI 简述这是一项I/II期试验，研究RAGE抑制剂TTP488用于减少早期乳腺癌患者的心脏毒性。

?

适用疾病: Cancer Related Cognitive Decline；Non-metastatic Breast Cancer
干预: TTP488，ddAC/ddT，TC，TCHP
地点: United States
申办方: Georgetown University

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05269381 / NCI-2022-01258

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究新抗原肽疫苗联合Pembrolizumab用于晚期实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Anatomic Stage IIIB Breast Cancer AJCC v8
干预: Cyclophosphamide，Neoantigen Peptide Vaccine，Pembrolizumab，Sargramostim
地点: United States
申办方: Mayo Clinic

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05286437

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole

AI 简述这是一项II期试验，研究Lenvatinib联合Pembrolizumab和Letrozole用于内分泌耐药乳腺癌。

?

适用疾病: Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
干预: Oral Lenvatinib + Intravenous (IV) Pembrolizumab + Oral Letrozole
地点: Singapore
申办方: National Cancer Centre, Singapore

正在招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT05296564

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

AI 简述这是一项I/II期试验，研究HBI 0201-ESO TCRT联合环磷酰胺和氟达拉滨用于NY-ESO-1阳性转移性癌症，在以色列开展。

?

适用疾病: Sarcoma, Synovial；Sarcoma,Soft Tissue；Melanoma Stage IV
干预: CYCLOPHOSPHAMIDE and FLUDARABIN，Cyclophosphamide，HBI 0201-ESO TCRT，Aldesleukin
地点: Israel
申办方: Hadassah Medical Organization

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05297617

Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

AI 简述这是一项II期试验，研究抗芳香化酶抑制剂减量用于低危HR+ HER2-乳腺癌，在法国开展。

?

适用疾病: Breast Cancer
干预: Anti-aromatase inhibitor
地点: France
申办方: UNICANCER

正在招募 Phase 2 其他手术/操作放疗

ClinicalTrials.gov NCT05301881

COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study

AI 简述这是一项2期试验，研究局部消融后继续系统治疗用于寡进展转移性乳腺癌。在荷兰等地开展。

?

适用疾病: Breast Cancer Invasive；Metastatic Cancer；Oligoprogressive
干预: Surgery，Radiotherapy，Radiofrequent ablation
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05305924

Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

AI 简述这是一项2期试验，研究Fulvestrant导入期后联合Abemaciclib用于ER阳性HER2阴性转移性乳腺癌。在美国开展。

?

适用疾病: ER-Positive Breast Cancer；HER2-negative Breast Cancer
干预: Fulvestrant Run-In
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05306041

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

AI 简述这是一项2期试验，研究新辅助内分泌治疗加或不加Inavolisib用于HER2阳性HR阳性PIK3CA突变早期乳腺癌。在德国、意大利等地开展。

?

适用疾病: HER2-positive Breast Cancer
干预: Inavolisib，PHESGO，Endocrine therapy
地点: Germany，Italy
申办方: GBG Forschungs GmbH

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05318469

Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

AI 简述这是一项I/II期试验，研究Ivermectin联合Balstilimab或Pembrolizumab用于转移性三阴性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Triple-Negative Breast Carcinoma
干预: Ivermectin，Balstilmab，Pembrolizumab
地点: United States
申办方: Yuan Yuan

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05325632 / NCI-2022-03214

Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab

AI 简述这是一项II期试验，研究HER2靶向树突状细胞疫苗联合紫杉醇、曲妥珠单抗和帕妥珠单抗用于HER2阳性乳腺癌。

?

适用疾病: HER2-positive Breast Cancer；Stage I Breast Cancer；Stage II Breast Cancer
干预: HER-2 pulsed DC1，Trastuzumab，Pertuzumab，Paclitaxel
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1, Phase 2 生物制剂器械

ClinicalTrials.gov NCT05329532

Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer

AI 简述这是一项1/2期试验，研究Modi-1 Moditope联合帕博利珠单抗用于乳腺癌、头颈癌、卵巢癌或肾癌，在英国开展。

?

适用疾病: Triple Negative Breast Cancer；Renal Cell Cancer；High Grade Ovarian Serous Adenocarcinoma
干预: Modi-1 Moditope，Pembrolizumab，MicronJet600™ microneedle device (NanoPass)
地点: United Kingdom
申办方: Scancell Ltd

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05333328

OFS in Premenopausal Node+ Breast Cancer With Low Genomic Risk

AI 简述这是一项IV期试验，研究卵巢功能抑制联合内分泌治疗用于低基因组风险、淋巴结阳性、早期乳腺癌患者。在韩国开展。

?

适用疾病: Breast Cancer；Estrogen Receptor Positive Tumor；HER2-negative Breast Cancer
干预: Ovarian function suppression with endocrine treatments
地点: South Korea
申办方: Gangnam Severance Hospital

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05362760

Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management

AI 简述这是一项IV期试验，研究Abemaciclib联合内分泌治疗用于HR阳性HER2阴性晚期乳腺癌，在德国、瑞士开展。

?

适用疾病: Hormone Receptor-positive Metastatic Breast Cancer；HER2-negative Metastatic Breast Cancer
干预: Abemaciclib + Aromatase Inhibitor，Abemaciclib + Fulvestrant
地点: Germany，Switzerland
申办方: Prof. Wolfgang Janni

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05377996

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

AI 简述这是一项I/II期试验，研究Emiltatug Ledadotin（Emi-Le）用于实体瘤。

?

适用疾病: Triple Negative Breast Cancer；Breast Cancer；Endometrial Cancer
干预: Emi-Le
地点: United States
申办方: Day One Biopharmaceuticals, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05386108 / NCI-2023-00376

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

AI 简述这是一项I/II期试验，研究Abemaciclib和Elacestrant用于ER+/HER2-乳腺癌脑转移患者。

?

适用疾病: Breast Neoplasms；Brain Neoplasms；Neoplasms by Site
干预: Elacestrant，Abemaciclib
地点: United States，Belgium，France，Germany 等 6 个
申办方: Stemline Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05388149

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

AI 简述这是一项II期试验，研究Kadcyla和Neratinib用于HER2+乳腺癌分子残留病灶。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer
干预: Neratinib
地点: Canada
申办方: University Health Network, Toronto

正在招募 Phase 4 药物

ClinicalTrials.gov NCT05452213

Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

AI 简述这是一项IV期试验，分析Ribociclib在晚期乳腺癌中的疗效和耐药模式。

?

适用疾病: Breast Cancer；Breast Neoplasms；Breast Neoplasm Female
干预: Ribociclib
地点: Germany
申办方: Institut fuer Frauengesundheit

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05455619 / NCI-2023-05450

Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

AI 简述这是一项I/II期试验，研究Evexomostat联合PI3K或AKT抑制剂及fulvestrant用于HR+/HER2-乳腺癌。

?

适用疾病: HR+/HER2-negative Breast Cancer；Metastatic Breast Cancer；Stage III Breast Cancer
干预: Evexomostat
地点: United States
申办方: SynDevRx, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05458674 / NCI-2022-10204

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

AI 简述这是一项II期试验，研究Tucatinib联合Trastuzumab、Eribulin用于HER2阳性转移性乳腺癌。

?

适用疾病: Breast Cancer；Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Cancer；Stage III Breast Cancer
干预: Tucatinib，Eribulin，Trastuzumab
地点: United States
申办方: Criterium, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05467891 / NCI-2022-11057

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

AI 简述这是一项II期试验，研究Ribociclib联合医生选择的内分泌治疗用于局部区域复发、已切除的HR+、HER2-乳腺癌。

?

适用疾病: Locoregional Recurrence；Hormone Receptor-positive Breast Cancer；HER2-negative Breast Cancer
干预: Ribociclib，Fulvestrant，Anastrozole，Letrozole
地点: United States
申办方: Oana Danciu

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT05485766

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

AI 简述这是一项II期试验，在BRCA1/2突变三阴性乳腺癌中探索新辅助和辅助治疗策略。

?

适用疾病: Triple Negative Breast Neoplasms；Triple Negative Breast Cancer；Breast Neoplasms
干预: Pembrolizumab，Paclitaxel，Carboplatin，Olaparib
地点: Japan
申办方: Okayama University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05491083

Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer

AI 简述这是一项I/II期试验，研究Pembrolizumab联合ADG106用于晚期实体瘤和三阴性乳腺癌。

?

适用疾病: Advanced Solid Tumor；Triple Negative Breast Cancer
干预: Pembrolizumab & ADG106 (Phase Ib)，Pembrolizumab & ADG106 (Phase II)
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05491226

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation

AI 简述这是一项II期试验，研究Pembrolizumab联合放疗和Axatilimab用于三阴性乳腺癌。

?

适用疾病: TNBC - Triple-Negative Breast Cancer；Breast Cancer
干预: Pembrolizumab，Radiation Therapy，Axatilimab
地点: United States
申办方: Stephen Shiao

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05524584 / NCI-2022-07533

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

AI 简述这是一项II期试验，研究阿那曲唑、氟维司群和阿贝西利用于HR+HER2-转移性乳腺癌。

?

适用疾病: Breast Cancer；Metastatic Breast Cancer；Hormone Receptor-positive Breast Cancer
干预: Fulvestrant，Anastrozole，Abemaciclib
地点: United States
申办方: University of California, Irvine

正在招募 Phase 2 放疗

ClinicalTrials.gov / NCI NCT05528133 / NCI-2022-09416

Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究基因组引导的放疗用于三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Triple-Negative Breast Cancer
干预: Genomically Guided Radiation Therapy
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05530057

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer

AI 简述这是一项II期试验，比较Eribulin联合或不联合Samfenet用于HER2阳性晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer
干预: Eribulin Mesylate + Samfenet (Trastruzumab-biosimilar)，Eribulin Mesylate
地点: South Korea
申办方: Seoul National University Hospital

正在招募 Phase 2 放疗

ClinicalTrials.gov / NCI NCT05534438 / NCI-2022-07734

A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer

AI 简述这是一项II期试验，研究立体定向放射治疗联合药物治疗用于乳腺癌。

?

适用疾病: Oligometastatic Breast Carcinoma；Breast Cancer；Metastatic Breast Cancer
干预: Stereotactic body radiotherapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05550415

The Role of Simvastatin in the Epithelial-Mesenchymal Transition Process of Breast Cancer

AI 简述一项II期试验，研究Simvastatin在三阴性乳腺癌上皮间质转化中的作用（印尼）。

?

适用疾病: Triple Negative Breast Cancer；Chemotherapy Effect；Simvastatin Adverse Reaction
干预: Simvastatin 40mg，Placebo
地点: Indonesia
申办方: Indonesia University

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT05570253 / NCI-2022-08559

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

AI 简述这是一项II期试验，研究SDX-7320联合艾立布林用于乳腺癌。

?

适用疾病: Breast Cancer；Metastatic Triple-Negative Breast Cancer；Stage III Breast Cancer
干预: Eribulin，SDX-7320，Placebo
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05573126 / NCI-2023-07430

Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

AI 简述这是一项1/2期试验，研究EP0062单药或联合用于晚期ER+/HER2-乳腺癌。

?

适用疾病: Hormone Receptor-positive Breast Cancer；Hormone Receptor Positive HER-2 Negative Breast Cancer；Metastatic Breast Cancer
干预: EP0062，Elacestrant，Everolimus，Abemaciclib
地点: United States，Spain，United Kingdom
申办方: Ellipses Pharma

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05582538

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel

AI 简述这是一项II期试验，研究Ceralasertib联合Durvalumab和Nab-paclitaxel用于转移性三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer Metastatic
干预: Ceralasertib，Durvalumab，Nab-paclitaxel
地点: Italy
申办方: IFOM ETS - The AIRC Institute of Molecular Oncology

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT05601440

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

AI 简述这是一项II期试验，基于液体活检评估CDK4/6抑制剂耐药ER+/HER2-转移性乳腺癌。

?

适用疾病: Breast Cancer
干预: RP-6306，Gemcitabine，Observation，Niraparib
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05608252 / NCI-2023-00073

VS-6766+Abema+Fulv in Met HR+/HER- BC

AI 简述这是一项I/II期试验，研究VS-6766联合阿贝西利和氟维司群用于HR+/HER2-乳腺癌。

?

适用疾病: Breast Cancer；Hormone Receptor-positive Breast Cancer；Hormone Receptor Positive HER-2 Negative Breast Cancer
干预: VS-6766，Abemaciclib，Fulvestrant
地点: United States
申办方: Adrienne G. Waks

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05660083 / NCI-2025-05690

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

AI 简述这是一项II期试验，研究Alpelisib联合L-NMMA和纳米紫杉醇用于HER2阴性化生性乳腺癌。

?

适用疾病: HER2-negative Breast Cancer；Metastatic Breast Cancer；Metaplastic Breast Carcinoma
干预: L-NMMA
地点: United States
申办方: The Methodist Hospital Research Institute

正在招募 Phase 2 药物其他

ClinicalTrials.gov / NCI NCT05693766 / NCI-2023-01817

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort

AI 简述这是一项II期试验，通过基因标志物指导HR+/HER2-转移性乳腺癌治疗，在美国开展。

?

适用疾病: Invasive Mammary Carcinoma；Metastatic Breast Cancer；Stage IV Breast Cancer
干预: Capecitabine，Endocrine-therapy，MammoPrint ® and BluePrint assays
地点: United States
申办方: Sonya Reid

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05704829

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

AI 简述这是一项II期试验，比较Trastuzumab deruxtecan与化疗联合Trastuzumab、Pertuzumab用于HER2阳性早期乳腺癌。

?

适用疾病: HER2-positive Early Breast Cancer
干预: Trastuzumab deruxtecan，Standard-of-Care
地点: Germany
申办方: West German Study Group

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05706129

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究[68Ga]Ga-DPI-4452和[177Lu]Lu-DPI-4452用于多种晚期实体瘤。在澳大利亚、法国等地开展。

?

适用疾病: Clear Cell Renal Cell Cancer (ccRCC)；Pancreatic Ductal Adenocarcinoma (PDAC)；Colorectal Cancer (CRC)
干预: [68Ga]Ga-DPI-4452，[177Lu]Lu-DPI-4452
地点: Australia，France
申办方: ITM Oncologics GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05708235

A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population

AI 简述这是一项II期试验，研究Giredestrant、Abemaciclib、Inavolisib用于HR阳性/HER2阴性早期乳腺癌。

?

适用疾病: Breast Cancer
干预: Giredestrant，Abemaciclib，Inavolisib
地点: Spain，United Kingdom
申办方: MedSIR

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05716516 / NCI-2023-05453

STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)

AI 简述这是一项II期试验，在美国研究Estradiol用于ER阳性晚期乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Estradiol
地点: United States
申办方: Dartmouth-Hitchcock Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05720260

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

AI 简述这是一项II期试验，在台湾研究免疫治疗、激素治疗和AKT抑制剂用于绝经前ER阳性转移性乳腺癌。

?

适用疾病: Premenopausal Breast Cancer；Metastatic Breast Cancer；ER Positive Breast Cancer
干预: Goserelin，Fulvestrant，Capivasertib，Durvalumab
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05735080 / NCI-2023-04176

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

AI 简述这是一项1/2期试验，研究INX-315用于晚期乳腺癌和卵巢癌等，在美国和澳大利亚开展。

?

适用疾病: Breast Cancer；Breast Cancer Metastatic；Hormone Receptor Positive Tumor
干预: INX-315，Fulvestrant，Abemaciclib
地点: United States，Australia
申办方: Incyclix Bio

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05748834

Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Tucatinib联合Doxil用于HER2阳性转移性乳腺癌。

?

适用疾病: Breast Cancer
干预: Tucatinib，Doxil
地点: United States
申办方: SCRI Development Innovations, LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05768139 / NCI-2023-02413

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

AI 简述这是一项1/2期试验，研究Tersolisib单用或联用其他药物用于晚期实体瘤，在美国、比利时、法国、德国等地开展。

?

适用疾病: Breast Cancer；Solid Tumors, Adult；Metastatic Malignant Solid Tumor
干预: STX-478，Fulvestrant，Ribociclib，Palbociclib
地点: United States，Belgium，France，Germany 等 5 个
申办方: Eli Lilly and Company

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05795101 / NCI-2023-03834

TRUDI: TDXD+Durva in HER2+/Low IBC

AI 简述这是一项II期试验，研究Trastuzumab deruxtecan联合Durvalumab用于HER2阳性或低表达乳腺癌。

?

适用疾病: Invasive Breast Cancer；Inflammatory Breast Cancer Stage III；HER2-positive Breast Cancer
干预: Trastuzumab deruxtecan，Durvalumab
地点: United States
申办方: Filipa Lynce, MD

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05800275

Capecitabine, Tucatinib, and Intrathecal Trastuzumab for Breast Cancer Patients With Leptomeningeal Disease

AI 简述这是一项II期试验，研究卡培他滨、Tucatinib和鞘内曲妥珠单抗用于HER2阳性乳腺癌脑膜转移，在法国开展。

?

适用疾病: Leptomeningeal Metastasis；Leptomeningeal Disease；HER2-positive Metastatic Breast Cancer
干预: Tucatinib Oral Tablet，Capecitabine tablets，Trastuzumab Injection
地点: France
申办方: UNICANCER

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05816655

Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

AI 简述这是一项II期试验，比较Letrozole+Ribociclib与Fulvestrant+Letrozole+Ribociclib用于激素受体阳性HER2阴性转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Fulvestrant plus AI plus ribociclib，AI plus ribociclib
地点: South Korea
申办方: Korea University Guro Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05824975

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

AI 简述这是一项I/II期试验，研究GI-102单药或联合其他药物用于晚期实体瘤。在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Soft Tissue Sarcoma (STS)
干预: GI-102 subcutaneous (SC)，GI-102，doxorubicin，paclitaxel
地点: United States，South Korea
申办方: GI Innovation, Inc.

正在招募 Phase 2 器械药物

ClinicalTrials.gov / NCI NCT05837455 / NCI-2023-05555

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer

AI 简述这是一项II期试验，研究生物标志物指导的新辅助治疗用于II/III期ER阳性HER2阴性乳腺癌。

?

适用疾病: Breast Cancer；Cancer of the Breast；Stage II Breast Cancer
干预: VENTANA MIB-1 Ki67 assay，Oncotype DX® Recurrence Score，PAM50-based Prosigna breast cancer gene signature assay，Anastrozole
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT05846789 / NCI-2023-10636

SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers

AI 简述这是一项II期试验，在美国开展，研究标准化学治疗联合或未联合托珠单抗用于三阴性及ER低表达乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Triple Negative Breast Cancer；Estrogen-receptor-low Breast Cancer
干预: SOC Chemotherapy，Tocilizumab
地点: United States
申办方: Kathy Miller

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05866432

Phase II Study of Dato-DXd in Triple-negative Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases

AI 简述这是一项II期试验，研究Dato-DXd用于三阴性乳腺癌伴新发或进展性脑转移。

?

适用疾病: Breast Cancer Stage IV
干预: Datopotamab deruxtecan
地点: Austria
申办方: Medical University of Vienna

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05867251 / NCI-2023-06475

Study of AVZO-021 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究AVZO-021单药或联合用药用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor；HR+/HER2- Breast Cancer；HR+, HER2-, Advanced Breast Cancer
干预: AVZO-021，Palbociclib，Fulvestrant，Letrozole
地点: United States，Australia
申办方: Avenzo Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05900206

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

AI 简述这是一项II期试验，比较Trastuzumab deruxtecan与标准新辅助治疗用于HER2阳性乳腺癌，在瑞典开展。

?

适用疾病: Breast Cancer
干预: Trastuzumab deruxtecan，Docetaxel，Paclitaxel，Carboplatin
地点: Sweden
申办方: Karolinska University Hospital

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05902988 / NCI-2023-08591

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

AI 简述这是一项I/II期试验，研究VLS-1488用于晚期实体瘤，包括卵巢癌、肺癌、乳腺癌等，在美国开展。

?

适用疾病: Advanced Solid Tumor；High Grade Serous Adenocarcinoma of Ovary；Squamous Non-small-cell Lung Cancer
干预: VLS-1488
地点: United States
申办方: Volastra Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05955170

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer

AI 简述这是一项II期试验，研究Tucatinib联合口服依托泊苷和Trastuzumab用于转移性HER2+乳腺癌。

?

适用疾病: HER2-positive Breast Cancer
干预: Tucatinib in Combination of Oral VP16 and trastuzumab
地点: France
申办方: Institut Curie

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT05973864

Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

AI 简述这是一项II期试验，研究卡培他滨联合Pembrolizumab用于三阴性乳腺癌化疗免疫治疗和手术后，在法国开展。

?

适用疾病: Triple Negative Breast Neoplasms
干预: Pembrolizumab injection，Capecitabine tablets，Local radiotherapy
地点: France
申办方: UNICANCER

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05982093

Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

AI 简述这是一项II期试验，研究Elacestrant联合或未联合Triptorelin用于绝经前Luminal型乳腺癌，在西班牙开展。

?

适用疾病: Breast Cancer；HER2-negative Breast Cancer；Hormone Receptor Positive Tumor
干预: Elacestrant，Triptorelin，Tamoxifen 20 mg
地点: Spain
申办方: SOLTI Breast Cancer Research Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05982678

Basket Study for Oligo-metastatic Breast Cancer

AI 简述这是一项II期试验，研究Trastuzumab deruxtecan用于HER2阳性寡转移性乳腺癌，在荷兰开展。

?

适用疾病: HER2-positive Breast Cancer
干预: Trastuzumab deruxtecan
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT05985655 / NCI-2026-01491

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GTAEXS617用于多种晚期实体瘤。

?

适用疾病: Head and Neck Squamous Cell Carcinoma (HNSCC)；Pancreatic Adenocarcinoma；Non-small Cell Lung Cancer (NSCLC)
干预: GTAEXS617，SoC
地点: United States，Belgium，United Kingdom
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT06016387

Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

AI 简述这是一项II期试验，在加拿大研究Tucatinib、曲妥珠单抗和卡培他滨联合脑及脊柱放疗用于HER2阳性乳腺癌伴脑膜转移。

?

适用疾病: HER2-positive Breast Cancer；LMD
干预: Tucatinib 150 MG，Trastuzumab，Capecitabine，Brain & Spinal Radiation
地点: Canada
申办方: Sunnybrook Health Sciences Centre

正在招募 Phase 1, Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT06026657 / NCI-2023-06508

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

AI 简述这是一项I/II期试验，研究吉西他滨和NK细胞联合或不联合Naxitamab用于转移性HER2阴性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；HER2-Negative Breast Carcinoma；Stage IV Breast Cancer
干预: Biospecimen Collection，Computed Tomography，Gemcitabine，Magnetic Resonance Imaging
地点: United States
申办方: Margaret Gatti-Mays

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06062498 / NCI-2023-07168

Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

AI 简述这是一项2期试验，比较艾拉司群单药与联合CDK4/6抑制剂用于ER+/HER2-晚期或转移性乳腺癌。

?

适用疾病: Estrogen-receptor-positive Breast Cancer；HER2/Neu-Negative Breast Cancer；Advanced Breast Cancerv
干预: elacestrant, palbociclib, abemaciclib, ribociclib
地点: United States
申办方: Northwestern University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06078384

Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC

AI 简述这是一项II期试验，研究根据肿瘤浸润淋巴细胞水平决定的Pembrolizumab和化疗用于早期三阴性乳腺癌。

?

适用疾病: Triple-negative Breast Cancer
干预: Pembrolizumab 25 mg/ml，Paclitaxel injection
地点: France，Spain
申办方: UNICANCER

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06099769 / NCI-2023-09254

A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

AI 简述这是一项II期试验，在美国比较Enzalutamide单用或联合Mifepristone与化疗用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Enzalutamide，Mifepristone，TPC
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06105684 / NCI-2025-02749

Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer

AI 简述这是一项II期试验，研究低剂量卡培他滨用于晚期乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Capecitabine Pill
地点: United States
申办方: University of Alabama at Birmingham

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06110793 / NCI-2023-11123

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

AI 简述这是一项I/II期试验，研究Lenvatinib、Pembrolizumab和Fulvestrant用于乳腺癌。在美国开展。

?

适用疾病: Metastatic Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Lenvatinib，Pembrolizuma，Fulvestrant
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06134375 / NCI-2025-05879

A Study of Tetrathiomolybdate (TM) Plus Capecitabine

AI 简述这是一项I/II期试验，研究Tetrathiomolybdate联合Capecitabine用于三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Residual Disease；Triple-Negative Breast Cancer
干预: Tetrathiomolybdate，Capecitabine，Pembrolizumab
地点: United States
申办方: Dartmouth-Hitchcock Medical Center

正在招募 Phase 2 放疗

ClinicalTrials.gov NCT06165419

Definitive Radiation for High-Risk Spine Metastases

AI 简述这是一项II期试验，研究脊柱立体定向放疗用于高风险脊柱转移瘤。

?

适用疾病: Metastatic Cancer；Metastatic Lung Cancer；Metastatic Breast Cancer
干预: SBRT to the spine
地点: United States
申办方: Stony Brook University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06176261 / NCI-2023-11062

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

AI 简述这是一项II期试验，研究Datopotamab Deruxtecan用于乳腺癌脑转移。

?

适用疾病: Breast Cancer；Breast Cancer Female；Metastatic Triple-Negative Breast Carcinoma
干预: Datopotamab Deruxtecan
地点: United States
申办方: Sarah Sammons, MD

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT06179303 / NCI-2022-06409

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

AI 简述这是一项II期试验，研究Abemaciclib用于晚期激素受体阳性HER2阴性乳腺癌。在美国开展。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Locally Advanced Unresectable HER2-Negative Breast Carcinoma
干预: Abemaciclib，Anastrozole，Biospecimen Collection，Computed Tomography
地点: United States
申办方: University of Washington

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06188520

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，在美国、澳大利亚、韩国、西班牙等地开展，研究AZD8421单药或联合用于ER+ HER2-晚期乳腺癌或高级别浆液性卵巢癌。

?

适用疾病: ER+ HER2- Advanced Breast Cancer；High-grade Serous Ovarian Cancer (HGSOC)
干预: AZD8421，Camizestrant，Ribociclib，Palbociclib
地点: United States，Australia，South Korea，Spain 等 1 个
申办方: AstraZeneca

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06189209

Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

AI 简述这是一项II期试验，在印度开展，研究Tenalisib用于转移性三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer (TNBC)
干预: Tenalisib
地点: India
申办方: Rhizen Pharmaceuticals SA

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06193525

FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test

AI 简述这是一项II期试验，研究Talazoparib用于晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer
干预: Talazoparib
地点: Netherlands
申办方: Erasmus Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06201234

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

AI 简述这是一项II期试验，在德国研究Elacestrant聯合Olaparib用于晚期HR+/HER2-乳腺癌。

?

适用疾病: Hormone Receptor Positive HER-2 Negative Breast Cancer；Advanced or Metastatic Breast Cancer；BRCA1 Mutation
干预: Olaparib + Elacestrant，Olaparib
地点: Germany
申办方: GBG Forschungs GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06207734

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

AI 简述这是一项2期试验，在德国研究转移性HR阳性、HER2阴性乳腺癌患者停用CDK4/6抑制剂Palbociclib的效果。

?

适用疾病: Breast Cancer
干预: Continuation of CDK4/6 inhibitor Palbociclib，Discontinuation of CDK4/6 inhibitor Palbociclib，Continuation of CDK4/6 inhibitor -Palbociclib，Discontinuation of CDK4/6 inhibitor -Palbociclib
地点: Germany
申办方: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06224673 / NCI-2024-00073

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

AI 简述这是一项II期试验，研究ARX788用于HER2低表达晚期乳腺癌。在美国开展。

?

适用疾病: HER2 Low Breast Carcinoma；Triple Negative Breast Cancer；Hormone-receptor-positive Breast Cancer
干预: ARX788，Computed Tomography (CT)，Biospecimen Collection，Amiloride
地点: United States
申办方: Laura Huppert, MD, BA

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06225284

Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients

AI 简述这是一项II期试验，研究新辅助化疗加或不加GnRH激动剂用于绝经前三阴性乳腺癌。在台湾开展。

?

适用疾病: Triple Negative Breast Cancer；Premenopausal Breast Cancer
干预: Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
地点: Taiwan
申办方: National Taiwan University Hospital

正在招募 Phase 1, Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06238921 / NCI-2024-01238

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

AI 简述这是一项1/2期试验，研究戈沙妥珠单抗联合Zimberelimab和SRS用于三阴性乳腺癌脑转移。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer；Stage IV Breast Cancer
干预: Stereotactic Radiation，Zimberelimab，Sacituzumab govitecan
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06245889 / NCI-2024-09874

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

AI 简述这是一项II期试验，在美国研究PET动力学指导的适应性新辅助治疗用于II-III期三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: Paclitaxel，Carboplatin，Pembrolizumab，Doxorubicin
地点: United States
申办方: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06259929

NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer

AI 简述这是一项II期试验，在意大利研究Abemaciclib和Giredestrant用于ER阳性、HER2阴性早期乳腺癌的术前治疗。

?

适用疾病: Breast Cancer
干预: Abemaciclib 150 MG + Giredestrant 30 MG
地点: Italy
申办方: Fondazione Oncotech

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06263543 / NCI-2025-02384

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

AI 简述这是一项II期试验，研究Sacituzumab govitecan用于ER+/HER2低表达转移性乳腺癌。

?

适用疾病: Breast Cancer；Metastatic Breast Cancer；Advanced Breast Cancer
干预: Sacituzumab govitecan
地点: United States
申办方: Reshma L. Mahtani, D.O.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06265025

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究GM103瘤内注射用于多种晚期实体瘤。

?

适用疾病: Head and Neck Cancer；Malignant Melanoma；Colorectal Cancer
干预: GM103 (Part A)，GM103 (Part B)，GM103 and Pembrolizumab (Part C)
地点: South Korea
申办方: GeneMedicine Co., Ltd.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06268665

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy

AI 简述这是一项II期试验，研究酸樱桃汁用于预防紫杉醇引起的神经病变。

?

适用疾病: Breast Cancer；Breast Cancer Stage I；Breast Cancer Stage II
干预: Tart Cherry Juice
地点: United States
申办方: University of California, Davis

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov NCT06291064

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

AI 简述这是一项II期试验，在尼日利亚女性三阴性乳腺癌中研究环磷酰胺、表柔比星、多西他赛和卡铂化疗方案。

?

适用疾病: Triple Negative Breast Cancer
干预: Cyclophosphamide，Epirubicin，Docetaxel，Carboplatin
地点: Nigeria
申办方: University of Chicago

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06298084

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd

AI 简述这是一项I/II期试验，研究HER3-DXd单药及联合用于T-DXd后进展的晚期乳腺癌。

?

适用疾病: Breast Cancer Metastatic；HER2-positive Metastatic Breast Cancer；HER2 Low Breast Carcinoma
干预: Patritumab deruxtecan，Olaparib
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06318897 / NCI-2024-02384

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究Pembrolizumab联合卡铂和紫杉醇新辅助治疗cT1b-T1cN0M0三阴性乳腺癌。

?

适用疾病: Stage 1 cT1b-T1cN0M0；Triple Negative Breast Cancer；Stage IA Breast Cancer
干预: Carboplatin，Paclitaxel，Pembrolizumab，Doxorubicin
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06342037

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

AI 简述这是一项II期试验，研究Tiragolumab联合阿替利珠单抗和伊匹木单抗用于晚期三阴性乳腺癌，在荷兰开展。

?

适用疾病: Metastatic Breast Cancer
干预: Tiragolumab，Atezolizumab，Ipilimumab
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06348134

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

AI 简述这是一项II期试验，研究抗HER2治疗用于尼日利亚HER2+乳腺癌女性术前术后。

?

适用疾病: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast；HER2-positive Breast Cancer；Breast Cancer
干预: Trastuzumab emtansine，Pertuzumab Injection，Docetaxel，Tamoxifen
地点: Nigeria
申办方: University of Chicago

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06353997

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

AI 简述这是一项II期试验，研究INBRX-106联合Pembrolizumab用于II/III期三阴性乳腺癌的新辅助治疗。

?

适用疾病: Triple Negative Breast Cancer
干预: Pembrolizumab，INBRX-106
地点: United States
申办方: Providence Health & Services

正在招募 Phase 2 药物其他

ClinicalTrials.gov NCT06358573

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

AI 简述这是一项II期试验，研究瘤内INT230-6后接新辅助免疫化疗用于早期三阴性乳腺癌。

?

适用疾病: Triple-negative Breast Cancer；TNBC - Triple-Negative Breast Cancer
干预: INT230-6，neoadjuvant immuno-chemotherapy
地点: Switzerland
申办方: Swiss Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06361940

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

AI 简述这是一项II期试验，研究芳香化酶抑制剂或他莫昔芬用于HR阳性HER2阴性乳腺癌。

?

适用疾病: Breast Cancer
干预: Aromatase inhibitors or tamoxifen
地点: United States
申办方: Medical College of Wisconsin

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06365788

Bicalutamide and Abemaciclib in Inoperable or Metastatic Androgen Receptor-positive Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究Bicalutamide和Abemaciclib用于雄激素受体阳性三阴性乳腺癌，在比利时开展。

?

适用疾病: Triple Negative Breast Neoplasms
干预: Abemaciclib，Bicalutamide
地点: Belgium
申办方: Universitaire Ziekenhuizen KU Leuven

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06369285 / NCI-2024-06850

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Alisertib联合内分泌治疗用于HR阳性HER2阴性复发或转移性乳腺癌。

?

适用疾病: Hormone Receptor Positive HER-2 Negative Breast Cancer；Metastatic Breast Cancer；Recurrent Breast Cancer
干预: Alisertib，Endocrine therapy
地点: United States，Portugal，Spain
申办方: Puma Biotechnology, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06374459 / NCI-2024-07328

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

AI 简述这是一项I/II期试验，研究Zunsemetinib联合卡培他滨用于激素受体阳性HER2阴性伴骨转移的转移性乳腺癌。

?

适用疾病: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer；Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma
干预: Zumsemetinib，Capecitabine，Zoledronic acid，Denosumab
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06380816

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

AI 简述这是一项I/II期试验，在UK研究UCB4594用于晚期实体瘤，包括头颈鳞癌、非小细胞肺癌等。

?

适用疾病: Advanced Solid Tumours；Squamous Cell Carcinoma of Head and Neck；Carcinoma, Non-Small-Cell Lung
干预: UCB4594
地点: United Kingdom
申办方: Cancer Research UK

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06395519

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

AI 简述这是一项I/II期试验，研究PARG抑制剂ETX-19477用于晚期实体恶性肿瘤。在美国开展。

?

适用疾病: Advanced or Metastatic Solid Tumors；Breast Cancer；Ovarian Cancer
干预: ETX-19477
地点: United States
申办方: 858 Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06399757 / NCI-2024-04491

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究APL-5125用于晚期实体瘤。在美国开展。

?

适用疾病: Colorectal Cancer；Cholangiocarcinoma；Appendiceal Adenocarcinoma
干预: APL-5125
地点: United States
申办方: Apollo Therapeutics Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06409390 / NCI-2024-03962

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

AI 简述这是一项II期试验，研究基于进化动力学的序贯疗法用于转移性乳腺癌，在美国开展。

?

适用疾病: Metastatic Breast Cancer；Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma
干预: Taxotere，Cytoxan，Trastuzumab deruxtecan，Sacituzumab govitecan
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 4 药物

ClinicalTrials.gov NCT06429761

Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients

AI 简述这是一项IV期试验，评估Trastuzumab deruxtecan用于印度乳腺癌患者的安全性，在印度开展。

?

适用疾病: BREAST CANCER
干预: Trastuzumab deruxtecan
地点: India
申办方: AstraZeneca

正在招募 Phase 2 药物手术/操作

ClinicalTrials.gov / NCI NCT06434064 / NCI-2024-03909

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究他莫昔芬和聚乙二醇脂质体多柔比星用于转移性或不可手术的局部晚期三阴性乳腺癌，在美国开展。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Locally Advanced Unresectable Triple-Negative Breast Carcinoma
干预: Biopsy，Biospecimen Collection，Computed Tomography，Echocardiography
地点: United States
申办方: Roswell Park Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06439693 / NCI-2024-06769

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

AI 简述这是一项在美国开展的II期试验，研究序贯治疗用于初治HER2阳性转移性乳腺癌。

?

适用疾病: Breast Cancer Female；Breast Cancer；Breast Cancer Metastatic
干预: Nab-Paclitaxel，Paclitaxel，Docetaxel，Phesgo
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06441890

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

AI 简述这是一项II期试验，研究紫杉类联合曲妥珠单抗用于HER2阳性乳腺癌新辅助治疗。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer
干预: Paclitaxel，Nab-paclitaxel，Docetaxel，Trastuzumab
地点: United States
申办方: University of Illinois at Chicago

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT06450314

Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

AI 简述这是一项II期试验，研究停用抗HER2维持治疗用于血液检测阴性的转移性HER2阳性乳腺癌，在法国开展。

?

适用疾病: Metastatic Breast Cancer；HER2-positive Breast Cancer
干预: Discontinuation of the anti-HER2 maintenance therapy，Monitoring with signatera test
地点: France
申办方: UNICANCER

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06452394

NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline

AI 简述这是一项II期试验，研究多西环素靶向乳腺癌干细胞，在瑞士开展。

?

适用疾病: Breast Cancer
干预: Doxycyclin
地点: Switzerland
申办方: Swiss Cancer Institute

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06460298 / NCI-2024-07988

ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

AI 简述这是一项I/II期试验，研究ProAgio联合吉西他滨用于转移性三阴性乳腺癌，在美国等地开展。

?

适用疾病: Triple Negative Breast Cancer；Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma
干预: ProAgio Dose Levels (DL) 1,2,3,4，ProAgio Dose Expansion
地点: United States
申办方: ProDa BioTech, LLC

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06471673

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

AI 简述这是一项I/II期试验，在美国开展，研究BRIA-OTS细胞免疫治疗用于转移性复发性乳腺癌。

?

适用疾病: Breast Cancer；Breast Tumor；Cancer of Breast
干预: BC1 cell line，Bria-OTS regimen and CPI (tislelizumab)，Bria-OTS regimen and CPI (tislelizumab) expansion cohort
地点: United States
申办方: BriaCell Therapeutics Corporation

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06486883

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype

AI 简述这是一项II期试验，比较T-DXd与CDK4/6i联合内分泌治疗用于HR阳性HER2低表达晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer；Advanced Breast Carcinoma；Hormone Receptor Positive Breast Carcinoma
干预: Trastuzumab deruxtecan (T-DXd, DS-8201a)，CDK4/6i plus ET
地点: Austria，Belgium，France，Germany 等 5 个
申办方: MedSIR

正在招募 Phase 2 生物制剂药物其他

ClinicalTrials.gov / NCI NCT06492759 / NCI-2024-03412

High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究高剂量放疗联合Pembrolizumab和化疗用于PD-L1阳性转移性三阴性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Triple-Negative Breast Carcinoma；Stage IV Breast Cancer
干预: Radiation Therapy，Pembrolizumab，Nab-paclitaxel，Paclitaxel
地点: United States
申办方: Emory University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06508216

A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer

AI 简述这是一项I/II期试验，研究Dato-DXd和Durvalumab用于早期复发的转移性三阴性乳腺癌。

?

适用疾病: Breast Cancer
干预: Dato-DXd，Durvalumab
地点: France
申办方: Gustave Roussy, Cancer Campus, Grand Paris

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06517212

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

AI 简述这是一项II期试验，研究替西帕肽减重用于MRD阳性早期乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；Breast Neoplasms；Breast Cancers
干预: Tirzepatide
地点: United States
申办方: Baylor Research Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06518837

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

AI 简述这是一项II期试验，研究Tirzepatide用于早期激素受体阳性/HER2阴性乳腺癌患者的减重。

?

适用疾病: Hormone Receptor-Positive Breast Cancer；HER2-Negative Breast Cancer
干预: Tirzepatide
地点: United States
申办方: Rutgers, The State University of New Jersey

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06533826 / NCI-2024-09124

TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

AI 简述一项II期试验，研究Dato-DXd或T-DXd用于ADC难治性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；HER2-low Breast Cancer；Metastatic Breast Cancer
干预: Trastuzumab Deruxtecan，Datopotamab Deruxtecan
地点: United States
申办方: Ana C Garrido-Castro, MD

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06568692 / NCI-2024-08946

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

AI 简述这是一项II期试验，研究PCS6422联合卡培他滨用于晚期或转移性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；TNBC - Triple-Negative Breast Cancer；HER2-negative Breast Cancer
干预: PCS6422 and capecitabine，Capecitabine
地点: United States
申办方: Processa Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06595563

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

AI 简述这是一项II期试验，研究89Zr-trastuzumab PET/CT作为生物标志物用于抗体药物偶联物序贯治疗HER2阳性晚期乳腺癌，在比利时、荷兰开展。

?

适用疾病: HER2-positive Metastatic Breast Cancer；HER2-positive Advanced Breast Cancer
干预: Trastuzumab emtansine
地点: Belgium，Netherlands
申办方: Jules Bordet Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06616987

Prevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer

AI 简述这是一项II期试验，评估Sacituzumab Govitecan联合pegfilgrastim预防转移性三阴性乳腺癌中性粒细胞减少。

?

适用疾病: Breast Cancer Metastatic
干预: Sacituzumab Govitecan with pegfilgrastim
地点: South Korea
申办方: Yeon Hee Park

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06618287 / NCI-2024-09548

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究BMS-986507联合奥希替尼或帕博利珠单抗或纳武利尤单抗用于晚期实体瘤，在多国开展。

?

适用疾病: Lung Cancer；Breast Cancer；Advanced Malignant Solid Tumor
干预: BMS-986507，Osimertinib，Pembrolizumab，Nivolumab
地点: United States，Australia，Canada，Chile 等 5 个
申办方: Bristol-Myers Squibb

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06631092

Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer

AI 简述这是一项I/II期试验，研究个性化新抗原靶向癌症疫苗NECVAX-NEO1用于新辅助三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: Oral DNA Vaccine
地点: Germany
申办方: NEC Bio B.V

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06657222

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究TUB-030用于晚期实体瘤。在美国、加拿大、罗马尼亚、西班牙等地开展。

?

适用疾病: Advanced Solid Tumors；HNSCC；SCLC
干预: TUB-030
地点: United States，Canada，Romania，Spain
申办方: Tubulis GmbH

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06665178

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

AI 简述这是一项II期试验，在加拿大研究Sacituzumab Govitecan用于ER+/HER2-低表达转移性乳腺癌。

?

适用疾病: Breast Cancer
干预: Sacituzumab Govitecan
地点: Canada
申办方: British Columbia Cancer Agency

正在招募 Phase 1, Phase 2 生物制剂诊断检测

ClinicalTrials.gov / NCI NCT06682793 / NCI-2025-01614

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

AI 简述这是一项I/II期试验，研究A2B395（一种CAR-T）用于表达EGFR且HLA-A*02缺失的实体瘤。

?

适用疾病: Solid Tumor, Adult；Colorectal Cancer；Non-Small Cell Lung
干预: A2B395，xT CDx with HLA-LOH assay
地点: United States
申办方: A2 Biotherapeutics Inc.

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov / NCI NCT06686394 / NCI-2025-03803

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

AI 简述这是一项I/II期试验，研究Patritumab Deruxtecan联合其他抗癌药用于HER2阳性乳腺癌。在美国、加拿大、以色列、日本等地开展。

?

适用疾病: Breast Neoplasms；Breast Cancer；Stage III Breast Cancer
干预: Patritumab deruxtecan，Trastuzumab，Trastuzumab Biosimilar，Pertuzumab
地点: United States，Canada，Israel，Japan 等 2 个
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06690840

Atezolizumab and Chemotherapy Treatment as T-cell Activators in Metastatic Triple Negative Breast Cancer Patients

AI 简述这是一项II期试验，研究Atezolizumab联合环磷酰胺和长春瑞滨用于转移性三阴性乳腺癌，在意大利开展。

?

适用疾病: Triple Negative Breast Cancer
干预: Atezolizumab in combination with Cyclophosphamide and Vinorelbine
地点: Italy
申办方: European Institute of Oncology

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06750484 / NCI-2025-03048

Trial of Trastuzumab Deruxtecan in Previously Treated HER2

AI 简述这是一项II期试验，研究Trastuzumab Deruxtecan用于经治的HER2阴性转移性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer Metastatic；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Trastuzumab Deruxtecan
地点: United States
申办方: Yale University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06793553

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

AI 简述这是一项2期试验，在PD-L1+三阴性乳腺癌中研究PTX+BV诱导后接Atezolizumab+Nab-PTX。在日本开展。

?

适用疾病: Metastatic Breast Cancer
干预: Induction therapy
地点: Japan
申办方: Japan Breast Cancer Research Group

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov / NCI NCT06797635 / NCI-2025-06674

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

AI 简述这是一项II期试验，研究Patritumab deruxtecan联合Pembrolizumab用于早期乳腺癌。

?

适用疾病: Breast Neoplasms；Breast Cancer；Stage II Breast Cancer
干预: Patritumab deruxtecan，Pembrolizumab，Paclitaxel，Carboplatin
地点: United States，South Korea，Spain，Taiwan
申办方: Merck Sharp & Dohme LLC

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06827613 / NCI-2025-02223

A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究STAR0602联合Sacituzumab Govitecan用于晚期实体瘤。

?

适用疾病: Triple Negative Locally Advanced Non-resectable Breast Cancer；HR+, HER2-, Advanced Breast Cancer；Stage IV Breast Cancer
干预: STAR0602，Sacituzumab Govitecan (SG)
地点: United States，Canada
申办方: Marengo Therapeutics, Inc.

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06837792

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

AI 简述这是一项II期试验，比较Trastuzumab Deruxtecan与内分泌治疗用于低HER2、HR+晚期乳腺癌，在韩国开展。

?

适用疾病: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
干预: Experimental treatment arm，Control treatment arm
地点: South Korea
申办方: Yonsei University

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06845319 / NCI-2025-08420

NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients

AI 简述这是一项II期试验，研究卡铂、紫杉醇联合帕博利珠单抗用于三阴性乳腺癌新辅助治疗。

?

适用疾病: Triple Negative Breast Cancer；Stage II Breast Cancer；Stage IIIA Breast Cancer
干预: Carboplatin，Paclitaxel，Pembrolizumab
地点: United States
申办方: Medical University of South Carolina

正在招募 Phase 2 生物制剂手术/操作放疗

ClinicalTrials.gov / NCI NCT06860815 / NCI-2025-00340

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

AI 简述这是一项II期试验，研究西米普利单抗联合放射性栓塞用于肝转移性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Carcinoma in the Liver
干预: Biopsy，Biospecimen Collection，Cemiplimab，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06875128 / NCI-2025-08927

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

AI 简述这是一项2期试验，研究肝脏直接给药高剂量美法仑后接标准治疗用于肝转移为主的转移性乳腺癌，在美国和意大利开展。

?

适用疾病: Metastatic Breast Cancer in the Liver；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: Melphalan/HDS followed by Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)，Physician's choice of SOC (eribulin, vinorelbine, or capecitabine)
地点: United States，Italy
申办方: Delcath Systems Inc.

正在招募 Phase 4 药物

ClinicalTrials.gov NCT06920810

Viscum Album for TNBC on Adjuvant Pembrolizumab

AI 简述这是一项IV期试验，研究Viscum album用于辅助帕博利珠单抗治疗的三阴性乳腺癌。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer
干预: viscum album
地点: South Korea
申办方: Ilsan Cha hospital

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT06923527 / NCI-2025-07533

Circulating Tumor DNA

AI 简述这是一项II期试验，研究Elacestrant用于ER+乳腺癌，在美国开展。

?

适用疾病: ER+ Breast Cancer；Stage IIB Breast Cancer；Stage III Breast Cancer
干预: Elacestrant
地点: United States
申办方: Yale University

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06926920 / NCI-2025-05319

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

AI 简述这是一项I/II期试验，研究Sacituzumab Govitecan不同剂量方案用于晚期三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Sacituzumab Govitecan-hziy (SG)
地点: United States，Australia，South Korea
申办方: Gilead Sciences

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT06953882 / NCI-2025-05716

Impact of Omitting Chemo Based on Patient's Selection for ER-Positive, HER2-Negative Breast Cancer With Ribociclib and Endocrine Therapy

AI 简述这是一项II期试验，研究基于患者选择省略化疗，使用Ribociclib和内分泌治疗用于ER阳性HER2阴性乳腺癌，在美国开展。

?

适用疾病: HER2 Negative Breast Cancer；Stage II Breast Cancer；Stage IIIA Breast Cancer
干预: Ribociclib 400mg，Letrozole 2.5mg，Anastrazole 1mg，Goserelin 3.6 MG
地点: United States
申办方: Yale University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06954480

Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究Datopotamab Deruxtecan联合Durvalumab对比Datopotamab Deruxtecan用于PD-L1阴性转移性三阴性乳腺癌，在英国开展。

?

适用疾病: Triple Negative Breast Cancer
干预: Datopotamab Deruxtecan (Dato-DXd)，Durvalumab
地点: United Kingdom
申办方: Queen Mary University of London

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT06963905 / NCI-2025-08055

Saci Nivo Rela for TNBC

AI 简述这是一项I/II期试验，在美国研究Relatlimab和纳武利尤单抗联合Sacituzumab Govitecan用于转移性三阴性乳腺癌。

?

适用疾病: Metastatic Triple-negative Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Relatlimab FDC + Nivolumab，Sacituzumab Govitecan (SG)，Nivolumab
地点: United States
申办方: Yale University

正在招募 Phase 2 药物

ClinicalTrials.gov NCT06976944

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究帕博利珠单抗联合紫杉醇加或不加贝伐珠单抗用于复发性三阴性乳腺癌。

?

适用疾病: Recurrent Triple-Negative Breast Cancer
干预: Pembrolizumab，Paclitaxel，Bevacizumab
地点: Japan
申办方: Yukinori Ozaki

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07007559 / NCI-2025-07107

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

AI 简述这是一项II期试验，研究Evorpacept联合曲妥珠单抗和化疗用于HER2阳性转移性乳腺癌，在美国、加拿大、法国、意大利等地开展。

?

适用疾病: Breast Cancer, Metastatic；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Evorpacept (ALX148)，Trastuzumab，Paclitaxel，Capecitabine
地点: United States，Canada，France，Italy 等 4 个
申办方: ALX Oncology Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07011654 / NCI-2025-03798

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

AI 简述这是一项I/II期试验，研究Naxitamab和Sacituzumab Govitecan用于转移性三阴性乳腺癌，在美国开展。

?

适用疾病: Metastatic Triple-Negative Breast Cancer；Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma
干预: Sacituzumab govitecan，Naxitamab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07016399 / NCI-2025-03600

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

AI 简述这是一项II期试验，研究Darolutamide单药或联合标准治疗用于II-IIIA期AR+三阴性乳腺癌。

?

适用疾病: Anatomic Stage II Breast Cancer AJCC v8；Anatomic Stage IIIA Breast Cancer AJCC v8；Triple-Negative Breast Carcinoma
干预: Biospecimen Collection，Breast Biopsy Procedure，Carboplatin，Cyclophosphamide
地点: United States
申办方: Vandana Abramson

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07017673

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究Ivonescimab联合卡铂和多西他赛用于早期三阴性乳腺癌。

?

适用疾病: TNBC；TNBC - Triple-Negative Breast Cancer；Early Stage Triple-Negative Breast Carcinoma
干预: Ivonescimab，Carboplatin，Docetaxel
地点: United States
申办方: Cedars-Sinai Medical Center

正在招募 Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT07053085 / NCI-2025-06969

A Study of Surgery and Radiotherapy in People With Breast Cancer

AI 简述这是一项II期试验，研究手术和放疗用于HER2阳性转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer；HER2-positive Breast Cancer；Stage IV Breast Cancer
干预: Lumpectomy or mastectomy，Radiotherapy，Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07064018 / NCI-2025-03409

Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies

AI 简述这是一项I/II期试验，研究Spedox-6用于多种晚期实体瘤，在美国开展。

?

适用疾病: Soft-tissue Sarcoma；Triple Negative Breast Cancer；Non-small Cell Lung Cancer
干预: Spedox-6，Pegfilgrastim，Filgrastim
地点: United States
申办方: University of California, Irvine

正在招募 Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT07069595 / NCI-2025-05695

PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease

AI 简述这是一项II期试验，研究Datopotamab deruxtecan用于残留病灶三阴性乳腺癌。

?

适用疾病: Breast Cancer；Residual Disease；Triple Negative Breast Cancer (TNBC)
干预: Datopotamab deruxtecan，Circulating tumor DNA (ctDNA) testing
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07074106

TIL-Driven De-escalated Chemotherapy in Stage I-II TNBC

AI 简述这是一项II期试验，评估TIL指导的减量化疗用于I-II期三阴性乳腺癌，在巴西开展。

?

适用疾病: Breast Cancer
干预: Carboplatin and a Taxane
地点: Brazil
申办方: D'Or Institute for Research and Education

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07078604 / NCI-2025-04327

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

AI 简述这是一项II期试验，在美国研究STEMVAC联合化疗用于PD-L1阴性转移性三阴性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Triple-Negative Breast Carcinoma；Stage IV Breast Cancer
干预: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine，Chemotherapy，Computed Tomography，Computed Tomography Assisted Biopsy
地点: United States
申办方: University of Washington

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07102381 / NCI-2025-09014

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

AI 简述这是一项II期试验，研究Zanidatamab联合化疗用于HER2阳性乳腺癌新辅助治疗，在美国、意大利等地开展。

?

适用疾病: HER2-positive Breast Cancer；Breast Cancer；Stage II Breast Cancer
干预: Zanidatamab，Paclitaxel，Docetaxel，Carboplatin
地点: United States，Italy，Spain
申办方: Jazz Pharmaceuticals

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07104266

Triple Negative Breast Cancer and Celecoxib. Pilot Study

AI 简述这是一项II期试验，研究塞来昔布与安慰剂用于三阴性乳腺癌，在加拿大开展。

?

适用疾病: Triple-Negative Breast Cancer
干预: Celecoxib (Celebrex)，Placebo
地点: Canada
申办方: Université de Sherbrooke

正在招募 Phase 2 生物制剂药物

ClinicalTrials.gov NCT07108309

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究BCD-236联合化疗用于白俄罗斯和俄罗斯复发转移性三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: BCD-236，Chemotherapy
地点: Belarus，Russia
申办方: Biocad

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07112053 / NCI-2025-04692

A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

AI 简述这是一项II期试验，在美国开展，研究STEMVAC疫苗联合内分泌治疗或化疗用于转移性HR阳性HER2阴性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic HER2-Negative Breast Carcinoma；Metastatic Hormone Receptor-Positive Breast Carcinoma
干预: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine，Capecitabine，Computed Tomography，Cyclin-Dependent Kinase 4 Inhibitor
地点: United States
申办方: University of Washington

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07115043 / NCI-2025-09704

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究AZD6750联合rilvegostomig用于多种晚期实体瘤。在美国、澳大利亚、日本、韩国等地开展。

?

适用疾病: Melanoma；Non-small Cell Lung Cancer；Squamous Cell Carcinoma (Skin)
干预: AZD6750，rilvegostomig
地点: United States，Australia，Japan，South Korea
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07164976

Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer

AI 简述这是一项I/II期试验，研究Ribociclib用于HR阳性HER2阴性转移性乳腺癌，在日本开展。

?

适用疾病: Breast Cancer
干预: Ribociclib 400mg，Ribociclib 600mg，Ribociclib 600mg
地点: Japan
申办方: Nagoya City University

正在招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07188246

Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

AI 简述这是一项II期试验，研究SBRT联合瘤内注射帕博利珠单抗后新辅助化疗用于乳腺癌（II/III期、三阴性）。在加拿大开展。

?

适用疾病: Breast Cancer；Breast Cancer Stage II；Breast Cancer Stage III
干预: Radiation，Pembrolizumab (KEYTRUDA®)
地点: Canada
申办方: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07189871 / NCI-2026-03797

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

AI 简述这是一项I/II期试验，研究177Lu-BetaBart用于复发/难治性局部晚期不可切除或转移性实体瘤。

?

适用疾病: Castration-Resistant Prostate Cancer (CRPC)；Colorectal Cancer；NSCLC (Non-small Cell Lung Cancer)
干预: 177Lu-BetaBart
地点: United States
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07193394

Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Tucatinib联合Trastuzumab用于HER3突变、HER2未扩增转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer ( HER2 Negative)；Unresectable Breast Cancer
干预: Tucatinib (ONT-380)，Trastuzumab (Herceptin)
地点: France
申办方: Institut Curie

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07195227

Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer

AI 简述这是一项II期试验，研究Camizestrant联合Ribociclib用于激素受体阳性乳腺癌。在德国、西班牙等地开展。

?

适用疾病: Hormon Receptor Positive Breast Cancer；Breast Cancer
干预: Camizestrant，Ribociclib
地点: Germany，Spain
申办方: MedSIR

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07198724 / NCI-2025-09606

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

AI 简述这是一项I/II期试验，研究Elacestrant联合Trastuzumab Deruxtecan用于CDK4/6抑制剂和内分泌治疗耐药的HR+/HER2低表达转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer；HER2 Low Breast Carcinoma；HER2-negative Breast Cancer
干预: Elacestrant，Trastuzumab Deruxtecan
地点: United States
申办方: Kristina A. Fanucci

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07220135 / NCI-2025-08852

Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer

AI 简述这是一项II期试验，比较THP与TCHP用于HER2阳性乳腺癌。

?

适用疾病: Breast Cancer；Stage II Breast Cancer；Stage IIIA Breast Cancer
干预: Carboplatin，Docetaxel，Trastuzumab (or biosimilar)，Pertuzumab (or biosimilar)
地点: United States
申办方: University of Kansas Medical Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07222215 / NCI-2026-00737

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

AI 简述这是一项II期试验，比较卡培他滨联合Elacestrant与卡培他滨单药用于ER+乳腺癌。

?

适用疾病: Estrogen-receptor-positive Breast Cancer；Metastatic Breast Cancer；Breast Cancer
干预: Capecitabine，Elacestrant
地点: United States
申办方: Kristina A. Fanucci

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07227233 / NCI-2026-03907

Artificial Intelligence and Machine Learning to Guide CDK4/6 Inhibitor Rechallenge in Breast Cancer.

AI 简述这是一项II期试验，研究一种不同于之前使用的CDK4/6抑制剂联合fulvestrant用于激素受体阳性乳腺癌。

?

适用疾病: Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: A CDK4/6 inhibitor different from the first that the participant had received, plus fulvestrant.，Treatment of physician's choice
地点: United States
申办方: University of California, San Diego

正在招募 Phase 4 药物

ClinicalTrials.gov NCT07257484

Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors

AI 简述这是一项4期试验，研究替尔泊肽用于绝经后HR+乳腺癌幸存者肥胖。在美国开展。

?

适用疾病: Obesity (Disorder)；Breast Cancer
干预: Tirzepatide
地点: United States
申办方: Weill Medical College of Cornell University

正在招募 Phase 2 药物放疗

ClinicalTrials.gov / NCI NCT07276880 / NCI-2025-08351

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

AI 简述这是一项II期试验，研究术前化疗、Pembrolizumab联合低或高剂量放疗用于淋巴结阳性三阴性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer (TNBC)；HER2-Negative Breast Carcinoma
干预: Neoadjuvant Pembrolizumab，low dose neoadjuvant boost，High dose neoadjuvant boost
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07287098 / NCI-2026-03377

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

AI 简述这是一项II期试验，研究Imlunestrant用于绝经前ER+/HER2-早期乳腺癌。

?

适用疾病: Breast Neoplasms；Stage I Breast Cancer；Stage II Breast Cancer
干预: Imlunestrant，Goserelin，Tamoxifen 20 mg
地点: United States，Belgium，France，Germany 等 3 个
申办方: Eli Lilly and Company

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07287917 / NCI-2026-00497

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究AMXT 1501和DFMO联合标准疗法用于晚期实体瘤。

?

适用疾病: Melanoma (Skin Cancer)；HER2-low Hormone Receptor Positive Breast Cancer；Metastatic Malignant Solid Tumor
干预: AMXT 1501 Dicaprate，DFMO，Fulvestrant，Capivasertib
地点: United States
申办方: Aminex Therapeutics, Inc.

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07288359

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究GVV858单用或联合内分泌治疗用于HR+/HER2-乳腺癌和晚期实体瘤。

?

适用疾病: Advanced HR+/HER2- Breast Cancer；Advanced CCNE1-amplified Solid Tumors；Metastatic Castration-resistant Prostate Cancer
干预: GVV858，Fulvestrant，Letrozole
地点: United States，Czechia，Denmark，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07292168

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

AI 简述这是一项I/II期试验，在俄罗斯研究FGFR1抗体OM-RCA-01用于表达FGFR1的转移性肿瘤。

?

适用疾病: Renal Cell Carcinoma Metastatic；Prostate Cancer Metastatic；Non-small Cell Lung Cancer Metastatic
干预: humanized monoclonal anti-FGFR1 antibody OM-RCA-01
地点: Russia
申办方: Kidney Cancer Research Bureau

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07340541 / NCI-2026-03903

Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies

AI 简述这是一项2期试验，研究生物标志物驱动的多种疗法（如SERD+abemaciclib）用于乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；Metastatic Breast Cancer；Triple Negative Breast Cancer
干预: SERD* + abemaciclib，SERD* + everolimus，SERD* + everolimus or capecitabine，SOC
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT07341737

SL-28 for Advanced Solid Tumours

AI 简述这是一项1/2期试验，研究SL-28用于多种晚期实体瘤（如头颈癌、胰腺癌、肺癌）。在澳大利亚开展。

?

适用疾病: Head & Neck Cancer；Pancreas Carcinoma；Pancreas Cancer, Metastatic
干预: SL-28，SL-28，SL-28
地点: Australia
申办方: Second Life Therapeutics

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07368998

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

AI 简述这是一项II期试验，研究Inavolisib联合Fulvestrant用于乳腺癌，在美国、阿根廷等地开展。

?

适用疾病: Breast Cancer
干预: Inavolisib，Fulvestrant
地点: United States，Argentina，Australia，Belgium 等 4 个
申办方: Hoffmann-La Roche

正在招募 Phase 2 器械药物

ClinicalTrials.gov NCT07371585

Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management

AI 简述这是一项II期试验，在法国、德国、西班牙等地研究T-DXd联合帕妥珠单抗用于一线HER2阳性转移性乳腺癌。

?

适用疾病: Breast Cancer Stage IV
干预: Digital Health Tools，T-DXd，Pertuzumab
地点: France，Germany，Spain
申办方: SOLTI Breast Cancer Research Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07395336

Elacestrant and Exemestane for Patients With Pretreated HR+/HER2- Metastatic Breast Cancer and [18F] FES-avid Lesions (COMBINE)

AI 简述这是一项II期试验，在意大利开展，研究Elacestrant和依西美坦用于HR+/HER2-转移性乳腺癌。

?

适用疾病: Breast Cancer
干预: elacestrant and exemestane
地点: Italy
申办方: European Institute of Oncology

正在招募 Phase 2 药物

ClinicalTrials.gov / NCI NCT07402473 / NCI-2026-01295

Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

AI 简述这是一项II期试验，优化Trastuzumab、Pertuzumab等新辅助治疗用于HER2阳性早期乳腺癌。在美国开展。

?

适用疾病: HER2-positive Early-stage Breast Cancer；Stage II Breast Cancer；Stage IIIA Breast Cancer
干预: Trastuzumab，Pertuzumab，Docetaxel，Carboplatin
地点: United States
申办方: Rutgers, The State University of New Jersey

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07405801

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

AI 简述这是一项II期试验，研究Inavolisib联合Ribociclib和Fulvestrant用于晚期乳腺癌。

?

适用疾病: Breast Cancer
干预: Inavolisib，Ribociclib，Fulvestrant，Placebo
地点: United States，Argentina，Brazil，Canada 等 8 个
申办方: Hoffmann-La Roche

正在招募 Phase 2 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07407920 / NCI-2025-08252

Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial

AI 简述这是一项II期试验，优化HER2+早期乳腺癌的辅助全身治疗，在美国开展。

?

适用疾病: Anatomic Stage I Breast Cancer AJCC v8；Anatomic Stage II Breast Cancer AJCC v8；Early Stage HER2-Positive Breast Carcinoma
干预: Biospecimen Collection，Hormone Therapy，Pembrolizumab，Pertuzumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07427394

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

AI 简述这是一项II期试验，研究Camizestrant联合Atirmociclib用于晚期乳腺癌，在美国和英国等地开展。

?

适用疾病: Advanced Breast Cancer
干预: Camizestrant，Atirmociclib
地点: United States，United Kingdom
申办方: AstraZeneca

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07441889 / NCI-2026-04796

HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006)

AI 简述这是一项I/II期试验，研究HER2 FPBMC用于转移性乳腺癌和前列腺癌。

?

适用疾病: Breast Cancer；Prostate Cancer；Stage IV Breast Cancer
干预: HER2 FPBMC
地点: United States
申办方: University of Virginia

正在招募 Phase 2 诊断检测药物

ClinicalTrials.gov / NCI NCT07459673 / NCI-2026-01854

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

AI 简述这是一项II期试验，研究基于ctDNA的序贯抗HER2治疗用于HER2阳性转移性乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer；Breast Cancer Stage IV
干预: Personalis NeXT Personal，Natera Signatera，fam-trastuzumab deruxtecan-nxki (T-DXd)，pertuzumab, called T-DXd+P
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07506876

Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer

AI 简述这是一项II期试验，研究新辅助化疗联合内分泌治疗用于HER2阳性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer - Infiltrating Ductal Carcinoma；HER-2 Positive Breast Cancer
干预: Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
地点: United States
申办方: Legacy Health System

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07558733

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

AI 简述一项I/II期试验，研究Sapanisertib和Serabelisib联合其他药物用于HR+ HER2-晚期乳腺癌。在美国开展。

?

适用疾病: HR+ HER2- Breast Cancer
干预: Serabelisib，Sapanisertib，Fulvestrant
地点: United States
申办方: Faeth Therapeutics

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov / NCI NCT07612215 / NCI-2026-03773

Elacestrant in Advanced Triple Positive Breast Cancer

AI 简述这是一项I/II期试验，研究Elacestrant联合曲妥珠单抗和帕妥珠单抗用于HER2阳性乳腺癌。

?

适用疾病: ER Positive, HER2 Positive Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Elacestrant，Trastuzumab，Pertuzumab
地点: United States
申办方: NYU Langone Health

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07631052

Capecitabine in ER+/HER2-negative Breast Cancer

AI 简述这是一项II期试验，在加拿大研究Capecitabine用于ER阳性、HER2阴性乳腺癌。

?

适用疾病: ER-positive, HER2-negative Breast Cancer；Breast Cancer Stage I；Breast Cancer Stage II
干预: Capecitabine
地点: Canada
申办方: University Health Network, Toronto

即将招募 Phase 3 生物制剂其他

ClinicalTrials.gov NCT06434077

Clinical Trial Protocol: Randomized Placebo-Controlled Pilot Study of GcMAF (Soloways TM) in Patients With Metastatic Breast Cancer

AI 简述这是一项III期试验，比较GcMAF与安慰剂用于转移性乳腺癌，在俄罗斯开展。

?

适用疾病: Breast Cancer
干预: GcMAF injections (100 ng)，placebo
地点: Russia
申办方: S.LAB (SOLOWAYS)

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07178730

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

AI 简述这是一项III期试验，比较Sacituzumab Govitecan联合Pembrolizumab与标准化疗用于II-III期三阴性乳腺癌，在德国开展。

?

适用疾病: Breast Cancer；Triple-negative Breast Cancer
干预: Sacituzumab govitecan，Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]，SoC Chemotherapy
地点: Germany
申办方: West German Study Group

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07647328

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

AI 简述这是一项III期试验，研究Camizestrant联合Ribociclib用于ER阳性HER2阴性晚期乳腺癌，在美国、法国等地开展。

?

适用疾病: ER-Positive HER2-Negative Breast Cancer
干预: Camizestrant，Ribociclib
地点: United States，France，Germany，Italy 等 4 个
申办方: AstraZeneca

即将招募 Phase 2

NCI NCT06214793 / NCI-2024-01694

Taletrectinib for the Treatment of Patients with CDH1-Mutated, Metastatic Invasive Lobular Breast Cancer, TaCe-1 Trial

AI 简述这是一项II期试验，研究Taletrectinib用于CDH1突变转移性浸润性小叶乳腺癌。

?

适用疾病: Stage IV Breast Cancer；HER2 Negative Breast Carcinoma；Metastatic Lobular Breast Carcinoma
干预: 未列出
地点: United States
申办方: Case Comprehensive Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05067530

Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study

AI 简述这是一项2期试验，研究Palbociclib联合紫杉醇和卡铂用于三阴性乳腺癌，在波兰开展。

?

适用疾病: Triple Negative Breast Neoplasms
干预: Palbociclib，Paclitaxel，Carboplatin
地点: Poland
申办方: Medical University of Gdansk

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05128734

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AI 简述这是一项II期试验，研究替莫唑胺单用或联合奥拉帕利用于三阴性乳腺癌，在加拿大开展。

?

适用疾病: Breast Cancer Triple Negative
干预: Temozolomide，Olaparib
地点: Canada
申办方: AHS Cancer Control Alberta

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05986071

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

AI 简述这是一项I/II期试验，研究M1774联合Fulvestrant用于HR+/HER2-晚期乳腺癌。

?

适用疾病: Breast Cancer
干预: M1774，Fulvestrant injection
地点: France
申办方: Institut Paoli-Calmettes

即将招募 Phase 1, Phase 2 生物制剂

ClinicalTrials.gov NCT06023277

A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer

AI 简述这是一项I/II期试验，研究ConvitVax用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: ConvitVax
地点: United States，Venezuela
申办方: Jacinto Convit World Organization Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06371807

Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab

AI 简述这是一项II期试验，在新辅助化疗中联用Pembrolizumab用于高风险三阴性乳腺癌。

?

适用疾病: Early Breast Cancer；Triple Negative Breast Cancer
干预: Pembrolizumab injection
地点: Portugal
申办方: Fundacao Champalimaud

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07005882

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

AI 简述这是一项II期试验，研究Elacestrant联合PULSAR放疗用于HR+/HER2-乳腺癌术前治疗，在意大利开展。

?

适用疾病: Breast Cancer Patients；Breast Cancer Early Stage Breast Cancer (Stage 1-3)；HR+/HER2- Breast Cancer
干预: Elacestrant，PULSAR
地点: Italy
申办方: Azienda Ospedaliero-Universitaria Careggi

即将招募 Phase 2 药物放疗

ClinicalTrials.gov NCT07015853

ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation

AI 简述这是一项II期试验，研究Pembrolizumab联合放疗和Axatilimab用于转移性三阴性乳腺癌。

?

适用疾病: TNBC - Triple-Negative Breast Cancer；Breast Cancer
干预: Pembrolizumab，Radiotherapy，Axatilimab
地点: United States
申办方: Stephen Shiao

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07151586

Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer

AI 简述这是一项II期试验，在法国研究交替使用戈沙妥珠单抗和德曲妥珠单抗用于转移性或局部晚期三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Neoplasms；Neoplasm Metastasis；HER 2 Low-expressing Breast Cancer
干预: Sacituzumab Govitecan / Trastuzumab Deruxtecan
地点: France
申办方: UNICANCER

即将招募 Phase 1, Phase 2 药物手术/操作放疗

ClinicalTrials.gov / NCI NCT07217990 / NCI-2025-07434

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

AI 简述这是一项I/II期试验，研究新辅助化疗和放疗方案用于早期乳腺癌的个体化治疗，在美国开展。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer；Triple Negative Breast Cancer
干预: Neoadjuvant Chemotherapy，Radiation Therapy，MRI，Breast Cancer Surgery
地点: United States
申办方: Ohio State University Comprehensive Cancer Center

即将招募 Phase 1, Phase 2 药物其他

ClinicalTrials.gov NCT07292142

FMT in Triple Negative Breast Cancer Guided by ctDNA

AI 简述这是一项I/II期试验，在加拿大研究粪便微生物移植用于ctDNA指导的三阴性乳腺癌。

?

适用疾病: Breast Cancer
干预: Fecal Microbiota Transplantation (FMT)，No Intervention.
地点: Canada
申办方: Jewish General Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07299409

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

AI 简述这是一项II期试验，研究Sacituzumab Govitecan用于晚期初治三阴性乳腺癌。在加拿大开展。

?

适用疾病: Advanced Triple Negative Breast Cancer；Breast Cancer Metastatic；Breast Cancer
干预: Sacituzumab Govitecan (SG)
地点: Canada
申办方: Nathalie Levasseur

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07394946

Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.

AI 简述这是一项II期试验，在巴基斯坦开展，研究来曲唑用于激素受体阳性、HER2阴性、淋巴结阳性早期乳腺癌。

?

适用疾病: Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer
干预: Letrozole
地点: Pakistan
申办方: Cancer Care Hospital & Research Centre Foundation, Lahore

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07428018

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib

AI 简述这是一项II期试验，在意大利研究Abemaciclib用于HR+/HER2-早期乳腺癌的新辅助治疗。

?

适用疾病: Breast Cancer；HER2 + Breast Cancer；HR Positive
干预: Abemaciclib
地点: Italy
申办方: Mario Negri Institute for Pharmacological Research

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07458113

Sac-TMT for Active TNBC Brain Metastases

AI 简述这是一项II期试验，研究Sacituzumab tirumotecan用于活动性三阴性乳腺癌脑转移。

?

适用疾病: Metastatic Triple Negative Breast Cancers
干预: Sacituzumab tirumotecan
地点: United States
申办方: Yale University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07458204

Peritumoral and Periganglionic Infiltration of Levobupivacaine Prior to Conservative Surgery for Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究左布比卡因浸润用于三阴性乳腺癌保守手术。在法国开展。

?

适用疾病: Triple-negative Breast Cancer
干预: LVB infiltration
地点: France
申办方: Institut Jean-Godinot

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07528768

Gemcitabine vs Paclitaxel in Caribbean Women of African Ancestry With Metastatic Triple-Negative Breast Cancer

AI 简述这是一项II期试验，比较吉西他滨与紫杉醇用于转移性三阴性乳腺癌，在加勒比非裔女性中开展。

?

适用疾病: Triple Negative Breast Cancer；Metastatic Triple-negative Breast Cancer
干预: Gemcitabine (1000 mg/m^2)，Paclitaxel 80 mg/m2 weekly
地点: Barbados，Jamaica，Trinidad and Tobago
申办方: AntiCancer Research Jamaica

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07552181

Phase II Trial of Pembrolizumab/Chemotherapy With Live Biotherapeutic Product MO-03 in Patients With Early Stage Triple Negative Breast Cancer

AI 简述这是一项II期试验，在美国研究Pembrolizumab联合化疗和活体生物治疗产品MO-03用于早期三阴性乳腺癌。

?

适用疾病: TNBC - Triple-Negative Breast Cancer；TNBC；Early Stage Triple-Negative Breast Carcinoma
干预: Live biotherapeutic product: MO-03 1 capsule PO BID
地点: United States
申办方: Yuan Yuan

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07565324

Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)

AI 简述这是一项2期试验，研究超声和ctDNA指导的新辅助全身治疗用于HER2阳性早期乳腺癌，在台湾开展。

?

适用疾病: HER-2 Positive Breast Cancer
干预: Lipo-Dox®，Cyclophosphamide，Trastuzumab (Herceptin)，Pertuzumab
地点: Taiwan
申办方: National Taiwan University Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07610525

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

AI 简述这是一项II期试验，研究血和影像指导的新辅助治疗用于早期三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Blood and Image Guided；Optimization of Neoadjuvant Therapy
干预: Paclitaxel + Carboplatin，Pembrolizumab
地点: United States
申办方: M.D. Anderson Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07619365

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

AI 简述这是一项II期试验，研究Trastuzumab deruxtecan联合Lovastatin用于HER2低表达和超低表达晚期或转移性乳腺癌。

?

适用疾病: Breast Cancer；Advanced Breast Cancer；Metastatic Breast Cancer
干预: Trastuzumab deruxtecan，Lovastatin
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07681297

Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and Central Nervous System Disease

AI 简述这是一项I/II期试验，研究替雷利珠单抗联合贝伐珠单抗和卡培他滨用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor Cancer；Triple-Negative Breast Cancer (TNBC)；CNS Disease
干预: Tislelizumab + Bevacizumab + Capecitabine
地点: Singapore
申办方: National University Hospital, Singapore

正在招募 Phase 3

NCI NCT05645536 / NCI-2023-08920

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

AI 简述这是一项III期试验，针对HR阳性、HER2阴性乳腺癌患者完成OVELIA研究后的安全性扩展研究，在美国开展。

?

适用疾病: Hormone Receptor Positive Breast Carcinoma；HER2 Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Tolmar Inc.

正在招募 Phase 3 联合产品

ClinicalTrials.gov NCT06195709

ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients

AI 简述这是一项III期试验，研究FES-PET和循环生物标志物用于ER阳性HER2阴性转移性乳腺癌。

?

适用疾病: Breast Carcinoma
干预: Endocrine therapy，Endocrine therapy combined with the local treatment of FES-negative lesions，Chemotherapy
地点: France
申办方: Institut Curie

正在招募阶段未标明

NCI NCT02945579 / NCI-2016-01929

Eliminating Surgery or Radiotherapy after Neoadjuvant Systemic Therapy in Treating Patients with Breast Cancer

AI 简述这是一项试验，评估新辅助系统治疗后省略手术或放疗用于乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；HER2-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT03076372 / NCI-2017-01170

A Study Evaluating MM-310 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究MM-310用于多种晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Prostate Adenocarcinoma；Non-Small Cell Lung Cancer
干预: 未列出
地点: United States
申办方: Merrimack Pharmaceuticals

正在招募 Phase 1

NCI NCT03129139 / NCI-2018-00874

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究Minnelide胶囊单用或联合白蛋白紫杉醇用于晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Minneamrita Therapeutics LLC

正在招募阶段未标明

NCI NCT03796559 / NCI-2019-03806

Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

AI 简述这是一项试验，研究Magseed用于早期乳腺癌腋窝淋巴结的长期定位。在美国开展。

?

适用疾病: Stage I Breast Cancer；Stage IA Breast Cancer；Stage IB Breast Cancer
干预: 未列出
地点: United States
申办方: Endomagnetics Inc

正在招募阶段未标明

NCI NCT03769415 / NCI-2019-04924

RNA Expression and Molecular Subtype Analysis to Optimize Novel Therapy for Metastatic Breast Cancer, HARMONY Study

AI 简述这是一项试验，分析RNA表达和分子亚型以优化转移性乳腺癌的新疗法，在美国开展。

?

适用疾病: Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT04064359 / NCI-2019-07280

Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors

AI 简述这是一项I期试验，研究OBT076用于复发/转移性CD205+实体瘤。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Oxford BioTherapeutics Ltd

正在招募 Phase 1

NCI NCT04360330 / NCI-2020-03765

Breast Radiotherapy (SABER) for the Treatment of Hormone Receptor Positive HER2 Negative Early Stage Breast Cancer

AI 简述这是一项I期试验，研究乳腺放疗用于激素受体阳性HER2阴性早期乳腺癌。

?

适用疾病: Stage I Breast Cancer；Stage IIA Breast Cancer；Hormone Receptor Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: University of Miami Miller School of Medicine-Sylvester Cancer Center

正在招募 Phase 1

NCI NCT04389632 / NCI-2020-03931

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

AI 简述这是一项I期试验，研究Sigvotatug Vedotin用于晚期实体瘤，在美国、法国、韩国、西班牙等地开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Unresectable Esophageal Carcinoma
干预: 未列出
地点: United States
申办方: Seagen, a wholly owned subsidiary of Pfizer

正在招募阶段未标明

NCI NCT04368702 / NCI-2020-04571

Image Guided Radiation Therapy with MRI for the Treatment of Cancer, CONFIRM Study

AI 简述这是一项磁共振引导放射治疗的研究，用于多种癌症。

?

适用疾病: Malignant Solid Tumor；Stage I Laryngeal Throat Cancer；Stage II Laryngeal Throat Cancer
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

正在招募 Phase 1

NCI NCT04429542 / NCI-2020-04796

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

AI 简述这是一项I期试验，研究BCA101单药及联合治疗用于EGFR驱动的晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Non-Small Cell Squamous Lung Cancer；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Bicara Therapeutics

正在招募 Phase 1

NCI NCT04389281 / NCI-2020-05653

X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma

AI 简述这是一项I期试验，研究X射线补骨脂素激活癌症治疗用于头颈癌、乳腺癌、肉瘤和黑色素瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Recurrent Soft Tissue Sarcoma；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Immunolight, LLC

正在招募 Phase 1

NCI NCT04450732 / NCI-2020-05876

Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究GQ1001用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Malignant Solid Tumor；Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: GeneQuantum Healthcare (Suzhou) Co., Ltd.

正在招募 Phase 1

NCI NCT04485013 / NCI-2020-07730

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

AI 简述这是一项I期试验，研究TTX-080用于晚期实体瘤，包括头颈鳞癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Tizona Therapeutics, Inc

正在招募 Phase 1

NCI NCT04997993 / NCI-2021-09149

Leflunomide for the Treatment of PTEN-Altered Advanced Solid Tumors and Triple-Negative Breast Cancer

AI 简述这是一项I期试验，研究来氟米特用于PTEN改变晚期实体瘤和三阴性乳腺癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Icahn School of Medicine at Mount Sinai

正在招募 Phase 1

NCI NCT05238922 / NCI-2022-03370

Study of INCB123667 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究INCB123667用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage II Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Incyte Corporation

正在招募 Phase 1

NCI NCT05378464 / NCI-2022-04424

Adoptive T-Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine, Pepinemab and Trastuzumab for the Treatment of HER2 Positive Metastatic Breast Cancer

AI 简述这是一项I期试验，研究HER2脉冲树突状细胞疫苗、Pepinemab和Trastuzumab后T细胞治疗用于HER2阳性转移性乳腺癌。

?

适用疾病: Stage IV Breast Cancer；Metastatic HER2-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Moffitt Cancer Center

正在招募阶段未标明

NCI NCT05309655 / NCI-2022-06768

Cardiac Imaging Stress Tests to Evaluate Cardiac Outcomes in Stage I-III Breast Cancer Patients Receiving Near Complete Estrogen Deprivation Therapy, CROWN Study

AI 简述这是一项观察性研究，通过心脏影像负荷试验评估接受近完全雌激素剥夺治疗的I-III期乳腺癌患者的心脏结局。在美国开展。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Duke University Medical Center

正在招募阶段未标明

NCI NCT04722341 / NCI-2022-09048

Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators

AI 简述这是一项关于限时进食对癌症影响的试验，涉及直肠癌和乳腺癌患者。

?

适用疾病: Stage II Rectal Cancer；Stage III Rectal Cancer；Stage IV Rectal Cancer
干预: 未列出
地点: United States
申办方: Cedars-Sinai Medical Center

正在招募 Phase 1

NCI NCT05464667 / NCI-2023-03172

Pre-operative Radiation Therapy for the Treatment of Females with Early Stage Biologically Favorable Breast Cancer

AI 简述这是一项I期试验，在美国开展，研究术前放疗用于早期生物学有利的乳腺癌。

?

适用疾病: Stage I Breast Cancer；HER2 Negative Breast Carcinoma；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: University of Pittsburgh Cancer Institute (UPCI)

正在招募阶段未标明

NCI NCT06055881 / NCI-2023-03208

Radiation Therapy for the Treatment of Patients with Metastatic Breast Cancer with Disease Progression at a Limited Number of Sites, BOSS Trial

AI 简述这是一项试验，研究放疗用于转移性乳腺癌患者在有限部位进展时的治疗。

?

适用疾病: Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Rochester

正在招募阶段未标明

NCI NCT05505643 / NCI-2023-03236

Cryoablation Compared to Lumpectomy for the Treatment of Patients with Breast Cancer, COOL-IT Trial

AI 简述这是一项试验，比较冷冻消融与肿块切除术用于早期乳腺癌患者，在美国开展。

?

适用疾病: Stage IA Breast Cancer；HER2 Negative Breast Carcinoma；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Siteman Cancer Center at Washington University

正在招募 Phase 1

NCI NCT05719558 / NCI-2023-03815

A Study of ASP1002 in Adults for Treatment of Solid Tumors

AI 简述这是一项I期试验，在美国研究ASP1002用于多种晚期实体瘤。

?

适用疾病: Metastatic Urothelial Cancer；Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Astellas Pharma BV

正在招募 Phase 1

NCI NCT05720117 / NCI-2023-05249

A Study of PYX-201 in Advanced Solid Tumors

AI 简述这是一项I期试验，在美国研究PYX-201用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Pyxis Oncology, Inc

正在招募阶段未标明

NCI NCT05837767 / NCI-2023-06276

Lattice Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

AI 简述这是一项临床试验，研究姑息放疗用于软组织转移的实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1

NCI NCT06066424 / NCI-2023-08351

TROP2-CAR-NK for the Treatment of Patients with Advanced Solid Tumors

AI 简述这是一项I期试验，研究TROP2-CAR-NK细胞用于晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT05989724 / NCI-2023-08586

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SON-DP用于标准治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer；Stage IV Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Qurgen Inc.

正在招募 Phase 1

NCI NCT05848739 / NCI-2023-08892

A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors

AI 简述这是一项1-2期试验，研究ST316用于晚期不可切除和转移性实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Colorectal (Colon or Rectal) Cancer；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: Sapience Therapeutics

正在招募 Phase 1

NCI NCT05932862 / NCI-2023-10500

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究XL309单药或联合治疗用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Exelixis Inc

正在招募 Phase 1

NCI NCT05957536 / NCI-2024-01363

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

AI 简述这是一项I期试验，研究D3L-001单药用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: D3 Bio (Wuxi) Co., Ltd

正在招募 Phase 1

NCI NCT06389123 / NCI-2024-03571

A Theranostic Approach ([68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G) for the Detection and Treatment of Metastatic Cancers

AI 简述这是一项I期试验，研究[68Ga]Ga DOTA-5G和[177Lu]Lu DOTA-ABM-5G用于转移性癌症的检测和治疗，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: University of California Davis Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06244485 / NCI-2024-04787

A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究Valemetostat Tosylate联合DXd ADC用于实体瘤患者。

?

适用疾病: Metastatic Lung Non-Squamous Non-Small Cell Carcinoma；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1

NCI NCT06233942 / NCI-2024-05419

Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors

AI 简述这是一项1a/1b期试验，研究BG-C9074单独及联合其他抗癌疗法用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: BeOne Medicines

正在招募 Phase 1

NCI NCT06475937 / NCI-2024-09195

A Study of DM001 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究DM001用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Xadcera Biopharmaceutical (Suzhou) Co., Ltd.

正在招募阶段未标明

NCI NCT06855654 / NCI-2025-00134

A Skills-based Intervention for Promoting Resilience in Stress Management for Patients with Metastatic Breast Cancer, PRISM-MBC Trial

AI 简述这是一项基于技能的干预试验，旨在促进转移性乳腺癌患者的压力管理韧性。

?

适用疾病: Stage IV Breast Cancer；Metastatic Breast Carcinoma；Recurrent Breast Cancer
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06638307 / NCI-2025-02117

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

AI 简述这是一项I期试验，研究MEN2312用于晚期乳腺癌，在美国开展。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Stemline Therapeutics, Inc.

正在招募阶段未标明

NCI NCT06896162 / NCI-2025-02181

A Precision Oncology Navigation and Expert Review Intervention for Improving Referral to Genome Informed Therapy among Patients with Stage IV Lung, Colorectal, Breast or Bladder Cancers, PROGRESS Trial

AI 简述这是一项试验，评估基因组指导治疗转诊改进用于IV期肺癌、结直肠癌、乳腺癌或膀胱癌，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1

NCI NCT06906900 / NCI-2025-02319

Tumor Treating Fields Therapy (NovoTTF™-200M and NovoTTF-200A Systems) for the Treatment of Refractory Spinal Metastasis

AI 简述这是一项I期试验，研究肿瘤电场治疗用于难治性脊柱转移瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IVB Hepatocellular Cancer；Stage IV Lung Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

正在招募 Phase 1

NCI NCT06752681 / NCI-2025-03245

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究DAY301用于局部晚期或转移性实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；FIGO Stage III Ovarian Cancer；Advanced Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: Day One Biopharmaceuticals, Inc.

正在招募 Phase 1

NCI NCT06823167 / NCI-2025-03470

A Phase 1 Study of IM-1021 in Participants With Advanced Cancer

AI 简述这是一项I期试验，在美国开展，研究IM-1021用于多种晚期实体瘤。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
干预: 未列出
地点: United States
申办方: Immunome, Inc.

正在招募 Phase 1

NCI NCT07015697 / NCI-2025-05451

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究皮下注射Trastuzumab Deruxtecan用于转移性实体瘤患者。

?

适用疾病: Metastatic Malignant Solid Tumor；Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8；Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
干预: 未列出
地点: United States
申办方: Daiichi Sankyo

正在招募 Phase 1

NCI NCT06458712 / NCI-2025-05692

Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies

AI 简述这是一项I期试验，在美国、法国等地研究DSB2455用于晚期实体瘤。

?

适用疾病: Advanced Malignant Solid Tumor；Stage II Pancreatic Cancer；Stage III Pancreatic Cancer
干预: 未列出
地点: United States
申办方: Duke Street Bio Ltd

正在招募 Phase 1

NCI NCT07030712 / NCI-2025-06272

A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)

AI 简述这是一项1期试验，研究MK-8294用于晚期实体瘤，包括食管鳞癌和头颈鳞癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Merck Sharp and Dohme LLC

正在招募阶段未标明

NCI NCT07178665 / NCI-2025-06537

Accelerated Partial Breast Irradiation before Surgery for the Treatment of Early Stage Breast Cancer

AI 简述这是一项试验，研究术前加速部分乳房照射用于早期乳腺癌，在美国开展。

?

适用疾病: Stage 0 Breast Cancer；Stage IA Breast Cancer；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Rutgers Cancer Institute of New Jersey

正在招募 Phase 1

NCI NCT06997029 / NCI-2025-06578

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

AI 简述这是一项I期试验，研究BMS-986500单药或联合治疗用于晚期实体瘤，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Bristol-Myers Squibb

正在招募阶段未标明

NCI NCT07218432 / NCI-2025-07348

Radiofrequency Electromagnetic Fields Therapy using the TheraBionic P1 Device prior to Surgery for the Treatment of Stage I-III Resectable Breast Cancer

AI 简述这是一项无分期的试验，研究TheraBionic P1设备治疗可手术I-III期乳腺癌，在美国开展。

?

适用疾病: Stage I Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: Wayne State University/Karmanos Cancer Institute

正在招募 Phase 1

NCI NCT07165132 / NCI-2025-07443

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

AI 简述这是一项I期试验，研究RYZ401用于表达SSTR的实体瘤，在美国、加拿大等地开展。

?

适用疾病: Metastatic Gastrointestinal Neuroendocrine Tumor G1；Malignant Solid Tumor；Stage II Pancreatic Neuroendocrine Tumor
干预: 未列出
地点: United States
申办方: RayzeBio, Inc.

正在招募 Phase 1

NCI NCT06959706 / NCI-2025-08169

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究TGW101用于晚期实体瘤，包括转移性及局部晚期实体瘤等，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Castration-Resistant Prostate Cancer
干预: 未列出
地点: United States
申办方: Tagworks Pharmaceuticals BV

正在招募 Phase 1

NCI NCT07197671 / NCI-2025-08356

Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer

AI 简述这是一项I期试验，研究Y-NM600联合免疫检查点抑制剂用于转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Head and Neck Squamous Cell Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: University of Wisconsin Carbone Cancer Center - University Hospital

正在招募阶段未标明

NCI NCT07227831 / NCI-2025-08501

Amplitude-Modulated Radiofrequency Electromagnetic Field Therapy for the Treatment of Patients with Locally Advanced, Unresectable, or Metastatic Hormone Receptor Positive HER2 Negative Breast Cancer who Progressed on Previous Therapy

AI 简述这是一项试验，研究调幅射频电磁场疗法用于局部晚期或转移性HR阳性HER2阴性乳腺癌。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Wayne State University/Karmanos Cancer Institute

正在招募 Phase 1

NCI NCT07213791 / NCI-2025-09175

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

AI 简述这是一项I期试验，在美国等地研究LY4337713用于FAP阳性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Eli Lilly and Company

正在招募 Phase 1

NCI NCT07222267 / NCI-2025-09708

An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors

AI 简述这是一项I期试验，研究BG-75202单用或联合其他药物治疗晚期实体瘤。在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: BeOne Medicines

正在招募 Phase 1

NCI NCT06809114 / NCI-2026-00164

FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AT03-65用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: Axcynsis Therapeutics Pte Ltd

正在招募 Phase 1

NCI NCT07356453 / NCI-2026-00571

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

AI 简述这是一项I期试验，在美国研究PARG抑制剂FORX-428用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Stage III Breast Cancer
干预: 未列出
地点: United States
申办方: FoRx Therapeutics

正在招募 Phase 1

NCI NCT07218003 / NCI-2026-00632

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

AI 简述这是一项I期试验，研究RNDO-564单药或联合Pembrolizumab用于Nectin-4阳性实体瘤，在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Stage III Head and Neck Squamous Cell Cancer；Stage IV Head and Neck Squamous Cell Cancer
干预: 未列出
地点: United States
申办方: Rondo Therapeutics

正在招募 Phase 1

NCI NCT07361562 / NCI-2026-00709

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，在美国研究选择性ERBB2抑制剂CGT4255用于晚期实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Lung Cancer
干预: 未列出
地点: United States
申办方: Cogent Biosciences, Inc.

正在招募阶段未标明

NCI NCT07487844 / NCI-2026-01819

Pulsed Electric Field Ablation for the Treatment of Metastatic Soft Tissue Lesions in Patients with Breast Cancer

AI 简述这是一项研究脉冲电场消融治疗乳腺癌转移性软组织病变的试验，在美国开展。

?

适用疾病: Metastatic Malignant Neoplasm to Soft Tissues；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: University of California San Francisco

正在招募 Phase 1

NCI NCT05841563 / NCI-2026-03026

Clinical Trial of PM54 in Advanced Solid Tumors Patients.

AI 简述这是一项I期试验，在美国开展，研究PM54用于晚期实体瘤患者。

?

适用疾病: Advanced Malignant Solid Tumor；Stage III Esophageal Adenocarcinoma；Stage IV Esophageal Adenocarcinoma
干预: 未列出
地点: United States
申办方: PharmaMar SA

正在招募 Phase 1

NCI NCT07541573 / NCI-2026-03508

A Camelid Nanobody B7-H3 Tri-Specific Killer Engager (GTB-5550) for the Treatment of Advanced Solid Tumors that Failed Prior Therapy

AI 简述这是一项I期试验，研究GTB-5550用于既往治疗失败的晚期实体瘤，在美国开展。

?

适用疾病: Recurrent Fallopian Tube Cancer；Recurrent Primary Peritoneal Cancer；Recurrent Bladder Urothelial Cancer
干预: 未列出
地点: United States
申办方: University of Minnesota/Masonic Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT02926690 / NCI-2017-00301

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

AI 简述这是一项I期试验，研究OTS167PO用于晚期乳腺癌和三阴性乳腺癌。

?

适用疾病: Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer；Stage IV Breast Cancer；Triple-Negative Breast Cancer
干预: OTS167PO
地点: United States
申办方: OncoTherapy Science, Inc.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT03740256

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors

AI 简述这是一项I期试验，研究CAdVEC用于HER2阳性晚期实体瘤，在美国开展。

?

适用疾病: Bladder Cancer；Head and Neck Squamous Cell Carcinoma；Cancer of the Salivary Gland
干预: CAdVEC
地点: United States
申办方: Baylor College of Medicine

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT04020575 / NCI-2021-09742

Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)

AI 简述这是一项I期试验，研究自体huMNC2-CAR44或huMNC2-CAR22 T细胞用于转移性乳腺癌，在美国开展。

?

适用疾病: Metastatic Breast Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells，huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
地点: United States
申办方: Minerva Biotechnologies Corporation

正在招募 Phase 1 生物制剂药物其他

ClinicalTrials.gov NCT04119024

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究基因修饰免疫细胞用于晚期黑色素瘤或转移性实体瘤。

?

适用疾病: Metastatic Malignant Solid Neoplasm；Metastatic Melanoma；Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
干预: Biopsy，Biospecimen Collection，Computed Tomography，Cyclophosphamide
地点: United States
申办方: Anusha Kalbasi

正在招募 Phase 1 器械药物

ClinicalTrials.gov / NCI NCT04150042 / NCI-2021-00604

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

AI 简述这是一项I期试验，研究Melphalan和BCNU联合自身干细胞移植用于转移性胰腺癌。

?

适用疾病: Pancreatic Adenocarcinoma Metastatic；BRCA1 Mutation；BRCA2 Mutation
干预: Melphalan，BCNU，Vitamin B12B，Vitamin C
地点: United States
申办方: General Oncology, Inc.

正在招募 EARLY / Phase 1 诊断检测药物

ClinicalTrials.gov / NCI NCT04174352 / NCI-2019-07924

FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer

AI 简述这是一项早期I期试验，在美国研究FES PET/CT指导他莫昔芬用于ERα+转移性乳腺癌。

?

适用疾病: ERα+ Breast Cancer；ESR1 Gene Mutation；Stage III Breast Cancer
干预: Tamoxifen，FES PET/CT
地点: United States
申办方: University of Wisconsin, Madison

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04222413 / NCI-2020-00306

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

AI 简述这是一项I期试验，研究Metarrestin（ML-246）用于转移性实体瘤，包括胰腺癌和乳腺癌。

?

适用疾病: Advanced Solid Tumors；Metastatic Pancreatic Cancer；Pediatric Solid Tumor
干预: Metarrestin
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 生物制剂联合产品

ClinicalTrials.gov / NCI NCT04282044 / NCI-2021-03252

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

AI 简述这是一项I期试验，研究CRX100单药或联合帕博利珠单抗用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Triple Negative Breast Cancer；Colorectal Cancer
干预: CRX100 suspension for infusion，Fludarabine，Cyclophosphamide
地点: United States
申办方: BioEclipse Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04315233

Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

AI 简述这是一项I期试验，研究Ribociclib联合Belinostat用于转移性三阴性乳腺癌和复发性卵巢癌。

?

适用疾病: Metastatic Breast Cancer；Recurrent Ovarian Carcinoma
干预: Ribociclib，Belinostat
地点: United States
申办方: University of Utah

正在招募 Phase 1 药物

ClinicalTrials.gov NCT04427293

Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)

AI 简述这是一项I期试验，研究Lenvatinib联合Pembrolizumab术前用于早期三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: Lenvatinib，Pembrolizumab
地点: United States
申办方: University of Illinois at Chicago

正在招募 Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT04521764 / NCI-2020-06009

A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer

AI 简述这是一项I期试验，研究疫苗MV-s-NAP用于侵袭性转移性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Invasive Breast Carcinoma；Metastatic Breast Adenocarcinoma
干预: Oncolytic Measles Virus Encoding Helicobacter pylori Neutrophil-activating Protein，Computed Tomography，Magnetic Resonance Imaging，Biopsy
地点: United States
申办方: Mayo Clinic

正在招募阶段未标明诊断检测手术/操作

ClinicalTrials.gov NCT04671511

Targeted Axillary Dissection (TAD) in Early-stage Node Positive Breast Cancer

AI 简述这是一项试验，研究靶向腋窝淋巴结清扫用于早期淋巴结阳性乳腺癌。在加拿大开展。

?

适用疾病: Breast Cancer Female；Early-stage Breast Cancer；Lymph Node Metastases
干预: Targeted Axillary Dissection，Ultrasound of the axilla
地点: Canada
申办方: Jewish General Hospital

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04872166 / NCI-2024-05422

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer

AI 简述这是一项I期试验，研究BTX-A51用于晚期实体瘤和乳腺癌。

?

适用疾病: Advanced Solid Tumor；Metastatic Breast Cancer；Metastatic Malignant Solid Tumor
干预: BTX-A51
地点: United States
申办方: Edgewood Oncology Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT04969835 / NCI-2022-06539

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

AI 简述这是一项I期试验，研究AVA6000用于多种实体瘤，在美国和英国开展。

?

适用疾病: Salivary Gland Tumor；Urothelial Carcinoma；Ovarian Carcinoma
干预: AVA6000
地点: United States，United Kingdom
申办方: Avacta Life Sciences Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05005403 / NCI-2025-01100

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

AI 简述这是一项I期试验，研究Azirkitug单药或联合其他药物用于非小细胞肺癌等实体瘤，在美国、加拿大等地开展。

?

适用疾病: Non-Small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Micro Satellite Stable Colorectal Cancer
干预: Azirkitug，Budigalimab，Bevacizumab，Telisotuzumab Adizutecan
地点: United States，Canada，Israel，Japan 等 2 个
申办方: AbbVie

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05029999 / NCI-2022-08956

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

AI 简述这是一项I期试验，研究CD40激动剂、Flt3配体和化疗用于HER2阴性乳腺癌。

?

适用疾病: HER2-negative Breast Cancer；Metastatic Breast Cancer；Stage III Breast Cancer
干预: PLD Chemotherapy，CDX-1140，CDX-301
地点: United States
申办方: University of Texas Southwestern Medical Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05076760 / NCI-2022-02030

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

AI 简述这是一项I期试验，研究MEM-288溶瘤病毒单用或联合标准治疗用于晚期实体瘤。

?

适用疾病: Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MEM-288 Intratumoral Injection，Nivolumab，Docetaxel
地点: United States
申办方: Memgen, Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05092373 / NCI-2021-11360

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax

AI 简述这是一项I期试验，研究肿瘤电场治疗联合卡博替尼或Pembrolizumab+白蛋白紫杉醇用于腹部/胸部晚期实体瘤。

?

适用疾病: Advanced Breast Carcinoma；Advanced Endometrial Carcinoma；Advanced Fallopian Tube Carcinoma
干预: Atezolizumab，Cabozantinib S-malate，Nab-paclitaxel，Tumor Treating Fields Therapy
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05098210 / NCI-2021-10199

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

AI 简述这是一项I期试验，研究个体化新抗原肽疫苗联合纳武利尤单抗用于黑色素瘤、乳腺癌或非小细胞肺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Clinical Stage IV Cutaneous Melanoma AJCC v8；Locally Advanced Cutaneous Melanoma
干预: Neoantigen Peptide Vaccine，Nivolumab，Poly ICLC，Echocardiography
地点: United States
申办方: Fred Hutchinson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05107674 / NCI-2023-00784

A Study of NX-1607 in Adults With Advanced Malignancies

AI 简述这是一项I期试验，研究NX-1607用于晚期恶性肿瘤。

?

适用疾病: Ovarian Cancer, Epithelial；Gastric Cancer；GastroEsophageal Junction (GEJ) Cancer
干预: NX-1607，Paclitaxel
地点: United States，United Kingdom
申办方: Nurix Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05187832

A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

AI 简述这是一项I期试验，研究AND019用于ER阳性HER2阴性晚期或转移性乳腺癌。在美国开展。

?

适用疾病: Advanced or Metastatic Breast Cancer
干预: AND019 PO QD
地点: United States
申办方: Kind Pharmaceuticals LLC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05216432 / NCI-2022-01323

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

AI 简述这是一项I期试验，在美国、澳大利亚等地研究RLY-2608单药或联合内分泌治疗用于晚期实体瘤或乳腺癌。

?

适用疾病: PIK3CA Mutation；Solid Tumor, Adult；HER2-negative Breast Cancer
干预: RLY-2608，Fulvestrant，Palbociclib 125mg，Ribociclib 400mg
地点: United States，Australia，France，Italy 等 1 个
申办方: Relay Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05283330 / NCI-2022-07733

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

AI 简述这是一项I期试验，研究²¹²Pb-DOTAM-GRPR1用于GRPR阳性的复发或转移性实体瘤。

?

适用疾病: Cervical Cancer；Breast Cancer；Colon Cancer
干预: ²¹²Pb-DOTAM-GRPR1
地点: United States
申办方: Orano Med Theranostics, SAS

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05304962 / NCI-2022-03843

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

AI 简述这是一项1期试验，研究RGT-419B单用或联合内分泌治疗用于HR阳性HER2阴性晚期乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: RGT-419B，RGT-419B in combination with hormonal therapy
地点: United States
申办方: Regor Pharmaceuticals Inc.

正在招募 Phase 1 药物手术/操作

ClinicalTrials.gov / NCI NCT05372640 / NCI-2022-04100

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

AI 简述这是一项I期试验，研究ZEN003694联合Abemaciclib用于转移性或不可切除的NUT癌、乳腺癌及其他实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma
干预: Abemaciclib，BET Bromodomain Inhibitor ZEN-3694，Biopsy Procedure，Biospecimen Collection
地点: United States
申办方: National Cancer Institute (NCI)

正在招募阶段未标明放疗

ClinicalTrials.gov NCT05377047

Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer

AI 简述这是一项试验，研究立体定向消融放疗（SABR）用于IV期寡转移乳腺癌。

?

适用疾病: Breast Cancer Stage IV；Oligometastatic Disease
干预: SABR
地点: Sweden
申办方: Vastra Gotaland Region

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05403554

A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers

AI 简述这是一项I期试验，研究NI-1801单药或联合用药用于间皮素表达阳性的实体瘤（卵巢癌、三阴性乳腺癌等），在法国、意大利开展。

?

适用疾病: Epithelial Ovarian Cancer；Triple Negative Breast Cancer；Non-squamous Non-small-cell Lung Cancer
干预: Biological NI-1801，NI-1801 in combination with anti-PD1 (Pembrolizumab)，NI-1801 in combination with paclitaxel，Paclitaxel
地点: France，Italy
申办方: Light Chain Bioscience - Novimmune SA

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05422794 / NCI-2022-04956

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

AI 简述这是一项1期试验，研究ZEN003694联合帕博利珠单抗和标准化疗用于晚期三阴性乳腺癌。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Locally Advanced Triple-Negative Breast Carcinoma
干预: BET Bromodomain Inhibitor ZEN-3694，Biopsy Procedure，Biospecimen Collection，Computed Tomography
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT05464810 / NCI-2022-02545

Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer

AI 简述这是一项早期I期试验，研究来曲唑联合或不联合辛伐他汀用于I-III期HR+、HER2-乳腺癌。

?

适用疾病: Anatomic Stage I Breast Cancer AJCC v8；Anatomic Stage II Breast Cancer AJCC v8；Anatomic Stage III Breast Cancer AJCC v8
干预: Letrozole，Simvastatin
地点: United States
申办方: Emory University

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT05483491 / NCI-2022-07699

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

AI 简述这是一项I期试验，研究KK-LC-1 TCR-T细胞用于胃癌、乳腺癌、宫颈癌、肺癌等实体瘤。

?

适用疾病: Gastric Cancer；Breast Cancer；Cervical Cancer
干预: KK-LC-1 TCR-T cells，Aldesleukin
地点: United States
申办方: Christian Hinrichs

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05492682

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

AI 简述这是一项I期试验，研究PeptiCRAd-1联合环磷酰胺和Pembrolizumab用于黑色素瘤、三阴性乳腺癌、非小细胞肺癌等。

?

适用疾病: Melanoma (Skin)；Triple-Negative Breast Cancer；Non-Small Cell Lung Cancer
干预: PeptiCRAd-1，Cyclophosphamide，Pembrolizumab
地点: Germany，Italy
申办方: Valo Therapeutics Oy

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05504707 / NCI-2022-06875

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

AI 简述这是一项I期试验，研究HER2和HER3树突状细胞疫苗用于早期三阴性或ER低阳性乳腺癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Stage I Breast Cancer
干预: HER2 - primed Dendritic cells，HER3 - primed Dendritic cells
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05508906 / NCI-2022-08654

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

AI 简述这是一项Ib期试验，研究Palazestrant联合Ribociclib等药物用于ER+/HER2-乳腺癌，在美国和澳大利亚开展。

?

适用疾病: Metastatic Breast Cancer；ER-positive Breast Cancer；HER2-negative Breast Cancer
干预: Palazestrant，Ribociclib，Alpelisib，Everolimus
地点: United States，Australia
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05544240

Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SYNC-T免疫疗法用于晚期/转移性实体瘤，在墨西哥开展。

?

适用疾病: Metastatic Cancer；Metastatic Breast Cancer；Metastatic Lung Cancer
干预: SV-101
地点: Mexico
申办方: Williams Cancer Foundation

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05627960 / NCI-2023-01295

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies

AI 简述这是一项I期试验，研究AG-01抗体用于晚期实体瘤，包括三阴性乳腺癌、非小细胞肺癌等。

?

适用疾病: Triple Negative Breast Cancer；Hormone-Resistant Breast Cancer；Non Small Cell Lung Cancer
干预: AG-01 Compound
地点: United States
申办方: A&G Pharmaceutical Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05683418 / NCI-2023-01194

A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

AI 简述这是一项I期试验，研究TOS-358联合Fulvestrant或Palbociclib用于HR+ HER2-乳腺癌。在美国、西班牙等地开展。

?

适用疾病: HR+/HER2-negative Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: TOS-358，Fulvestrant，Palbociclib，Ribociclib
地点: United States，Spain
申办方: Totus Medicines

正在招募阶段未标明器械其他手术/操作

ClinicalTrials.gov / NCI NCT05746325 / NCI-2023-00240

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

AI 简述这是一项试验，研究肿瘤电场治疗用于乳腺癌或肺癌患者的软脊膜转移，在美国开展。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Malignant Neoplasm in the Leptomeninges
干预: Digital Photography，Lumbar Puncture，Magnetic Resonance Imaging，Medical Device Usage and Evaluation
地点: United States
申办方: Mayo Clinic

正在招募 Phase 1 药物

ClinicalTrials.gov NCT05746897

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究NM1F（抗PVRIG）用于晚期实体瘤，包括卵巢癌、黑色素瘤等，在美国开展。

?

适用疾病: Ovarian Cancer；Melanoma；Triple Negative Breast Cancer
干预: NM1F Injection，Pembrolizumab injection
地点: United States
申办方: Hefei TG ImmunoPharma Co., Ltd.

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT05753657

A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer.

AI 简述这是一项早期I期试验，在以色列研究Pioglitazone用于Alpelisib治疗转移性乳腺癌引起的高胰岛素血症。

?

适用疾病: Metastatic Breast Cancer；Hyperinsulinism；Hyperglycemia Drug Induced
干预: Pioglitazone
地点: Israel
申办方: Rambam Health Care Campus

正在招募 Phase 1 联合产品药物

ClinicalTrials.gov / NCI NCT05768932 / NCI-2023-02515

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

AI 简述这是一项1期试验，研究BAL0891用于晚期实体瘤或复发/难治性急性髓系白血病，在美国、韩国等地开展。

?

适用疾病: Advanced Solid Tumor；TNBC - Triple-Negative Breast Cancer；Gastric Cancer
干预: BAL0891，Tislelizumab，Paclitaxel
地点: United States，South Korea
申办方: SillaJen, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05868226 / NCI-2023-04698

PRE-I-SPY Phase I/Ib Oncology Platform Program

AI 简述这是一项I期试验，研究多种药物联合用于HER2阳性乳腺癌和转移性癌症。

?

适用疾病: HER2-positive Breast Cancer；Metastatic Cancer；Metastatic Breast Cancer
干预: ALX148，Fam-Trastuzumab Deruxtecan-Nxki，Zanidatamab，Tucatinib
地点: United States
申办方: QuantumLeap Healthcare Collaborative

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05872295 / NCI-2026-00679

IKS014 in Advanced Solid Tumors That Express HER2

AI 简述这是一项I期试验，研究IKS014用于HER2阳性晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Breast Cancer；Gastric Cancer；Gastroesophageal-junction Cancer
干预: IKS014
地点: United States，Australia，New Zealand，Singapore
申办方: Iksuda Therapeutics Ltd.

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT05877599 / NCI-2023-04428

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

AI 简述这是一项I期试验，研究TP53 R175H靶向T细胞用于HLA-A*02:01阳性晚期实体瘤，在美国开展。

?

适用疾病: Non-small Cell Lung Cancer；Head and Neck Squamous Cell Carcinoma；Colorectal Carcinoma
干预: Autologous, engineered T Cells targeting TP53 R175H
地点: United States
申办方: AstraZeneca

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05900895 / NCI-2025-05420

Estradiol Plus Olaparib for Breast Cancer (PHOEBE)

AI 简述这是一项I期试验，研究雌二醇联合Olaparib用于转移性雌激素受体阳性乳腺癌，在美国开展。

?

适用疾病: Metastatic Breast Cancer；Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma
干预: Olaparib，17b-estradiol
地点: United States
申办方: Mary D Chamberlin

正在招募阶段未标明器械药物

ClinicalTrials.gov / NCI NCT05977036 / NCI-2023-08527

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

AI 简述这是一项生物标志物驱动的早期治疗选择研究，用于HR+ HER2-转移性或不可切除乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Unresectable Breast Cancer；Stage III Breast Cancer
干预: DiviTum® TKa assay，CDK4/6 + Endocrine therapy
地点: United States
申办方: Washington University School of Medicine

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT05983432 / NCI-2023-10398

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

AI 简述这是一项I期试验，研究BL-B01D1用于转移性或不可切除非小细胞肺癌及其他实体瘤，在美国、法国等地开展。

?

适用疾病: Non Small Cell Lung Cancer；Lung Cancer；Breast Cancer
干预: BL-B01D1
地点: United States，France，Italy，Japan 等 1 个
申办方: SystImmune Inc.

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT05989828 / NCI-2023-04697

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

AI 简述这是一项I期试验，研究A2-ESO-1 TCR-T细胞用于NY-ESO-1阳性三阴性乳腺癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Aldesleukin，Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes，Biopsy，Biospecimen Collection
地点: United States
申办方: University of Southern California

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT05996107 / NCI-2023-10444

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

AI 简述这是一项I期试验，研究Ribociclib联合术后放疗用于高危HR+/HER2-乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Stage II Breast Cancer；Stage III Breast Cancer
干预: Ribociclib，Postoperative Radiation Therapy
地点: United States
申办方: University of Michigan Rogel Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06022029

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

AI 简述这是一项I期试验，研究瘤内ONM-501单药或联合cemiplimab用于晚期实体瘤和淋巴瘤。

?

适用疾病: Triple Negative Breast Cancer；Diffuse Large B Cell Lymphoma；Follicular Lymphoma
干预: ONM-501，Cemiplimab
地点: United States，Australia
申办方: OncoNano Medicine, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06075810

A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer

AI 简述这是一项I期试验，研究口服MBQ-167用于晚期乳腺癌。

?

适用疾病: Breast Cancer；Breast Neoplasm；Breast Cancer Stage IV
干预: MBQ-167
地点: United States，Puerto Rico
申办方: MBQ Pharma

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06139107 / NCI-2024-09184

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

AI 简述这是一项I期试验，研究Abemaciclib联合Letrozole用于早期乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Stage IA Breast Cancer；Stage IIA Breast Cancer
干预: Abemaciclib，Letrozole
地点: United States
申办方: Mridula George, MD

正在招募阶段未标明其他手术/操作放疗

ClinicalTrials.gov NCT06144346

Metastases Directed Therapy for Oligometastatic Breast Cancer

AI 简述这是一项试验，研究立体定向消融放疗用于寡转移性乳腺癌。

?

适用疾病: Breast Cancer；Metastatic Cancer；Metastatic Breast Cancer
干预: Stereotactic Ablative Radiation Therapy，Locoregional treatment，Standard of Care
地点: Egypt
申办方: National Cancer Institute, Egypt

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06150664 / NCI-2024-04028

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

AI 简述这是一项I期试验，研究CTX-8371用于多种晚期恶性肿瘤。

?

适用疾病: Non Small Cell Lung Cancer；Triple Negative Breast Cancer；Hodgkin Lymphoma
干预: CTX-8371
地点: United States
申办方: Compass Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06162559

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

AI 简述这是一项I期试验，研究Tucatinib联合曲妥珠单抗和帕妥珠单抗用于HER2阳性乳腺癌。

?

适用疾病: Breast Cancer
干预: Tucatinib，Trastuzumab，Pertuzumab
地点: Netherlands
申办方: The Netherlands Cancer Institute

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06242470 / NCI-2024-04298

A Study of MGC026 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究MGC026用于晚期实体瘤患者，在美国、澳大利亚、英国等地开展。

?

适用疾病: Advanced Solid Tumor；Advanced Cancer；Metastatic Cancer
干预: MGC026 Dose Escalation，MGC026 Dose for Expansion
地点: United States，Australia，United Kingdom
申办方: MacroGenics

正在招募 Phase 1 器械药物

ClinicalTrials.gov / NCI NCT06246968 / NCI-2024-01265

A Study of Pembrolizumab and Cryoablation in People With Breast Cancer

AI 简述这是一项I期试验，在美国研究帕博利珠单抗联合冷冻消融用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Breast Cancer；Breast Cancer Stage IV
干预: Pembrolizumab，Cryoablation
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06253871

A Phase 1/1b Study of IAM1363 in HER2 Cancers

AI 简述这是一项I/Ib期试验，研究IAM1363用于HER2相关肿瘤，在美国、法国、爱尔兰、意大利等地开展。

?

适用疾病: HER2 Mutation-Related Tumors；HER2；HER2-positive Breast Cancer
干预: IAM1363
地点: United States，France，Ireland，Italy 等 4 个
申办方: Iambic Therapeutics, Inc

正在招募阶段未标明手术/操作

ClinicalTrials.gov NCT06281210

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

AI 简述这是一项试验，评估新辅助治疗后通过真空辅助活检实现病理完全缓解以避免乳腺癌手术。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer；HER2-positive Breast Cancer
干预: Omission of surgical treatment
地点: Italy
申办方: European Institute of Oncology

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov NCT06305962

177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

AI 简述这是一项早期I期试验，研究177Lu-抗PD-L1单域抗体用于转移性实体瘤。

?

适用疾病: PDL1 Gene Mutation；Non Small Cell Lung Cancer；Small Cell Lung Cancer ( SCLC )
干预: 177Lu-RAD204
地点: Australia
申办方: Radiopharm Theranostics, Ltd

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06324240 / NCI-2022-01950

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

AI 简述这是一项I期试验，研究个性化疫苗联合伊匹木单抗和帕博利珠单抗用于三阴性乳腺癌，在美国开展。

?

适用疾病: Anatomic Stage I Breast Cancer AJCC v8；Anatomic Stage IA Breast Cancer AJCC v8；Anatomic Stage IB Breast Cancer AJCC v8
干预: Ipilimumab，Pembrolizumab，Vaccine Therapy
地点: United States
申办方: Emory University

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06347068 / NCI-2024-02642

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

AI 简述这是一项I期试验，研究iC9-CAR.B7-H3 T细胞用于复发难治性三阴性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Relapse；Resistant Cancer
干预: iC9-CAR.B7-H3 T Cell Therapy，cyclophosphamide，fludarabine
地点: United States
申办方: UNC Lineberger Comprehensive Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06400472 / NCI-2024-05353

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

AI 简述这是一项I期试验，研究LY4170156联合其他药物用于晚期实体瘤，在美国、澳大利亚等地开展。

?

适用疾病: Ovarian Neoplasms；Endometrial Neoplasms；Uterine Cervical Neoplasms
干预: LY4170156，bevacizumab，carboplatin，Itraconazole
地点: United States，Australia，France，Italy 等 3 个
申办方: Eli Lilly and Company

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06414733 / NCI-2025-03029

HER-2 B Cell Peptide Vaccine

AI 简述这是一项I期试验，在HER2阳性实体瘤中研究MVF-HER-2肽疫苗，在美国开展。

?

适用疾病: Metastatic Breast Cancer；Metastatic Gastrointestinal Carcinoma；HER2-positive Breast Cancer
干预: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 720
地点: United States
申办方: Pravin T.P Kaumaya

正在招募 EARLY / Phase 1 生物制剂手术/操作

ClinicalTrials.gov / NCI NCT06435351 / NCI-2024-04733

Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy

AI 简述这是一项早期I期试验，研究树突状细胞疫苗用于高风险三阴性乳腺癌。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer；Stage II Breast Cancer
干预: Leukapheresis，Dendritic Cell (DC) Vaccine
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06440005

A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究AGX101用于晚期实体瘤。

?

适用疾病: Cancer；Advanced Cancer；Locally Advanced Carcinoma
干预: AGX101
地点: United States
申办方: Angiex, Inc.

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06462963

OligoCare TwiCs (Trials Within Cohorts) Trial Comparing Acute Toxicity in Single-fraction vs Multiple-fraction SBRT for Metastasis-directed Treatment (SPRINT)

AI 简述这是一项在比利时、意大利、荷兰、瑞士等地开展的试验，比较单次与多次SBRT用于寡转移性乳腺癌、前列腺癌、非小细胞肺癌、结直肠癌。

?

适用疾病: Breast Cancer；Prostate Cancer；NSCLC
干预: single-fraction SBRT，multiple-fraction SBRT
地点: Belgium，Italy，Netherlands，Switzerland
申办方: European Organisation for Research and Treatment of Cancer - EORTC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06488378 / NCI-2024-06146

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

AI 简述这是一项Ib期试验，研究Axatilimab联合Olaparib用于BRCA1/2或PALB2突变、HER2阴性转移性乳腺癌在美国开展。

?

适用疾病: Breast Cancer；PALB2-Mutated Breast Carcinoma；HER2-negative Breast Cancer
干预: Axatilimab，Olaparib
地点: United States
申办方: Dana-Farber Cancer Institute

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06515470 / NCI-2024-08987

Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer

AI 简述这是一项I期试验，研究BTX-9341联合氟维司群用于晚期/转移性乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: BTX-9341，Fulvestrant
地点: United States
申办方: Biotheryx, Inc.

正在招募阶段未标明器械手术/操作

ClinicalTrials.gov NCT06532955

The Robot-LVA Study: Robot-assisted Microsurgical Lymphaticovenous Anastomosis in Breast Cancer-related Lymphedema

AI 简述这是一项试验，比较机器人辅助显微淋巴静脉吻合术与手动手术用于乳腺癌相关淋巴水肿，在荷兰开展。

?

适用疾病: Lymphedema；Lymphedema Arm；Lymphedema of Upper Arm
干预: Lymphaticovenous anastomosis using Microsure Motion Stabilizer，Lymphaticovenous anastomosis (manual)
地点: Netherlands
申办方: Maastricht University Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06533332

A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究ERX-315用于晚期实体瘤，包括转移性乳腺癌、卵巢癌等，在澳大利亚开展。

?

适用疾病: Advanced Solid Tumor；Metastatic Breast Cancer；Metastatic Ovarian Cancer
干预: ERX-315
地点: Australia
申办方: EtiraRx Australia Pty Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06545331 / NCI-2024-09409

Study of XB010 in Subjects With Solid Tumors

AI 简述这是一项I期试验，研究XB010联合Pembrolizumab用于多种晚期实体瘤。在美国、英国等地开展。

?

适用疾病: Locally Advanced or Metastatic Solid Tumors；Esophageal Squamous Cell Cancer；Head and Neck Squamous Cell Cancer
干预: XB010，Pembrolizumab
地点: United States，United Kingdom
申办方: Exelixis

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06545682 / NCI-2024-06339

Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)

AI 简述这是一项I期试验，研究Alpelisib联合Pembrolizumab用于转移性乳腺癌或黑色素瘤。在美国等地开展。

?

适用疾病: Melanoma (Skin Cancer)；Breast Cancer；Brain Metastasases
干预: Alpelisib + Pembrolizumab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06547840

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

AI 简述这是一项I期试验，研究MOv18 IgE用于表达叶酸受体α的实体瘤。在英国等地开展。

?

适用疾病: Advanced Ovarian Cancer；Platinum-resistant Ovarian Cancer；Triple Negative Breast Cancer (TNBC)
干预: MOv18 IgE
地点: United Kingdom
申办方: Epsilogen Ltd

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06562192 / NCI-2024-08464

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

AI 简述这是一项I期试验，研究[177Lu]Lu-NNS309用于胰腺癌、肺癌、乳腺癌和结直肠癌。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: [68Ga]Ga-NNS309，[177Lu]Lu-NNS309
地点: United States，Belgium，Canada，France 等 6 个
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06577987 / NCI-2024-07866

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

AI 简述这是一项I期试验，研究CID-078单药用于晚期实体瘤。

?

适用疾病: Advanced Solid Tumor；Metastatic Solid Tumor；Refractory Solid Tumor
干预: CID-078 Monotherapy
地点: United States
申办方: Circle Pharma

正在招募 Phase 1 生物制剂

ClinicalTrials.gov / NCI NCT06582017 / NCI-2024-07730

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

AI 简述这是一项I期试验，研究QXL138AM用于实体瘤和多发性骨髓瘤。在美国开展。

?

适用疾病: Ovarian Cancer；Pancreas Cancer；Urothelial Carcinoma
干预: QXL138AM Injection every 2 weeks by IV Infusion
地点: United States
申办方: Nammi Therapeutics Inc

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06586957 / NCI-2025-00731

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究NKT3964用于晚期/转移性实体瘤。在美国开展。

?

适用疾病: Solid Tumor；Advanced Solid Tumor；Solid Tumor, Adult
干预: NKT3964
地点: United States
申办方: NiKang Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06617169

Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

AI 简述这是一项I期试验，研究MNPR-101-PCTA-177Lu用于实体瘤。

?

适用疾病: Solid Tumor, Adult；Bladder Cancer；Urothelial Carcinoma
干预: MNPR-101-PCTA-177Lu
地点: Australia
申办方: Monopar Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06625775 / NCI-2024-09407

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

AI 简述这是一项I期试验，研究BBO-10203用于晚期实体瘤。

?

适用疾病: Solid Tumor, Adult；Metastatic Breast Cancer；Advanced Breast Cancer
干预: BBO-10203，Trastuzumab，Fulvestrant，Ribociclib
地点: United States，Australia，Brazil，France 等 1 个
申办方: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

正在招募 EARLY / Phase 1 药物

ClinicalTrials.gov / NCI NCT06637306 / NCI-2025-01827

Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

AI 简述这是一项早期I期试验，研究Dupilumab、Pembrolizumab、紫杉醇和卡铂新辅助治疗局部晚期三阴性乳腺癌。

?

适用疾病: Locally Advanced Triple Negative Breast Cancer；TNBC - Triple-Negative Breast Cancer；Stage II Breast Cancer
干预: Dupilumab，Pembrolizumab，Paclitaxel，Carboplatin
地点: United States
申办方: Rima Patel

正在招募 Phase 1 药物放疗

ClinicalTrials.gov / NCI NCT06678269 / NCI-2024-09678

A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer

AI 简述这是一项I期试验，研究Abemaciclib联合放疗用于转移性乳腺癌，在美国开展。

?

适用疾病: Metastatic Breast Cancer；Stage IV Breast Cancer；Breast Cancer
干预: Abemaciclib，Radiation Therapy
地点: United States
申办方: Memorial Sloan Kettering Cancer Center

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov / NCI NCT06691035 / NCI-2024-09583

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

AI 简述这是一项I期试验，研究Elacestrant联合DC1用于激素受体阳性转移性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer Metastatic Breast Cancer；HER2-negative Breast Cancer；Stage IV Breast Cancer
干预: Elacestrant，DC1 native/mutated ESR1
地点: United States
申办方: H. Lee Moffitt Cancer Center and Research Institute

正在招募 Phase 1 生物制剂其他

ClinicalTrials.gov NCT06746688

A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.

AI 简述这是一项I期试验，研究ES2B-C001-S01用于HER2阳性转移性乳腺癌，在奥地利等地开展。

?

适用疾病: Breast Cancer；Breast Cancer Metastatic
干预: ES2B-C001，ISA 51 VD
地点: Austria
申办方: ExpreS2ion Biotechnologies

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06771219 / NCI-2025-03137

SLV-154 Treatment of Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SLV-154用于转移性实体瘤。

?

适用疾病: Squamous Cell Cancer of Head and Neck (SCCHN)；NSCLC；SCLC
干预: SLV-154
地点: United States
申办方: Solve Therapeutics

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06774963

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

AI 简述这是一项I期试验，研究LNCB74用于晚期实体瘤，包括卵巢癌、乳腺癌等。

?

适用疾病: Ovarian Cancer；Breast Cancer；Endometrial Cancer
干预: LNCB74
地点: United States
申办方: NextCure, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06778863

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

AI 简述这是一项I期试验，研究CLSP-1025用于p53 R175H突变实体瘤。

?

适用疾病: Advanced Solid Tumor；Unresectable Solid Tumor；Metastatic Solid Tumor
干预: CLSP-1025
地点: United States
申办方: Clasp Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06784193 / NCI-2025-05945

Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究OP-3136用于晚期或转移性实体瘤，包括ER+HER2-乳腺癌、非小细胞肺癌和前列腺癌，在美国和澳大利亚开展。

?

适用疾病: Advanced or Metastatic ER+ HER2- Breast Cancer (mBC)；Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)；Advanced or Metastatic Castration-Resistant Prostate Cancer (mCRPC)
干预: OP-3136，Fulvestrant，Palazestrant
地点: United States，Australia
申办方: Olema Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT06799065

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

AI 简述这是一项I期试验，研究ATX-295用于晚期或转移性实体瘤。

?

适用疾病: Advanced Solid Tumors；Breast Cancer Recurrent；Ovarian Cancer
干预: ATX-295
地点: United States
申办方: Accent Therapeutics

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06867484

Breast Re-irradiation After Second Ipsilateral Lumpectomy

AI 简述这是一项试验，研究调强放疗用于第二次保乳术后再照射，在美国等地开展。

?

适用疾病: Breast Cancer；Cancer；Cancer of the Breast
干预: Intensity modulated radiation therapy (IMRT)
地点: United States
申办方: Youssef Zeidan

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06910657

IDOV-Immune for Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDOV-Immune用于晚期实体瘤，包括结直肠癌、胰腺癌等。在美国和澳大利亚开展。

?

适用疾病: Colorectal Cancer；Pancreatic Cancer；Melanoma
干预: IDOV-Immune (oncolytic vaccinia virus)
地点: United States，Australia
申办方: ViroMissile, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06949410 / NCI-2025-05515

HER2 Vaccine for Locally Advanced Breast Cancer

AI 简述这是一项I期试验，研究HER2疫苗用于局部晚期HER2阳性乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer；Stage III Breast Cancer
干预: HER2 Vaccine
地点: United States
申办方: Pravin T.P Kaumaya

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06959537 / NCI-2025-03170

A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)

AI 简述这是一项I期试验，研究低剂量环磷酰胺联合Axatilimab和Retifanlimab用于转移性三阴性乳腺癌。

?

适用疾病: Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: Cyclophosphamide，Axatilimab (SNDX-6352)，Retifanlimab
地点: United States
申办方: M.D. Anderson Cancer Center

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT06999187 / NCI-2025-07429

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

AI 简述这是一项I期试验，研究DR-0202用于晚期复发难治性癌，在美国开展。

?

适用疾病: Triple Negative Breast Cancer；HER2-negative Breast Cancer；Non Small Cell Lung Cancer
干预: DR-0202
地点: United States
申办方: Dren Bio

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07020117

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[225Ac]Ac-AKY-1189用于多种晚期实体瘤，在美国开展。

?

适用疾病: Urothelial Carcinoma Bladder；Triple Negative Breast Cancer (TNBC)；Hormone Receptor Positive Breast Adenocarcinoma
干预: [225Ac]Ac-AKY-1189 (therapeutic)，[64Cu]Cu-AKY-1189 (imaging)
地点: United States
申办方: Aktis Oncology, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07029399 / NCI-2025-05061

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究NKT5097 CDK2/CDK4降解剂联合内分泌治疗用于HR+乳腺癌和实体瘤。

?

适用疾病: HR+ Breast Cancer；Triple Negative Breast Cancer (TNBC)；CCNE1 Amplified Advanced Solid Tumors
干预: NKT5097 CDK2/CDK4 dual degrader，Fulvestrant，Letrozole
地点: United States
申办方: NiKang Therapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07081555

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

AI 简述这是一项I期试验，研究[177Lu]Lu-ABY-271用于HER2阳性转移性乳腺癌，在瑞典开展。

?

适用疾病: Metastatic Breast Cancer；HER2 + Breast Cancer
干预: [177Lu]Lu-ABY-271
地点: Sweden
申办方: Affibody

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07121244 / NCI-2025-08126

A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

AI 简述这是一项I期试验，研究68Ga-R11228和177Lu-R11228用于乳腺癌，在美国和澳大利亚开展。

?

适用疾病: Locoregionally Recurrent Hormone-receptor Positive Breast Cancer；Metastatic Hormone Receptor Positive Breast Cancer；Stage III Breast Cancer
干预: 68Ga-R11228，177Lu-R11228
地点: United States，Australia
申办方: Radionetics Oncology

正在招募 Phase 1 生物制剂药物手术/操作

ClinicalTrials.gov / NCI NCT07137416 / NCI-2025-05844

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

AI 简述这是一项I期试验，在美国开展，研究CX-5461联合T-DXd用于HER2阳性晚期乳腺癌及实体瘤。

?

适用疾病: Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8；Invasive Breast Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Echocardiography Test，Multigated Acquisition Scan
地点: United States
申办方: National Cancer Institute (NCI)

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07137871 / NCI-2025-06351

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

AI 简述这是一项I期试验，在美国开展，研究Avasopasem用于CDK4/6抑制剂及内分泌治疗后进展的转移性HR阳性乳腺癌。

?

适用疾病: Breast Cancer Metastatic；Stage IV Breast Cancer；Metastatic HER2-Negative Breast Carcinoma
干预: Avasopasem
地点: United States
申办方: The University of Texas Health Science Center at San Antonio

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07182149 / NCI-2026-01556

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究NRM-823用于晚期难治性实体瘤。

?

适用疾病: HNSCC；ESCC；Esophageal Adenocarcinoma
干预: NRM-823
地点: United States
申办方: Normunity AccelCo, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07190469 / NCI-2025-08590

PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer

AI 简述这是一项I期试验，在美国、加拿大等地研究PQ203用于晚期恶性实体瘤包括三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer (TNBC)；Advanced Solid Tumors Cancer；Metastatic Malignant Solid Tumor
干预: PQ203
地点: United States，Canada
申办方: ProteinQure Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07214662

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

AI 简述这是一项1期试验，研究GDC-0587单药或联合Giredestrant用于ER+/HER2-乳腺癌。

?

适用疾病: Breast Cancer
干预: GDC-0587，Giredestrant，Omeprazole
地点: United States，Taiwan
申办方: Genentech, Inc.

正在招募阶段未标明放疗

ClinicalTrials.gov / NCI NCT07242118 / NCI-2025-09481

Conformal Ablative Radiotherapy in Older Women (CARMEN) With Breast Cancer Undergoing Non-Operative Management

AI 简述这是一项试验，研究立体定向消融放疗用于接受非手术治疗的老年乳腺癌。在美国开展。

?

适用疾病: Breast Cancer Female；Stage I Breast Cancer；Stage IIA Breast Cancer
干预: SABR
地点: United States
申办方: University of Kansas Medical Center

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07261631

Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究[177Lu]Lu-DFC413用于多种实体瘤，在加拿大、丹麦、法国、德国等地开展。

?

适用疾病: Pancreatic Ductal Adenocarcinoma；Non-Small Cell Lung Cancer；HR+/HER2- Ductal and Lobular Breast Cancer
干预: 68Ga-NNS309，177Lu-DFC413
地点: Canada，Denmark，France，Germany 等 2 个
申办方: Novartis Pharmaceuticals

正在招募阶段未标明药物

ClinicalTrials.gov NCT07281001

A Study to Assess the Efficiency of Trastuzumab Deruxtecan in Russian Breast Cancer Patients

AI 简述这是一项NA期试验，研究德曲妥珠单抗用于俄罗斯HER2阳性乳腺癌患者。在俄罗斯开展。

?

适用疾病: HER2-positive Breast Cancer；Trastuzumab Deruxtecan
干预: T-DXd 5.4 mg/kg, IVD, 1 cycle every 21 days.
地点: Russia
申办方: Blokhin's Russian Cancer Research Center

正在招募阶段未标明器械手术/操作

ClinicalTrials.gov NCT07292246

A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)

AI 简述这是一项前瞻性队列研究，在希腊评估HandX辅助内镜下保留乳头乳房切除术用于乳腺癌。

?

适用疾病: Breast Cancer；BRCA 1 Gene Mutation；BRCA 2 Gene Mutation
干预: Endoscopic nipple sparing mastectomy，HandX endoscopic instrument
地点: Greece
申办方: Vasileios Kalles

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07297667

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

AI 简述这是一项I期试验，研究GCAR1 CAR-T细胞疗法用于复发难治GPNMB阳性实体瘤。在加拿大等地开展。

?

适用疾病: Alveolar Soft Part Sarcoma；Renal Cell Carcinoma；Triple Negative Breast Cancer
干预: Fludarabine，Cyclophosphamide，GCAR1
地点: Canada
申办方: Canadian Cancer Trials Group

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07310420 / NCI-2026-02412

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer

AI 简述这是一项I期试验，研究ZOLADEX用于HR+、HER2-晚期乳腺癌女性的卵巢抑制，在美国开展。

?

适用疾病: Advanced Breast Cancer；Stage III Breast Cancer；Stage IV Breast Cancer
干预: ZOLADEX
地点: United States
申办方: TerSera Therapeutics LLC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07311993 / NCI-2026-03476

Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

AI 简述这是一项I期试验，研究CLR 125用于三阴性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Refractory Triple-Negative Breast Carcinoma；Recurrent Triple-Negative Breast Carcinoma
干预: Iopofosine I 131，CLR 125
地点: United States
申办方: Cellectar Biosciences, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07318805 / NCI-2026-00338

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

AI 简述这是一项I期试验，研究PF-08032562用于晚期或转移性实体瘤，在美国开展。

?

适用疾病: Advanced Breast Cancer；Metastatic Breast Cancer (HR+/ HER2-)；Colorectal Cancer
干预: PF-08032562，Fulvestrant，Cetuximab，Fluorouracil
地点: United States
申办方: Pfizer

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07358377

A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative Cancer

AI 简述这是一项I期试验，在澳大利亚研究HRS-6209联合氟维司群用于HR阳性/HER2阴性乳腺癌。

?

适用疾病: Breast Cancer
干预: HRS-6209 Capsules and fulvestrant injection
地点: Australia
申办方: Atridia Pty Ltd.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07369505

Sapu003 in Advanced mTOR-sensitive Solid Tumors

AI 简述这是一项I期试验，研究Sapu003用于晚期mTOR敏感实体瘤，在澳大利亚开展。

?

适用疾病: Breast Cancer Metastatic；Renal Cell Carcinoma (RCC)；Neuroendocrine Tumors
干预: Sapu003，Exemestane 25 MG
地点: Australia
申办方: SAPU NANO (US) LLC

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07383506 / NCI-2026-04358

A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，在美国开展，研究突变选择性抑制剂CGT6297用于PIK3CA突变晚期实体瘤。

?

适用疾病: PIK3CA Mutations；Advanced Solid Tumors, Adult；Endometrial Cancer
干预: CGT6297
地点: United States
申办方: Cogent Biosciences, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07408089 / NCI-2026-02613

Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer

AI 简述这是一项I期试验，研究BBI-940用于晚期或转移性乳腺癌，在美国开展。

?

适用疾病: Breast Cancer；Metastatic Breast Cancer；Advanced Breast Cancer
干预: BBI-940，Fulvestrant
地点: United States
申办方: Boundless Bio, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07424547

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

AI 简述这是一项I期试验，研究SYS6043用于晚期/转移性实体瘤。

?

适用疾病: Cancer；Solid Tumor Cancer；Advanced Metastatic Cancer
干预: SYS6043
地点: United States
申办方: Conjupro Biotherapeutics, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov / NCI NCT07503808 / NCI-2026-03006

A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types

AI 简述这是一项I期试验，研究IDE034用于局部晚期或转移性实体瘤成人患者。

?

适用疾病: Esophageal Squamous Cell Carcinoma；High Grade Serous Ovarian Cancer；Head and Neck Squamous Cell Carcinoma
干预: IDE034
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07517198

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

AI 简述这是一项I期试验，确定EXS74539用于多种实体瘤的剂量。在美国开展。

?

适用疾病: Solid Tumor；Small Cell Lung Cancer (SCLC)；High Grade Neuroendocrine Cancer
干预: EXS74539
地点: United States
申办方: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07524322

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

AI 简述这是一项I期试验，研究RGT-490用于PIK3CA突变的晚期实体瘤。

?

适用疾病: Breast Cancer；Ovarian Cancer；Endometrial Cancer
干预: RGT-490
地点: United States
申办方: Regor Pharmaceuticals Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07524855

A Study of HLD-0117 in Patients With Metastatic Breast Cancer

AI 简述这是一项I期试验，研究HLD-0117用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: HLD-0117
地点: United States
申办方: Halda Therapeutics OpCo, Inc.

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07540572

A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究IDE574联合Fulvestrant用于多种晚期实体瘤，在美国开展。

?

适用疾病: ER+, HER 2- Breast Cancer；Non-small Cell Lung Cancer (NSCLC)；Castration-resistant Prostate Cancer (CRPC)
干预: IDE574，Fulvestrant injection
地点: United States
申办方: IDEAYA Biosciences

正在招募 Phase 1 生物制剂

ClinicalTrials.gov NCT07593820

A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers.

AI 简述这是一项I期试验，在西班牙开展，评估p95HER2.CAR-TECH2Me T细胞用于晚期胃癌、乳腺癌和子宫内膜癌。

?

适用疾病: Metastatic Gastric Cancer；Metastatic Breast Cancer；Endometrial Cancer Metastatic
干预: p95HER2.CAR-TECH2Me
地点: Spain
申办方: Vall d'Hebron Institute of Oncology

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07604571

Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

AI 简述这是一项I期试验，研究IEV407单药或联合氟维司群或来曲唑用于晚期HR+/HER2-乳腺癌，在美国、日本、新加坡开展。

?

适用疾病: Advanced HR+/HER2- Breast Cancer
干预: IEV407，Fulvestrant，Letrozole
地点: United States，Japan，Singapore
申办方: Novartis Pharmaceuticals

正在招募 Phase 1 药物

ClinicalTrials.gov NCT07646106

THE-0504 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究THE-0504用于多种实体瘤，在意大利开展。

?

适用疾病: Small Cell Lung Cancer (SCLC)；Colorectal Carcinoma (CRC)；Gastric Cancer (GC)
干预: THE-0504
地点: Italy
申办方: Thena Biotech S.r.l.

正在招募 Phase 1 生物制剂药物

ClinicalTrials.gov NCT07652242

First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC )

AI 简述这是一项I期试验，研究自扩增RNA疫苗ITI-5000单用或联合Pembrolizumab用于II-III期三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer (TNBC)
干预: ITI-5000 mRNA Vaccine，Pembrolizumab，ITI-5000 mRNA Vaccine
地点: United States
申办方: Immunomic Therapeutics, Inc.

正在招募阶段未标明

NCI NCT07214532 / NCI-2026-03251

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

AI 简述这是一项指导性试验，依据Signatera检测调整CDK4/6抑制剂治疗用于II期乳腺癌。

?

适用疾病: Stage II Breast Cancer；HER2 Negative Breast Carcinoma；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: 未列出
申办方: Natera, Inc.

正在招募 Phase 2

NCI NCT06450873 / NCI-2024-03999

Turkey Tail Mushroom for Treating Post-Menopausal Women with HER2-Negative ER-Positive Breast Cancer Undergoing Surgery

AI 简述这是一项II期试验，研究Turkey Tail Mushroom用于绝经后HER2阴性ER阳性乳腺癌患者手术前治疗。

?

适用疾病: HER2 Negative Breast Carcinoma；Estrogen Receptor-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Mayo Clinic in Arizona

正在招募阶段未标明放疗

ClinicalTrials.gov NCT03646955

Partial Breast Versus no Irradiation for Women With Early Breast Cancer

AI 简述这是一项试验，比较部分乳腺照射与不照射用于早期乳腺癌，在智利、丹麦、挪威、瑞典等地开展。

?

适用疾病: Local Neoplasm Recurrence；Distantly Metastatic Malignant Neoplasm；Death
干预: No partial breast irradiation
地点: Chile，Denmark，Norway，Sweden
申办方: Danish Breast Cancer Cooperative Group

正在招募 Phase 2 药物

ClinicalTrials.gov NCT05440227

PG2 Injection for the Treatment of moderate-to Severe Fatigue in Breast Cancer Patients

AI 简述这是一项2期试验，在Taiwan开展，研究PG2注射剂用于乳腺癌中重度疲劳。

?

适用疾病: Cancer-related Fatigue
干预: PG2 Lyo. Injection 500mg，Placebo 0.9% normal saline
地点: Taiwan
申办方: PhytoHealth Corporation

正在招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05451784

Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS

AI 简述这是一项I/II期试验，研究PD1+TILs输注用于转移性三阴性乳腺癌。

?

适用疾病: Metastatic Triple-Negative Breast Carcinoma
干预: PD1+ TILs (NUMARZU-001) product infusion
地点: Spain
申办方: Fundacio Clinic Barcelona

正在招募阶段未标明放疗

ClinicalTrials.gov NCT06925984

Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)

AI 简述这是一项II期试验，研究立体定向放疗用于少进展性ER+/HER-转移性乳腺癌。

?

适用疾病: OligoProgressive Metastatic Disease
干预: SBRT
地点: Belgium
申办方: Jules Bordet Institute

正在招募 Phase 2 药物

ClinicalTrials.gov NCT07383649

Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection

AI 简述这是一项II期试验，在美国开展，研究抗人巨细胞病毒治疗用于伴有颅内转移和CMV感染的乳腺癌。

?

适用疾病: Brain Cancer Metastatic；CMV Viremia
干预: Valganciclovir
地点: United States
申办方: The Methodist Hospital Research Institute

即将招募 Phase 3 药物

ClinicalTrials.gov NCT05388500

Protocol for Herceptin as Adjuvant Therapy With Reduced Exposure to Chemotherapy (PHARE-C)

AI 简述这是一项III期试验，比较Paclitaxel+Trastuzumab与Trastuzumab用于HER2+乳腺癌。

?

适用疾病: HER2-positive Breast Cancer
干预: Paclitaxel + Trastuzumab，Trastuzumab
地点: 未列出
申办方: Institut de cancérologie Strasbourg Europe

即将招募 Phase 3 药物

ClinicalTrials.gov NCT05698186

Thero2-01S22 in HER2-positive Breast Cancer

AI 简述这是一项III期试验，研究Thero2-01S22用于HER2阳性乳腺癌。

?

适用疾病: HER2-positive Breast Cancer
干预: Thero2-01S22，Placebo，Thero2-01S22，Placebo
地点: 未列出
申办方: Institut de cancérologie Strasbourg Europe

即将招募 Phase 3 药物

ClinicalTrials.gov NCT05901935

DP303c in Patients With HER2-positive Advanced Breast Cancer

AI 简述这是一项III期试验，比较DP303c与曲妥珠单抗联合化疗用于HER2阳性晚期乳腺癌。

?

适用疾病: HER2-positive Advanced Breast Cancer
干预: DP303c，Trastuzumab，Vinorelbine Tartrate，Capecitabine tablets
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 2, Phase 3 药物

ClinicalTrials.gov NCT06268327

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

AI 简述这是一项II/III期试验，比较顺铂+吉西他滨与卡培他滨用于三阴性乳腺癌非pCR患者。

?

适用疾病: Breast Cancer
干预: Cisplatin injection and gemcitabine，Capecitabine tablets
地点: 未列出
申办方: Assiut University

即将招募 Phase 3 药物

ClinicalTrials.gov NCT06835400

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

AI 简述这是一项III期试验，比较口服紫杉醇+Encequidar与静脉紫杉醇用于HER2阴性转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Paclitaxel Capsule，IV Paclitaxel，Encequidar tablet
地点: 未列出
申办方: Health Hope Pharma

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07340658

A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

AI 简述这是一项3期试验，比较来曲唑（联合ribociclib）与Femara（联合ribociclib）用于HR+/HER2-晚期乳腺癌。

?

适用疾病: Advanced, Metastatic Breast Cancer
干预: Letrozole SIE + Ribociclib + Oral placebo，Oral Femara® + Ribociclib + Injectable placebo
地点: 未列出
申办方: Rovi Pharmaceuticals Laboratories

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07406542

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

AI 简述这是一项III期试验，比较SYS6010与化疗用于HER2阴性、EGFR阳性复发或转移性乳腺癌。

?

适用疾病: Recurrent or Metastatic Breast Cancer
干预: SYS6010，Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07486687

Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy

AI 简述这是一项III期试验，研究帕博利珠单抗辅助治疗用于早期三阴性乳腺癌新辅助化疗后残留病变。

?

适用疾病: Triple Negative Breast Cancer (TNBC), Early Setting；Early Stage Triple-Negative Breast Carcinoma；Triple -Negative Breast Cancer
干预: Standard of care plus pembrolizumab，Standard of care (capecitabine or olaparib)
地点: 未列出
申办方: The Netherlands Cancer Institute

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07541079

A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)

AI 简述这是一项III期试验，研究Giredestrant用于ER+/HER2-早期乳腺癌且不耐受芳香化酶抑制剂的患者。

?

适用疾病: Early Breast Cancer
干预: Giredestrant
地点: 未列出
申办方: Genentech, Inc.

即将招募 Phase 3 生物制剂药物手术/操作

ClinicalTrials.gov NCT07578116

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

AI 简述这是一项III期试验，研究在标准治疗基础上增加手术和放疗用于初诊时已转移的HER2阳性乳腺癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic HER2-Positive Breast Carcinoma；Oligometastatic Breast Carcinoma
干预: Biopsy Procedure，Biospecimen Collection，Breast Conservation Treatment，Computed Tomography
地点: 未列出
申办方: SWOG Cancer Research Network

即将招募 Phase 3 药物

ClinicalTrials.gov NCT07683754

T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd

AI 简述这是一项III期试验，研究T-DXd为基础的治疗用于HER2+/HR+晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer；Metastatic Breast Cancer；HER2 Positive
干预: Trastuzumab deruxtecan，Trastuzumab，Pertuzumab，Endocrine Therapy
地点: 未列出
申办方: Daiichi Sankyo

暂时不招募 Phase 2

NCI NCT02411656 / NCI-2015-00671

Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

AI 简述这是一项II期试验，研究Pembrolizumab用于转移性、复发或晚期炎性乳腺癌或三阴性乳腺癌化疗后病情稳定患者。

?

适用疾病: Triple-Negative Breast Cancer；Stage IV Inflammatory Breast Cancer；Recurrent Breast Inflammatory Carcinoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 2

NCI NCT03417544 / NCI-2018-00401

Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases

AI 简述这是一项II期试验，研究阿特珠单抗、帕妥珠单抗和大剂量曲妥珠单抗用于HER2阳性乳腺癌中枢神经系统转移。

?

适用疾病: Stage IV Breast Cancer；Stage IV Breast Cancer；Metastatic Breast Carcinoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

暂时不招募 Phase 2

NCI NCT02971748 / NCI-2018-01297

Pembrolizumab in Treating Patients with Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy

AI 简述这是一项II期试验，研究Pembrolizumab用于激素受体阳性炎性乳腺癌。

?

适用疾病: Stage IIIB Breast Cancer；Stage IIIC Breast Cancer；Inflammatory Breast Cancer
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1, Phase 2

NCI NCT03131908 / NCI-2018-01609

PI3K-beta Inhibitor GSK2636771 and Pembrolizumab in Treating Patients with Stage III-IV Cancer and PTEN Loss

AI 简述这是一项I/II期试验，研究PI3K-beta抑制剂GSK2636771联合Pembrolizumab用于PTEN缺失的III-IV期癌症，在美国开展。

?

适用疾病: Stage III Cutaneous (Skin) Melanoma；Stage IV Cutaneous (Skin) Melanoma；Stage III Cutaneous (Skin) Melanoma
干预: 未列出
地点: United States
申办方: UT MD Anderson Cancer Center

暂时不招募 Phase 1

NCI NCT03970382 / NCI-2019-03772

A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors

AI 简述这是一项I期试验，研究基因编辑的TCR T细胞联合或不联合抗PD-1用于多种实体瘤。在美国开展。

?

适用疾病: Metastatic Urothelial Cancer；Metastatic Malignant Solid Tumor；Stage IV Colorectal (Colon or Rectal) Cancer
干预: 未列出
地点: United States
申办方: PACT Pharma, Inc.

暂时不招募 Phase 1

NCI NCT04650451 / NCI-2021-00052

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

AI 简述这是一项I期试验，研究HER2靶向双开关CAR-T细胞（BPX-603）用于HER2阳性实体瘤。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage III Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: Bellicum Pharmaceuticals

暂时不招募 Phase 1

NCI NCT04714983 / NCI-2021-00608

DNX-2440 for Resectable Colorectal Liver Metastasis

AI 简述这是一项I期试验，研究DNX-2440用于可切除的结直肠癌肝转移，在美国开展。

?

适用疾病: Metastatic Malignant Solid Tumor；Stage IV Gastric (Stomach) Cancer；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: DNAtrix, Inc.

暂时不招募 Phase 1, Phase 2

NCI NCT04946864 / NCI-2021-11630

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

AI 简述这是一项1/2期试验，研究APG-2575单药或联合用于转移性或局部晚期实体瘤及乳腺癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Locally Advanced Malignant Solid Tumor；Stage IV Breast Cancer
干预: 未列出
地点: United States
申办方: Ascentage Pharma

暂时不招募 Phase 1

NCI NCT05111561 / NCI-2021-11793

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients with Advanced/Metastatic or Unresectable Solid Tumors with RAS Alterations and Triple Negative Breast Cancer

AI 简述这是一项I期试验，研究ZEN003694联合Binimetinib用于RAS突变实体瘤和三阴性乳腺癌。

?

适用疾病: Metastatic Malignant Solid Tumor；Advanced Malignant Solid Tumor；Refractory Malignant Solid Tumor
干预: 未列出
地点: United States
申办方: University of Texas MD Anderson Cancer Center LAO

暂时不招募 Phase 1, Phase 2

NCI NCT05383196 / NCI-2022-07856

Onvansertib in Combination with Paclitaxel for the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

AI 简述这是一项I/II期试验，研究Onvansertib联合紫杉醇用于不能切除的局部晚期或转移性三阴性乳腺癌。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Dana-Farber Harvard Cancer Center

暂时不招募 Phase 1

NCI NCT05673200 / NCI-2022-10810

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

AI 简述这是一项I期试验，研究ASTX727联合化疗（紫杉醇）和免疫治疗（Pembrolizumab）用于转移性三阴性乳腺癌。

?

适用疾病: Stage III Breast Cancer；Stage IV Breast Cancer；Metastatic Triple-Negative Breast Carcinoma
干预: 未列出
地点: United States
申办方: Dana-Farber - Harvard Cancer Center LAO

暂时不招募 Phase 1

NCI NCT05958199 / NCI-2023-06569

A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7

AI 简述这是一项I期试验，研究NPX267用于表达HHLA2/B7-H7的实体瘤，在美国开展。

?

适用疾病: Malignant Solid Tumor；Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8；Stage IV Gastric (Stomach) Cancer
干预: 未列出
地点: United States
申办方: NextPoint Therapeutics, Inc.

暂时不招募 Phase 1

NCI NCT04120246 / NCI-2023-08394

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

AI 简述这是一项I期试验，研究Alpha-TEA联合曲妥珠单抗用于HER2阳性转移性乳腺癌。

?

适用疾病: Stage IV Breast Cancer；HER2-Positive Breast Carcinoma
干预: 未列出
地点: United States
申办方: Veana Therapeutics

即将招募 Phase 1 生物制剂

ClinicalTrials.gov NCT06195618

Personalized Vaccine for TNBC Immunotherapy

AI 简述这是一项I期试验，研究个体化疫苗用于三阴性乳腺癌。

?

适用疾病: Breast Cancer Female
干预: Peptide (neoantigen) pulsed autologous Dendritic cell
地点: Colombia
申办方: Universidad Nacional de Colombia

即将招募 Phase 1 基因治疗

ClinicalTrials.gov NCT06251544

TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer

AI 简述这是一项I期试验，研究HTR2 T细胞用于转移性乳腺癌。在美国开展。

?

适用疾病: Breast Cancer；Tumor, Breast；Breast Tumor
干预: HTR2 T Cells，HTR2 T Cells
地点: United States
申办方: Baylor College of Medicine

即将招募阶段未标明放疗

ClinicalTrials.gov NCT06611306

BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.

AI 简述这是一项试验，研究DE-iPTV用于不适合立体定向放疗的原发性乳腺癌脑转移患者。

?

适用疾病: Brain Metastases, Adult；Breast Cancer
干预: DE-iPTV
地点: United Kingdom
申办方: Imperial College London

即将招募阶段未标明放疗

ClinicalTrials.gov NCT06937281

SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors

AI 简述这是一项临床试验，评价立体定向消融放疗用于原发性和区域性乳腺肿瘤，在加拿大开展。

?

适用疾病: Breast Cancer；Metastases
干预: SABR
地点: Canada
申办方: British Columbia Cancer Agency

即将招募 Phase 1 生物制剂药物其他

ClinicalTrials.gov NCT07300475

Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients

AI 简述这是一项I期试验，研究个性化癌症疫苗联合化疗用于三阴性乳腺癌。在美国开展。

?

适用疾病: Triple Negative Breast Cancer
干预: Paclitaxel，Carboplatin，Pembrolizumab，Doxorubicin
地点: United States
申办方: Washington University School of Medicine

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07341867

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

AI 简述这是一项1期试验，研究多种抗癌药物剂量调整用于Duffy无效表型的多发性骨髓瘤和三阴性乳腺癌患者。在美国开展。

?

适用疾病: Multiple Myeloma；Triple Negative Breast Cancer；Duffy Blood Group, Chemokine Receptor Gene Mutation
干预: Dexamethasone，Bortezomib，LENALIDOMIDE，Daratumumab
地点: United States
申办方: Andrew Hantel, MD

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT07357948

Omission of Surgery for Triple-negative Breast Cancer in Complete Response After Neoadjuvant Chemo-immunotherapy

AI 简述这是一项无分期的试验，在法国研究免除手术用于新辅助 chemo-immunotherapy 后完全缓解的三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer；Non-Metastatic
干预: Omission of surgery
地点: France
申办方: Institut Curie

即将招募 Phase 1 药物放疗

ClinicalTrials.gov NCT07454668

Trastuzumab Deruxtecan + Stereotactic Radiosurgery (SRS) in HER2+ Breast Cancer Brain Metastases

AI 简述这是一项I期试验，研究Trastuzumab Deruxtecan联合立体定向放射治疗用于HER2阳性乳腺癌脑转移。

?

适用疾病: Breast Cancer；HER2-positive Breast Cancer；Brain Metastases
干预: Trastuzumab Deruxtecan，Stereotactic Radiosurgery
地点: United States
申办方: Baptist Health South Florida

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07545122

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

AI 简述这是一项I期人体首次试验，在澳大利亚评估CT-202（一种Nectin-4双特异性抗体）用于复发三阴性乳腺癌、结直肠癌、尿路上皮癌。

?

适用疾病: Triple Negative Breast Cancer (TNBC)；Colorectal Cancer；Urothelial Cancer
干预: CT-202
地点: Australia
申办方: Context Therapeutics Inc.

即将招募 Phase 1 其他手术/操作

ClinicalTrials.gov NCT07590583

Biology Guided Therapy Recommendations for Treatment Determination of Hormone Receptor-Positive Advanced, Unresectable or Metastatic Breast Cancer, ENDORSE Trial

AI 简述这是一项I期试验，研究生物学指导治疗用于激素受体阳性晚期乳腺癌。

?

适用疾病: Advanced Hormone Receptor-Positive Breast Carcinoma；Anatomic Stage III Breast Cancer AJCC v8；Anatomic Stage IV Breast Cancer AJCC v8
干预: Biopsy Procedure，Biospecimen Collection，Bone Scan，Computed Tomography
地点: United States
申办方: City of Hope Medical Center

即将招募阶段未标明其他手术/操作

ClinicalTrials.gov NCT07676344

CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer

AI 简述这是一项试验，在法国研究冷冻消融用于转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer
干预: Cryoablation，Patient-Reported Outcome Assessment
地点: France
申办方: Hospices Civils de Lyon

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT02802423

Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.

AI 简述这是一项I/II期试验，研究BLEX 404联合多西他赛用于晚期或转移性三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: BLEX 404 Oral Liquid
地点: 未列出
申办方: BioLite, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT04158856

Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

AI 简述这是一项II期试验，研究吡咯替尼联合曲妥珠单抗辅助治疗HER2阳性早期乳腺癌。

?

适用疾病: HER2-positive Breast Cancer
干预: Pyrotinib，Trastuzumab
地点: 未列出
申办方: xuexin he

即将招募阶段未标明手术/操作

ClinicalTrials.gov NCT04225858

Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy

AI 简述这是一项试验，评估新辅助化疗后乳腺癌患者省略前哨淋巴结活检。

?

适用疾病: Breast Cancer；Triple Negative Breast Cancer；HER2-positive Breast Cancer
干预: Omission of sentinel lymph node biopsy
地点: 未列出
申办方: The Netherlands Cancer Institute

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05232006

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers

AI 简述这是一项II期试验，研究Niraparib用于PALB2突变转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
干预: Niraparib
地点: 未列出
申办方: Assistance Publique - Hôpitaux de Paris

即将招募阶段未标明药物手术/操作

ClinicalTrials.gov NCT05285332

Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy

AI 简述这是一项分类治疗策略研究，评估手术和全身治疗用于新发转移性乳腺癌。

?

适用疾病: Breast Neoplasms；Treatment；Metastatic Breast Cancer
干预: surgical treatment 1，surgical treatment 2，Systemic therapy
地点: 未列出
申办方: Changhai Hospital

即将招募 Phase 1 药物

ClinicalTrials.gov NCT05698238

Clinical Study to Evaluate Safety and Dosing of CA9hu-1 in Patients With Advanced Solid Tumours

AI 简述这是一项I期试验，研究CA9hu-1用于晚期实体瘤，包括肾癌、三阴性乳腺癌等。

?

适用疾病: Clear Cell Renal Cell Carcinoma Metastatic；TNBC - Triple-Negative Breast Cancer；Head and Neck Cancer
干预: CA9hu-1
地点: 未列出
申办方: Mabpro, a.s.

即将招募 Phase 1, Phase 2 联合产品器械

ClinicalTrials.gov NCT05806385

Grouping Immune-modulation With Cryoablation (LOGIC) for Breast Cancers

AI 简述这是一项I/II期试验，研究冷冻消融联合PD1抑制剂用于三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: Cryoablation，Cryoablation combined with PD1 Inhibitor
地点: 未列出
申办方: Texas Tech University Health Sciences Center

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT05821686

Efficacy of Interleukin-2 in Triple Negative Breast Cancer

AI 简述这是一项I/II期试验，研究白细胞介素-2用于三阴性乳腺癌。

?

适用疾病: Triple Negative Breast Cancer
干预: Human Interleukin-2 (IL-2) (Proleukin)
地点: 未列出
申办方: Nova Scotia Health Authority

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06339281

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

AI 简述这是一项II期试验，研究甲磺酸阿帕替尼联合医生选择方案用于晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer
干预: apatinib mesylate+Capecitabine Tablets，apatinib mesylate+Fulvestrant injection
地点: 未列出
申办方: Li Huiping

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06407310

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究帕博利珠单抗联合卡铂和紫杉醇用于三阴性乳腺癌的新辅助治疗。

?

适用疾病: Triple Negative Breast Cancer
干预: Pembrolizumab，Carboplatin，Paclitaxel
地点: 未列出
申办方: Tel Aviv Medical Center

即将招募阶段未标明放疗

ClinicalTrials.gov NCT06489821

STereotactic Body Radiotherapy (SBRT) for Oligoprogressive Breast Cancer

AI 简述这是一项试验，研究立体定向体部放疗用于寡进展性转移性乳腺癌。

?

适用疾病: Metastatic Breast Cancer；Oligoprogression
干预: Stereotactic body radiotherapy
地点: 未列出
申办方: Juravinski Cancer Center

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06586866

JK-1201I in Triple Negative Breast Cancer Patients with Brain Metastases

AI 简述这是一项II期试验，研究JK-1201I用于三阴性乳腺癌伴脑转移。

?

适用疾病: Triple Negative Breast Cancer (TNBC)；Brain Metastasases
干预: JK-1201I
地点: 未列出
申办方: JenKem Technology Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06653972

Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer

AI 简述这是一项II期试验，研究长春瑞滨联合脂质体多柔比星两周方案用于HER2阴性晚期乳腺癌。

?

适用疾病: Her2-negative Metastatic Breast Cancer；Vinorelbine；Liposomal Doxorubicin
干预: Pegylated Liposomal Doxorubicin + vinorelbine,every cycle is 14d.
地点: 未列出
申办方: Wang Jiayu

即将招募阶段未标明药物

ClinicalTrials.gov NCT06718335

Pyrotinib in HER2-positive Early Breast Cancer

AI 简述这是一项试验，研究吡咯替尼用于HER2阳性早期乳腺癌。

?

适用疾病: HER2-positive Breast Cancer
干预: Pyrotinib
地点: 未列出
申办方: Nie Jianyun

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT06775236

Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors

AI 简述这是一项I/II期试验，研究SYS6010联合或不联合SYH2051对比化疗用于晚期乳腺癌等实体瘤。

?

适用疾病: Advanced Solid Tumors；Breast Cancer
干预: SYS6010 jnjection，monotherapy chemotherapy，SYH2051 tablets
地点: 未列出
申办方: CSPC Megalith Biopharmaceutical Co.,Ltd.

即将招募阶段未标明药物

ClinicalTrials.gov NCT06810492

The Efficacy and Safety of CDK4/6 Inhibitors in Combination with Endocrine Therapy in the Neoadjuvant Treatment

AI 简述这是一项试验，研究CDK4/6抑制剂联合内分泌治疗用于II-III期乳腺癌新辅助治疗。

?

适用疾病: Breast Cancer Stage III；Breast Cancer Stage II
干预: Ribociclib; abemaciclib; palbociclib; Dalpiciclib
地点: 未列出
申办方: Hongmei Zheng, PhD

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06849947

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

AI 简述这是一项II期试验，比较Ribociclib联合Fulvestrant与医生选择治疗用于HR+、HER2-转移性乳腺癌。

?

适用疾病: Breast Cancer Metastatic
干预: Ribociclib with fulvestrant，Physician's choice treatments group
地点: 未列出
申办方: Yeon Hee Park

即将招募 Phase 4 药物

ClinicalTrials.gov NCT06868017

Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles

AI 简述这是一项IV期试验，研究Initumab联合吡咯替尼和化疗用于HER2阳性乳腺癌新辅助治疗。

?

适用疾病: HER2 Positive Breast Cancer
干预: Cohort A will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 4 doses，Cohort B will receive an initial load dose of 8mg/kg and a maintenance dose of 6mg/kg intravenously on the first day of every three weeks for a total of 6 doses
地点: 未列出
申办方: The First Hospital of Jilin University

即将招募阶段未标明其他放疗

ClinicalTrials.gov NCT06882499

Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer II

AI 简述这是一项试验，研究立体定向放疗维持系统治疗对比医生选择方案用于寡进展乳腺癌。

?

适用疾病: Breast Cancer, Metastatic；Metastatic Breast Cancer
干预: Stereotactic Ablative Radiotherapy，Physician's choice of systemic treatment
地点: 未列出
申办方: Peter MacCallum Cancer Centre, Australia

即将招募 Phase 1 药物

ClinicalTrials.gov NCT06941142

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast Cancer

AI 简述这是一项1期试验，研究白蛋白结合型西罗莫司联合帕博西尼和氟维司群用于晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer
干预: Sirolimus (albumin - bound)，Palbociclib tablet，Fulvestrant injection
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06973525

This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.

AI 简述这是一项II期试验，研究曲妥珠单抗、吡咯替尼和白蛋白紫杉醇，或SHR-A1811用于HER2阳性乳腺癌的新辅助治疗。

?

适用疾病: HER2-positive Breast Cancer
干预: Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody，Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen.
地点: 未列出
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 2 联合产品

ClinicalTrials.gov NCT06975462

A Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain Metastases

AI 简述这是一项II期试验，研究SHR-A1811联合放疗用于HER2阳性及低表达乳腺癌脑转移。

?

适用疾病: Breast Cancer Metastatic
干预: SHR-A1811 and radiotherapy
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 2 药物

ClinicalTrials.gov NCT06975475

SHR-A1811 and THPy in First or Second Line for HER2 Positive Advanced Breast Cancer Brain Metastases

AI 简述这是一项II期试验，研究SHR-A1811联合曲妥珠、吡咯替尼和白蛋白紫杉醇用于HER2阳性晚期乳腺癌脑转移。

?

适用疾病: Breast Cancer
干预: SHR-A1811,tratuzumab,pyrotinib,Nab-Paclitaxel
地点: 未列出
申办方: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

即将招募 Phase 1 手术/操作放疗

ClinicalTrials.gov NCT06982222

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

AI 简述这是一项I期试验，研究Sn-117m-DTPA用于晚期骨转移癌。

?

适用疾病: Anatomic Stage IV Breast Cancer AJCC v8；Metastatic Breast Carcinoma；Metastatic Lung Non-Small Cell Carcinoma
干预: Biospecimen Collection，Bone Scan，Computed Tomography，Positron Emission Tomography
地点: 未列出
申办方: National Cancer Institute (NCI)

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07007780

Sacituzumab Tirumotecan in Neoadjuvant Treatment of Early-Stage TNBC

AI 简述这是一项II期试验，研究Sacituzumab Tirumotecan用于早期三阴性乳腺癌的新辅助治疗。

?

适用疾病: Triple -Negative Breast Cancer
干预: Sacituzumab Tirumotecan
地点: 未列出
申办方: Xijing Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07101159

Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients

AI 简述这是一项2期试验，研究Dalpiciclib辅助治疗用于HR阳性/HER2阴性早期乳腺癌。

?

适用疾病: Early Breast Cancer；Adjuvant Therapy；Hormone Receptor Positive / HER2-negative Breast Cancer
干预: Dalpiciclib，Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)，Dalpiciclib
地点: 未列出
申办方: Fujian Cancer Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07101614

A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC).

AI 简述这是一项II期试验，研究JS004联合特瑞普利单抗和化疗用于II-III期三阴性乳腺癌新辅助治疗。

?

适用疾病: TNBC - Triple-Negative Breast Cancer
干预: JS004 in combination with toripalimab and chemotherapy，Toripalimab and chemotherapy，Chemotherapy
地点: 未列出
申办方: Shengjing Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07102940

Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer

AI 简述这是一项II期试验，研究Eftilagimod Alfa联合化疗用于HR阳性/HER2阴性乳腺癌。

?

适用疾病: Breast Cancer；HER 2 Negative Breast Cancer；HR Positive/HER-2 Negative Breast Cancer
干预: Eftilagimod Alfa (Efti)，Docetaxel-cyclophosphamide (TC) intravenous (i.v)，Dose dense Adriamycin-cyclophosphamide (AC) i.v
地点: 未列出
申办方: George Washington University

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07103447

Prospective Multicenter Single-arm Trial: AK112 + Nab-paclitaxel/Carboplatin Neoadjuvant for TNBC

AI 简述这是一项II期试验，研究AK112联合白蛋白紫杉醇/卡铂新辅助治疗三阴性乳腺癌。

?

适用疾病: Breast Cancer - Female
干预: AK112, Carboplatin, Paxlitaxel
地点: 未列出
申办方: Shuangyue Liu

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07116824

HB1801 Combined Treatment of HER2-positive Breast Cancer

AI 简述这是一项II期试验，研究HB1801联合Trastuzumab、Pertuzumab和Docetaxel用于HER2阳性乳腺癌。

?

适用疾病: HER2-positive Breast Cancer
干预: HB1801，Trastuzumab，Pertuzumab，Docetaxel
地点: 未列出
申办方: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07129187

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant Response

AI 简述这是一项II期试验，研究SHR-A1811用于新辅助治疗后反应欠佳的HER2阳性早期乳腺癌。

?

适用疾病: Early Breast Cancer；HER2 + Breast Cancer；Stage II Breast Cancer
干预: SHR-A1811
地点: 未列出
申办方: Chuan Wang

即将招募 Phase 1, Phase 2 联合产品

ClinicalTrials.gov NCT07136428

Asciminib in HER2+ Breast Cancer Brain Metastases

AI 简述这是一项I/II期试验，研究Asciminib联合曲妥珠单抗用于HER2阳性乳腺癌脑转移。

?

适用疾病: HER2+ Metastatic Breast Cancer
干预: Asciminib and Trastuzumab
地点: 未列出
申办方: Duke University

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07173556

A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer

AI 简述这是一项Ib/II期试验，研究QLC1401联合CDK4/6或mTOR抑制剂用于ER+/HER2-晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer
干预: QLC1401，QLC1401
地点: 未列出
申办方: Qilu Pharmaceutical Co., Ltd.

即将招募 Phase 1, Phase 2 生物制剂药物

ClinicalTrials.gov NCT07260058

Immune Cell Therapy for Advanced Solid Tumors

AI 简述这是一项I/II期试验，研究自体免疫细胞联合标准化疗用于晚期实体瘤。

?

适用疾病: Lung Cancer (Locally Advanced or Metastatic)；Liver Cancer (Locally Advanced or Metastatic)；Colorectal Cancer (Locally Advanced or Metastatic)
干预: Autologous immune Cells，Standard chemotherapy
地点: 未列出
申办方: Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07367178

Study of Sacituzumab Govitecan With Atropine to Improve Tolerability in Advanced TNBC and HR+/HER2- Breast Cancer

AI 简述这是一项II期试验，研究戈沙妥珠单抗联合阿托品改善晚期TNBC和HR+/HER2-乳腺癌患者的耐受性。

?

适用疾病: Breast Cancer；Advanced HR+/HER2- Breast Cancer；Advanced Triple-Negative Breast Cancer
干预: Sacituzumab Govitecan (SG)，Atropine，G-CSF (Granulocyte colony-stimulating factor)
地点: 未列出
申办方: MedSIR

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07423117

A Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy

AI 简述这是一项I期试验，研究ITC-6146RO用于标准治疗失败的晚期或转移性实体瘤。

?

适用疾病: Metastatic Castration-resistant Prostate Cancer；Non-small Cell Lung Cancer；Triple Negative Breast Cancer
干预: ITC-6146RO
地点: 未列出
申办方: IntoCell, Inc

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07441512

A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

AI 简述这是一项II期试验，研究Inavolisib联合Eribulin用于PIK3CA突变的三阴性乳腺癌。

?

适用疾病: TNBC - Triple-Negative Breast Cancer；TNBC
干预: Inavolisib in Combination With Eribulin
地点: 未列出
申办方: Hu Hai

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07494448

Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer

AI 简述这是一项I/II期试验，研究Zanidatamab联合Tucatinib和化疗用于HER2阳性晚期乳腺癌。

?

适用疾病: HER 2 Positive Advanced Breast Cancer；Breast Cancer
干预: Zanidatamab，Tucatinib，Capecitabine，Eribulin Mesilate injection
地点: 未列出
申办方: MedSIR

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07580833

A Study to Investigate the Effect of Food on the Bioavailability of Oral Paclitaxel Administered With Encequidar in Participants With Advanced Solid Tumors

AI 简述这是一项I期试验，研究食物对口服紫杉醇联合Encequidar在晚期实体瘤患者中的影响。

?

适用疾病: Metastatic Breast Cancer
干预: Oral Paclitaxel in combination with Encequidar tablet
地点: 未列出
申办方: Health Hope Pharma

即将招募 Phase 1, Phase 2 药物

ClinicalTrials.gov NCT07581314

Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

AI 简述这是一项I/II期试验，研究口服Zn-Telomir用于晚期或转移性三阴性乳腺癌。

?

适用疾病: Triple-Negative Breast Cancer (TNBC)；Advanced Triple-Negative Breast Cancer；Metastatic Triple-negative Breast Cancer
干预: Zn-Telomir
地点: 未列出
申办方: Telomir Pharmaceuticals, Inc.

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07618923

Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer

AI 简述这是一项II期试验，研究Dalpiciclib联合AI后序贯SHR-A1811用于HR阳性/HER2低表达乳腺癌新辅助治疗。

?

适用疾病: Breast Cancer；HR Positive/HER2 Low Breast Cancer
干预: Dalpiciclib 125mg，Aromatase Inhibitor，SHR-A1811
地点: 未列出
申办方: Tang-Du Hospital

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07619066

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

AI 简述这是一项II期试验，研究Zongertinib联合Fulvestrant用于HER2突变HR阳性/HER2阴性晚期乳腺癌。

?

适用疾病: Advanced Breast Cancer；Hormone Receptor Positive / HER2-negative Breast Cancer；HER2 Mutation
干预: Zongertinib (BI 1810631)，Fulvestrant
地点: 未列出
申办方: MedSIR

即将招募 Phase 1 药物

ClinicalTrials.gov NCT07623369

A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors

AI 简述这是一项I期试验，研究HH160用于晚期实体瘤。

?

适用疾病: Solid Tumor；Non-small Cell Lung Cancer；Hepatocellular Carcinoma
干预: HH160
地点: 未列出
申办方: Huahui Health

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07679269

Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

AI 简述这是一项II期试验，研究Alpelisib长期用于PIK3CA相关过度生长和乳腺癌。

?

适用疾病: PIK3CA-Related Overgrowth Spectrum (PROS)；Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
干预: Alpelisib，Fulvestrant，Trastuzumab，Pertuzumab
地点: 未列出
申办方: Novartis Pharmaceuticals

即将招募 Phase 2 药物

ClinicalTrials.gov NCT07340619

Clinical Trial Evaluating the Biological Activity of a New Drug Identified as Prifetrastat (PF-07248144), Combined With Fulvestrant for the Treatment of Patients With Hormone Receptor Positive (HR+) and HER2 Negative (HER2-) Breast Cancer Extended to Other Organs.

AI 简述这是一项2期试验，研究prifetrastat联合fulvestrant用于转移性黑色素瘤。在法国开展。

?

适用疾病: Metastatic (Stage IV) Melanoma
干预: prifetrastat monotherapy for 15 days then combination with fulvestrant，prifetrastat in combination with fulvestrant
地点: France
申办方: UNICANCER

即将招募 Phase 2 药物

ClinicalTrials.gov NCT05522491

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

AI 简述这是一项II期试验，研究奥拉帕利用于BRCA1/2未突变且BRCA1启动子甲基化的复发转移性三阴性乳腺癌。

?

适用疾病: Solid Tumor
干预: Olaparib
地点: 未列出
申办方: Hebei Medical University Fourth Hospital

即将招募 Phase 2 放疗

ClinicalTrials.gov NCT07011823

Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC

AI 简述这是一项II期试验，研究Pembrolizumab联合部分乳腺照射用于早期三阴性乳腺癌。

?

适用疾病: Triple-Negative Breast Neoplasm
干预: Partial breast-irradiation
地点: 未列出
申办方: Gangnam Severance Hospital

术语	中文意思	对找临床试验有什么用
HER2 阳性乳腺癌 / HER2-positive breast cancer	癌细胞 HER2 蛋白表达高。HER2 是一个促进细胞生长的受体。	可以找 HER2 靶向药试验，比如 trastuzumab、pertuzumab、T-DXd 等相关试验。
三阴性乳腺癌 / TNBC	ER 阴性、PR 阴性、HER2 阴性。也就是三种常见靶点都没有。	通常会找免疫治疗、ADC、化疗组合、PARP 抑制剂等试验。
激素受体阳性 / HR-positive breast cancer	ER 或 PR 任意一个阳性，都可以叫 HR-positive。	常见方向是内分泌治疗、CDK4/6、PI3K/AKT/mTOR、SERD 等。
ER-positive	雌激素受体阳性。癌细胞可能受雌激素刺激生长。	可以找内分泌治疗相关试验。
PR-positive	孕激素受体阳性。经常和 ER 一起看。	也属于激素受体相关信息。
BRCA mutation	BRCA1 或 BRCA2 基因突变。可能是遗传性，也可能是肿瘤里的体细胞突变。	可以找 PARP 抑制剂、DNA 损伤修复相关试验。
转移性乳腺癌 / metastatic breast cancer	癌症已经扩散到乳房以外的远处器官，比如骨、肝、肺、脑等。	很多试验会限定 metastatic 或 advanced 患者。
CDK4/6	一类细胞周期相关靶点。CDK4/6 抑制剂常用于 HR-positive、HER2-negative 转移性乳腺癌。	可以找 palbociclib、ribociclib、abemaciclib 等相关试验。
First line	一线治疗。通常指确诊晚期或转移后，第一次系统治疗方案。	试验可能要求患者未接受过晚期一线治疗。
Second line	二线治疗。通常是一线治疗失败、进展或不能耐受后，换的下一套方案。	很多试验会写 after progression on first-line therapy。

Recruiting	正在招募，可能仍可申请参加。
Not yet recruiting	尚未开始招募，可关注后续开放时间。
Active, not recruiting	试验仍在进行，但通常不再招新患者。
Completed	试验已经完成。
Terminated	试验提前终止。
Unknown	公开页面上的状态不明确或未及时更新。

乳腺癌

当前同步到的治疗类试验